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Background: Streamlining onboarding processes for new hires to maximize 
efficiency and reduce costs while meeting regulatory requirements is a constant challenge 
for healthcare systems’ Employee Health staff.  Health screening is a required step and 
includes obtaining a detailed health history, tuberculosis screening, drug screens, 
immunizations, fit for duty examinations, obtaining medical records, clarification of 
disability accommodations, pre-work screens, and other tests which are time consuming 
and result in delays in hire dates. Faced with a high volume of potential new employee 
hires a major southeast healthcare system was concerned about delays in new hire start 
dates.  The two-step tuberculin skin test administration and follow-up process was 
identified as a potential area for concern to improve onboarding efficiency. 
Method: A quality improvement study was designed and implemented to 
compare baseline testing for new employees with an Interferon-Gamma Release Assay 
(IGRA) known as QuantiFERON®-TB Gold In-Tube Test (QFT®-GIT) to the two step 
PPD Tuberculin Skin Test (TST) for tuberculosis screening time, overall onboarding 
time, compliance with screening within 10 days of hire date, and associated costs. A 
retrospective electronic record review included a sample of 484 new hire employees.  
Results: Results showed that the QFT®-GIT for tuberculosis screening in 
comparison to the TST testing significantly reduced tuberculosis screening time for new 
hire employees (TST = 8.03 days, QFT®-GIT = 4.11 days; p<.0001) and overall 
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onboarding time (TST = 7.92 days, QFT®-GIT = 5.07 days; p<.0001) while improving 
compliance with tuberculosis screening within 10 days of hire date (TST = 92.92%, 
QFT®-GIT =100%; p<.0001).  
Conclusions: The utilization of QFT®-GIT for tuberculosis screening of new 
employees significantly reduced screening and onboarding time while improving 
compliance with screening within 10 days of the hire date. Anecdotal feedback from 
hiring managers and senior management indicated improved satisfaction with the 
Employee Health hiring process.  
Implications:   Healthcare systems should consider implementation of an IGRA 
to streamline processes for onboarding new employees. New processes require 
negotiations between healthcare systems and lab vendors, changes in policies and 
procedures, and employee health and laboratory staff development. Future research 
should focus on cost analyses, as well as, IGRA use for annual screenings.  
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Description of Clinical Problem 
Occupational health nurses in healthcare settings are challenged with promoting 
the health and safety of employees. This includes practicing current evidence-based 
interventions to prevent the spread of communicable disease including tuberculosis (TB) 
(Massante & Stinson, 2014). Healthcare workers are at increased risk for contracting 
mycobacterium tuberculosis (TB) from “sharing air space” with infected patients through 
airborne droplet transmission (Jensen, Lambert, Iademarco, & Ridzon, 2006). The 
Department of Health and Human Services Centers for Disease Control and Prevention 
(CDC) recommends that all healthcare workers receive initial screening for TB upon hire 
by a 2-step tuberculin skin test (TST) (Jensen et al., 2006).    The TST is performed by 
injecting tuberculin purified protein derivative (PPD) intradermally. If someone has been 
exposed to TB, they will develop induration at the injection site which is measured in 
millimeters in 48-72 hours. According to CDC guidelines for interpretation of healthcare 
worker TST results, a reading of >10 mm of induration is positive. However, if the 
healthcare worker has HIV or other immune compromised conditions, a positive reading 
is > 5 mm of induration. A positive result can indicate active TB, latent TB (LTBI), or 
may be due to history of vaccination with Bacillus Calmette-Guerin (BCG) vaccine or 
exposure to other non-tuberculin mycobacteria. Healthcare workers are at risk for 
spreading TB if they are not tested and unaware that they have latent TB and are 
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asymptomatic. Latent TB can be reactivated and the healthcare worker can then spread 
infection endangering the safety of patients and the community (Jensen et al., 2006). 
There are three main categories of problems with utilization of the two step 
tuberculin skin test: extended screening time, noncompliance, and potential inaccuracy in 
placement and results. Problems with extended screening time and noncompliance occur 
due to the multiple steps that are required to complete the two step tuberculin test. The 
two step baseline tuberculin skin test requires 4 steps including: step 1- Intradermal 
placement of PPD, step 2- read the result in 48-72 hours, step 3- placement of second step 
in 1-3 weeks after the first step, and step 4- read the second step in 48 to 72 hours (Jensen 
et al., 2006). If the patient is noncompliant with returning for PPD reading, then the PPD 
must be replaced. Accuracy of the two step tuberculin skin test occurs due to variation in 
skin test placement, subjective reader interpretation, false-positive results, and false-
negative results. Proper placement of the TST should include injection of 0.1ml of PPD 
solution injected intradermally on the inner forearm creating a pale skin elevation (wheal) 
of 6-10 mm. If a wheal does not appear, then the test is incorrectly placed and should be 
repeated. Inaccurate placement can lead to false-negative results when an untrained 
healthcare worker inadvertently places the skin test too deep or too shallow. Furthermore, 
errors in reader interpretation can lead to false-negative or false-positive results. 
Tuberculin skin tests results should measure millimeters of induration which is a raised, 
palpable area (Jensen et al., 2006). Often, inexperienced readers may inaccurately 
measure erythema rather than induration resulting in false-positive results.  These false-
positives may result in unnecessary anxiety for the patient and may lead to the patient 
taking LTBI treatment medications which have potential strong adverse side effects. In 
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contrast, some readers who are inexperienced or who do not understand the importance of 
accurate interpretation, may interpret results as negative which are really positive. In this 
case, the patient who needs treatment for LTBI will be left at risk for TB activation.  
Further compounding problems with false-positive results, tuberculin skin tests also react 
to Bacille Calmette-Guerin (BCG) vaccination and other non-tuberculous mycobacteria 
leading to false-positives (Swindells, Aliyu, Enoch, & Abubakar, 2009). Additionally, 
TST can give false negative results in immune suppressed individuals. In summary, the 
two step TST is subject to issues with extended screening time, noncompliance, and 
inaccuracies due to required multiple visits, variation in placement and readings, results, 
and false-positive or false-negatives (Swindells et al., 2009). 
The purpose of this DNP project was to compare baseline testing for new 
healthcare employees with QuantiFERON®-TB Gold In-Tube Test (QFT®-GIT) to the 
two step PPD TB skin test in regards to tuberculosis screening time, overall onboarding 
time, compliance with tuberculosis screening within 10 days of orientation, and costs. 
This quality improvement project assessed whether implementation of the QFT®-GIT in 
place of the two step TST, met the organizational goal to reduce the number of days to 
complete tuberculosis screening, reduce overall Employee Health onboarding clearance 
time, and improve compliance with completion of tuberculosis screening within 10 days 
of hire date, while maintaining cost-effectiveness.  
 
Scope of the Problem 
Tuberculosis remains a major threat in the world with 9 million new cases each 
year. TB is the leading cause of death by an infectious disease, killing 1.5 million people 
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annually and 4,100 daily. This represents a 50% decrease in TB deaths globally 
(“National Action Plan to Combat Multidrug-Resistant Tuberculosis,” 2015). Death rates 
in the United States have fallen below 10,000 annually largely due to implementation of 
CDC recommended infection control measures (Jensen et al., 2006; “National Action 
Plan to Combat Multidrug-Resistant Tuberculosis,” 2015). In 2015, South Carolina had 
104 cases of active TB, and 14 in the Upstate with less than 5 of those being in 
Spartanburg, South Carolina with a rate of 1.36 cases per 100,000 (South Carolina 
Department of Health and Environmental Services, 2016). Even though death rates are 
falling, it is estimated one third of the world’s population are infected with latent TB and 
are at risk for converting to active TB. Multidrug-resistant tuberculosis has also emerged 
threatening this progress. Action must be taken to prevent the spread of this drug resistant 
strain of TB. If efforts to prevent and diagnose latent and active TB are not actively 
continued, TB can spread rapidly around the world and to the United States and reverse 
decades of infection control measures (“National Action Plan to Combat Multidrug-
Resistant Tuberculosis,” 2015). 
Healthcare workers have up to 3 times higher risk of TB than the general 
population (Verkuijl & Middelkoop, 2016). The healthcare system accepts patients with 
TB and confines noncompliant TB patients for direct observed therapy. The healthcare 
system treated two patients with TB in 2015. Employees of the healthcare system may 
care for patients whose TB status is initially unknown for several days without 
respiratory protection and can unknowingly develop latent TB infection (Kathy Bryant, 
personal communication, November 2015). If an employee with undetected latent TB 
develops active TB, this employee can transmit TB to 10-15 other patients, coworkers, 
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family or community. This can be costly to the organization and the employee. If the TB 
strain is drug-susceptible then treatment consists of a four drug regimen for 6 months and 
can cost up to $17,000. However, if it is drug resistant, treatment is more complex and 
expensive costing $150,000 to $482,000. Compounding drug resistance, adherence to 
drug regimens is difficult due to side effects and length of required treatment. If an 
employee acquires active TB, then the employee is subject to lost work time up to 4 
months accounting for 30 percent of their income (“National Action Plan to Combat 
Multidrug-Resistant Tuberculosis,” 2015). Moreover, the organization can incur 
additional costs such as increased worker’s compensation benefits and interrupted 
staffing schedules or locum tenens coverage. Legally, the organization can also expect 
citations or sanctions by DHEC or other regulatory agencies if it is determined that 
proper infection control measures were not in place. From a public relations perspective, 
the organization may expect a tarnished reputation or at least some employee and public 
backlash that may instill a lack of trust or confidence as a healthcare institution or 
employer. 
Healthcare systems must continue to monitor CDC recommendations and DHEC 
regulations to prevent spread of TB. Detection of latent or active TB in new employees 
plays a large role in this effort. Healthcare systems are required to maintain stringent 
respiratory protection plan that includes appropriate ventilation of TB patient rooms, N-
95 mask fit testing, exposure follow up plans, and periodic testing of employees(Verkuijl 
& Middelkoop, 2016). Employee Health staff must refer all employees with positive 
tuberculosis screening to the health department for appropriate evaluation and treatment. 
Through appropriate surveillance, early detection of TB, and infection control measures 
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the organization can reduce the TB burden to the community, patients and employees 
(Jensen et al., 2006). 
 
Analysis of Current Practices 
The healthcare system currently employees approximately 6,800 employees and 
had experienced a 15% employee turnover rate in 2015 and 2016 which led to staffing 
issues and utilization of expensive locum tenens temporary contract employees (Kathy 
Sinclair, personal communication, March 2016). The hospital has 78 locum tenens 
Registered Nurses which costs the healthcare system $119,600 per RN or total 9.33 
million annually. Hiring a permanent RN would save $46,782 per position (Rachel 
Datillo, personal communication, July 2016). This does not include costs for non RN 
locum tenens employees. New hire RN orientation only occurs one time per month. If the 
new hire RN orientation is delayed due to incomplete tuberculosis screening or other 
requirements in Employee Health, then a locum tenens nurse will need to fill that spot for 
another month. The average full time RN salary is approximately $30 per hour, but locum 
tenens RNs cost approximately $60 per hour for 160 hours, totaling $10,800 for one 
month of locum tenens. Therefore, a one-month delay would cost $5,400 per month 
additional to the healthcare system. If only 2 RNs   per month have delayed orientation, 
this would cost the healthcare system $129,600 per year.  
Further contributing to short staffing concerns, the process for hiring positions 
requires multiple time consuming steps. Managers must go through a position committee 
for approval of any job postings. This process can take 1-3 weeks or more. Recruitment 
then must post the job, actively recruit, screen applications, and submit top applications 
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to the manager for review which can take 1-2 weeks or more. The Manager must then 
conduct interviews and select the candidate. Recruitment must then obtain the pay rate 
from the compensation department and negotiate the offer with the candidate which can 
take a few days. The average amount of days it takes to fill positions from job posting to 
job offer in 2015 was 51 days (47 for RNs), and the January to February 2016 average 
was 58 days (Rachel Dattilo, personal communication March, 2016). The 2016 days to 
fill job offers ended wrapped up at 47 days compared to the national standard of median 
of 48 days (Rachel Dattilo, personal communication, March 2017). Following this, it can 
take 1-2 weeks to get an appointment in Employee Health for pre-placement assessments. 
Once the new employee has an appointment in Employee Health, it could take 3 days to 
30 days to clear the employee for orientation. Clearance for orientation includes, health 
assessment, labs, immunization titers, drug screens, tuberculosis screening, review of 
medical records, and in some cases pre-work screen lift tests and fit for duties with a 
provider. This process could take 2 to 30 days with the Fall 2015 average being 15 days 
from time of first appointment to health clearance for orientation. Orientation only 
occurred twice per month except for RNs which was monthly, and new hires were 
required to attend. It was requested that new hires come to Employee Health at least 10 
days prior to orientation, so that orientation will not be delayed due to waiting for drug 
screen results, for completion of 2 step PPD tuberculin skin test, and fit for duty 
appointments. If drug screen results were not back in time, fit for duties are not 
completed or the employee does not complete the PPD tuberculin skin test process prior 
to orientation, then the employee would not be able to start work until the next orientation 
in 2-3 weeks. Delays in orientation only compounded the short staffing concerns. Senior 
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management asked the Employee Health department as well as Recruitment to assess 
procedures for expediting new employee total onboarding time. 
 The healthcare system Employee Health examined its processes to determine 
measures to contribute to this reduction in new employee onboarding time. In 2015, 
Employee Health screened approximately 100 to 125 new hire employees monthly. 
Employee Health completed tuberculosis screening with the two step PPD skin test. This 
process took 2-4 visits and sometimes took 10 days to 4 weeks or more to complete. The 
first visit took approximately 2 hours and cost $48.70 in staff time (5 min for PPD 
placement is $2.58 of time) plus $4 for the PPD test and 0.36 for the syringe and needle. 
This does not include the cost for other supplies, and lab processing. The second visit for 
PPD reading number one cost $10.15 in staff time. The third visit which would include 
PPD placement number 2 and lab result review cost total $10.15 in staff time (5 min of 
time for the PPD placement) plus $4.36 for PPD. The fourth visit which would include 
PPD reading cost approximately $10.15 in staff time (see Table 1.1). New employees 
were required to have at least 1 PPD skin test placed and read prior to orientation.  New 
employees sometimes failed to return for first PPD reading which resulted in the need for 
replacement and delay in orientation. Therefore, if the new employee failed to complete 
this first skin test prior to orientation, then the employee could not start work for 2 or 
more weeks, or 1 month for RNs. The second step of the tuberculin PPD skin test is also 
problematic. New employees were required to have the second PPD skin test placed and 
read within 10 days of orientation. However, 6-10% of new employees do not return for 
this second PPD which caused Employee Health staff to spend additional time contacting 
the new hire to request a return visit and replacement of the PPD. If the Employee Health 
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RN spent 15-30 min per noncompliant new hire employee contacting the employee and 
scheduling another visit, it cost approximately $7.75-$15.50 in salary time per person that 
is non-compliant. If the average non return rate of 10% which would result in $1,550 - 
$3,100 cost for contacting approximately 200 new hires to reschedule visits.  An extra 
PPD placement visit cost $14.51 per person or $2,902 for 200 new hires in staff time and 
supplies. This figure grows if you consider the costs of replacing 10% of 6,800 
employees for annual PPD skin tests. Noncompliance with completion of two step PPD 
within 10 days of orientation can also result in citation by the Department of Health and 
Environmental Services (DHEC), or other regulatory agencies (Jensen et al., 2006). 
Recent DHEC surveys have resulted in survey staff questioning Employee Health’s past 
practice of not reading step one. one A DHEC survey discovered one second step PPD 
not being read which could result in citation or penalty. A citation will reflect negatively 
on the organization and Employee Health. In fall of 2015 and early 2016, the Employee 
Health department reevaluated current practices and implemented processes to expedite 
new hire onboarding time, reduce tuberculosis screening time, improve new hire and 
manager satisfaction, and streamline processes. Some of these changes included adding 
appointment times, additional staffing, and renovation of a storage room to create another 
exam room. However, the largest change was implementation of an IGRA for 
tuberculosis screening. 
Employee Health began verifying all positive tuberculin skin tests with a QFT®-
GIT approximately 2 years before implementation of this study at the advice of the local 
department of health. If the test and symptom review were negative, then the employee 
did not have to be referred to DHEC for evaluation and treatment of LTBI. The test was 
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also utilized for tuberculosis screening for new employees who reported a history of a 
positive tuberculin skin test, but who did not have proper documentation. Staff were 
already familiar with the test and a contract was already in place with a local lab called 




Costs per Visit for New Hire Screening in Employee Health 
 
 
Employee Health average staff salary 
RN  $31 
OHT  $14 
Clerical $14.79 
LPN  $20 
 
Visit 1 Costs 
Clerical 15 min  $3.70 
OHT       1 hr.  $14.00 
RN     1 hr.  $31.00  (PPD placement, 5 min, $2.58)  
Plus PPD cost   $4.36  
Total visit 1   $53.06 
 
Visit 2 Costs 
Clerical   5 min  $1.23 
OHT  5 min  $1.17 
RN  15 min  $7.75 
Total visit 2   $10.15 
 
Visit 3 Costs 
Clerical 5 min  $1.23 
OHT  5 min  $1.17 
RN  15 min  $7.75 (PPD placement, 5 min, $2.58)    
Plus PPD cost   $4.36 
Total visit 3   $14.51 
 
Visit 4 Costs 
Clerical 5 min  $1.23 
OHT  5 min  $1.17 
RN  15 min  $2.58 
Total visit 4   $10.15 
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Total costs all 4 visits (cost of labs excluded) $87.87 
 
Annual cost new hire visits 2,000 new hires per year $175,740  
 
Missed visits 10% average (10% of average 2,000 new hires annually) 
Contacting noncompliant patient staff time 30min15.50  = $3,100 per year  
Cost of one Replacement visit $14.51 per patient = $2,902 Additional Cost of visits for 
noncompliant 200 employees  = $6,002  





Tuberculin skin test was the only available test for TB screening until 2001 when 
Interferon gamma release assays (IGRA) were developed. Interferon gamma release 
assay are blood tests for TB which specifically measure interferon-gamma which is 
released by T cells in response to tuberculosis antigens (Swindells et al., 2009). The first 
approved IGRA was the QuantiFERON®-TB test (QFT®) in 2001, followed by the 
QuantiFERON®-TB gold test (QFT®-G) in 2005, QuantiFERON®-TB Gold In-Tube 
(QFT®-GIT) test in 2007 and the T-SPOT® in 2008. In 2010, the CDC published 
updated guidelines for use of IGRA’s and approved both the QFT®-GIT and the T-
SPOT®. TB for healthcare worker TB screening (Mazurek et al., 2010). IGRA’s can 
potentially overcome issues with TST tuberculosis clearance screening time and 
compliance, as well as problems with inaccurate results. In contrast to TST, IGRA’s do 
not react to nontuberculous mycobacteria or BCG vaccination. IGRA’s can also be 
completed in one visit and eliminate the need for multiple visits. Furthermore, IGRAs 
have been found to have a higher correlation to TB exposure than TSTs improving 
accuracy. IGRA’s are more expensive than TST’s, but utilization is expect to reduce 
costs associated with staffing requirements, inadequate testing results, poor employee 
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compliance follow up, and potential DHEC citations for organization noncompliance 
(Mazurek et al., 2010).    
When a person is exposed to TB, they develop a white blood cell response 
(WBC). When white blood cells are re-exposed to TB, they secrete a small amount of 
interferon-gamma (TFN-ƴ) protein in response. The QFT®-GIT measures the TFN-ƴ 
protein response which is a marker for cell mediated immune response to mycobacterium 
tuberculosis. The procedure for testing includes drawing one milliliter of blood is 
collected in 3 tubes including the nil (negative control), TB antigen, and mitogen 
(positive control). The antigen peptides include ESAT-6, CFP-10, and TB7.7.  All tubes 
are gently shaken 10 times and must be transferred to a 37ºC+ 1 incubator within 16 
hours. Results are measured by TB antigen minus nil and positive is > 0.35 IU/ml. The 
advantages of this test include completion in one visit, result is unaffected by BCG 
vaccination, test has positive and negative controls, and interpretation of results is 
objective (Nienhaus, 2013). 
A potential barrier to implementation of IGRAs is the high cost of the lab test. 
The healthcare system microbiology department lab manager was contacted in 2015 to 
investigate the costs and acceptability associated with implementation of the QFT®-GIT 
or the T-SPOT®.TB for all new hires. The manager advised that the QFT®-GIT would 
be preferred for the healthcare system due to availability of a local external lab that is 
already conducting the test for the organization. This external lab has staff that are 
experienced with the testing and are better able to have consistent test performance than 
the in house lab. Experienced lab personnel conducting the test will ensure accurate, 
quality results and reporting. Furthermore, the manager reported that the T-SPOT®.TB 
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would require extra staff time for packaging to ship. It was discussed that the lab would 
have adequate facilities for incubating the tubes of blood (Frankie Rice, personal 
communication, September 2015). With the assistance of the lab manager, the price for 
the QFT®-GIT was negotiated from $85 to $53. While the QFT®-GIT is more expensive 
than the PPD, cost savings is found when you factor in staff time, and cost savings from 
not having delays in orientation, decreasing the amount of time locum tenens staff are 
utilized, and avoiding regulatory penalties. Onboarding just 2 full time RNs 1-month 
sooner every month would save the organization $129,600 in salaries. Another advantage 
of utilizing the QFT®-GIT is that new hire visits can be completed in 1 visit and 
therefore reducing Employee Health workload and reduced salary costs to track down 
each non-compliant new hire. Reducing each new hire visit from 4 to 1 visit opened up 
additional available appointment times for new hire and other visits increasing visit 
volume capacity in Employee Health. Potentially, this decrease in number of required 
visits would also improve new hire satisfaction with the process. Cost of implementation 
of QFT®-GIT can be a barrier or a benefit, while process improvement is a potential 




Estimated Cost for New Hire screening with QFT®-GIT 
 
Visit 1 Costs 
Clerical 15 min  $3.70 
OHT       1 hr., 5 min. $15.16 (blood draw additional 5 min $1.16) 
RN     55 min  $28.41   
QFT®-GIT   $53.00  
Total visit 1   $100.27 
Result follow up LPN 5 min $1.66 
 
Total new hire screening cost (titers, routine labs excluded) $101.93 
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Total cost 2,000 new hires annual with QFT®  $203,860 
 
Minus Cost of one locum tenens RN per month delayed by 2 step   $64,800 
Total annual cost of new hire screening         $139,800  
Minus cost of two locum tenens RN monthly due to delayed orientation -$129,600 
Total annual cost of new hire screening     $74,260 
 
Comparison 
Annual cost new hire screening  
with 2 step PPD  $175,740 with QFT® $74,240 
 




The purpose of this DNP project was to compare baseline testing for new 
healthcare employees with QuantiFERON®-TB Gold In-Tube Test (QFT®-GIT) to the 
two step PPD TB skin test in regards to tuberculosis screening time, overall onboarding 
time, compliance with tuberculosis screening within 10 days of orientation, and costs. 
This quality improvement project assessed whether implementation of the QFT®-GIT in 
place of the two step TST, met the organizational goal to reduce the number of days to 
complete tuberculosis screening, reduce overall Employee Health onboarding clearance 
time, and improve compliance with completion of tuberculosis screening within 10 days 
of hire date, while maintaining cost-effectiveness.  
Project Question/PICOT 
As a foreground question, among all adult newly hired healthcare employees at a 
healthcare system, how does baseline testing with QuantiFERON®-TB Gold In-Tube test 
(QFT®-GIT) compare with two step PPD TB skin test in regards to time for completion 
of tuberculosis screening, overall onboarding screening time, and compliance with 
screening within 10 days of orientation over a 2-month time frame (see Tables 3 and 4)? 







PICOT  PICOT components 
_________________________________________________________________ 
Population New hire employees at Spartanburg Regional Healthcare System 
 
Intervention QuantiFERON®-TB Gold In-Tube test (QFT®-GIT) for TB        
screening 
 
Comparison 2 step tuberculin PPD skin test for TB screening 
 
Outcome Reduction in completion time for TB screening reduction on overall 
onboarding time, and increased compliance with completion within 10 
days of orientation 
 
Time 2 months: chart review of 2 months with 2 step PPD standard of care, 
compared to 2 months with QFT®-GIT 
__________________________________________________________________ 






Key Terms  Definitions 
 
New Hire Employee  Any person newly hired to work scheduled for   
    health assessment in employee health after offer, prior to  
    orientation. 
 
QFT®-GIT   QuantiFERON®-TB Gold In-Tube blood test screening for 
    latent tuberculosis infection 
 
PPD    Purified protein derivative intradermal skin test for TB  
    screening 
 
Tuberculosis screening Time for employee to complete TB screening. For   
    Tb skin test- time from first skin test to reading of   
    second test. QFT®- time from lab draw to result. 
 
Onboarding Time Number of days from first visit to completion of all 
requirements to begin work including at least one TST 
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placement and reading or QFT®-GIT result, drug screen 
result, lab results, pre-work screen, fit for duty, 
documentation, fit for duties 
 
Compliance   Completion of PPD skin test or QFT®-GIT TB screening  
    within 10 days of orientation. Also, completion of  






 It was assumed that the new employee, employee health employees as well as 
hospital administration prefer for the amount of time it takes to clear employee health 
prior to orientation to be as short as possible. It was inferred that other healthcare 
organizations will prefer this shortened time as well. Another assumption is that the 
procedures in the hospital lab and external lab will be standardized and followed. It was 
assumed that laboratory staff were proficient and have achieved competency in all 
procedures for QFT®-GIT and lab equipment is in working order. It was assumed that 
lab interpretation of positive or negative results was accurate. Likewise, it was assumed 
the Chest X-ray procedures and interpretation was accurate.  
 The Centers for Disease (CDC) is recognized as national experts in tuberculosis 
control. It was assumed that this is true and that recommendations from CDC are best 
practice. Likewise, it was assumed that DHEC regulations are best practice and 
employees of DHEC have expert knowledge.  
 
 




 The healthcare system is required to complete tuberculosis screening on all new 
hire employees through tuberculin skin tests or blood assays for mycobacterium 
tuberculosis (Jensen et al., 2006). Employee Health has traditionally completed the 2 step 
PPD as a method of screening all new hires. Processes for completion of this 2 step 
process can be problematic due to compliance with visits, and false-positives due to BCG 
vaccination or reader interpretation. The 2 step PPD can take 10 days to weeks or longer 
to complete delaying orientation dates for new hires.  Employee health was tasked with 
review of regulations and processes to expedite new hire clearance. Tuberculosis 
screening was targeted in this process review. QuantiFERON ®-TB Gold In-Tube test is 
a blood test for latent TB and was identified as a possible method to overcome barriers to 
TSTs and would help expedite new hire clearance (Mazurek et al., 2010). Tuberculosis 
remains a threat to employees and to the community  (South Carolina Department of 
Health and Environmental Services, 2015). Early detection of TB is essential to stop the 
spread of TB (“National Action Plan to Combat Multidrug-Resistant Tuberculosis,” 
2015). This project examined whether baseline testing with QuantiFERON®-TB Gold 
In-Tube test would reduce tuberculosis screening time, overall onboarding time, and 
improve compliance while remaining cost effective in comparison to the 2 step PPD skin 
test. 






 A literature search was conducted in order to determine if a blood assay for 
mycobacterium tuberculosis would be acceptable for implementation of tuberculosis 
screening of new hires in a healthcare system Employee Health in place of the two-step 
PPD skin test. The primary purpose of the literature review was to answer the PICOT 
question: As a foreground question, among all adult newly hired healthcare employees at 
a healthcare system, how does baseline testing with QuantiFERON®-TB Gold In-Tube 
test (QFT®-GIT) compare with two step PPD TB skin test in regards to time for 
completion of tuberculosis screening, overall onboarding screening time, and compliance 
with screening within 10 days of orientation over a 2-month time frame? The literature 
review focused on articles that pertained to healthcare workers and screening in low 
incidence countries since the United States is considered to be low incidence overall. The 
healthcare system was considered to be low risk by CDC standards, however has been 
medium risk in the past. Therefore, studies that included medium or middle tuberculosis 
incidence were included in the review. The literature review examined whether blood 
assays for tuberculosis met with CDC and DHEC regulations, would be more efficient 
than the two-step tuberculin skin test process, have equal or better accuracy than TSTs, 
and be cost-efficient.  
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Literature Search Strategy 
 In order to make evidence-based practice change, clinicians should conduct a 
thorough search of peer-reviewed research (Melnyk & Fineout-Overholt, 2015). Thomas 
Cooper Library database links were used to browse different databases including 
CINAHL, PubMed and Science Direct. Keyword searches included a combination of 
IGRA, Interferon gamma, tuberculosis screening, quantiferon, employee, healthcare 
worker, and tuberculosis (see table 4). An initial search on Science Direct of “IGRA” 
revealed too many results which needed to be filtered to obtain applicable evidence. A 
search on Science Direct for keywords “Tuberculosis screening” and “employees” 
revealed 2,095 results. When this result was filtered for 2010-2016 there were 32 articles 
found, but these did not meet the inclusion criteria. Science Direct was searched for 
Quantiferon which revealed 2,181 results. Many of these results were not specifically 
about quantiferon and some were in other languages. The search was for 2016 and found 
65 results. The strategy was adjusted and this author searched keywords “quantiferon” 
and “employee”, 2008 to present and found 87 results with a few relevant articles. Then 
PubMed was searched for keywords “IGRA” and “Tuberculosis” and found 596 results. 
Filters of 5 years and newer was then added which narrowed it to 450 results. When a 
third keyword of “employee” was added in addition to “IGRA” and “Tuberculosis”, 
PubMed revealed 4 results with 1 applicable study. PubMed was searched for keywords 
“Quantiferon” and “healthcare workers” for the most recent 5 years and found 77 results. 
CINAHL proved to be the most user friendly for this author and all of the above the 
search strategies were utilized with multiple results found. A search for keywords 
“tuberculosis” and “IGRA” revealed 120 results with a few articles selected. The most 
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specific search that was helpful was “tuberculosis” and “employee” and “interferon 
gamma” which revealed 10 good results (see Table 2.1). Reference lists from the 
reviewed articles were also utilized to identify a few selected articles. Any articles that 
this author could not find full text articles for were obtained through the Thomas Cooper 
Library interlibrary loan request. During the course of the peer review, this author 
contacted South Carolina Department of Health and Environmental Control (DHEC) for 
guidance regarding a cluster of positive QFT®s with borderline results. The Columbia 
DHEC office referred this author to Dr. F Richard Ervin, regional TB clinician district 4 
who emailed relevant articles regarding QFT® cutoff and conversions which was 
incorporated into the table (Dr. F Richard Ervin, personal communication, March 2016).  
Initially selected articles included approximately 40 articles that were reviewed and 





Keyword   Combination of keywords 
IGRA    IGRA and Tuberculosis 
Tuberculosis screening Tuberculosis screening and employees 
Quantiferon   Quantiferon and employee 
Employee   Quantiferon and healthcare worker 
Healthcare worker  Tuberculosis and IGRA 
Tuberculosis   IGRA and tuberculosis and employee 














Criteria for inclusion/exclusion 
 
Inclusion criteria    Exclusion criteria 
 
English     Non-English 
Low or Medium TB risk setting  Single study primarily in High TB risk 
Published in 2005 and newer   Published prior to 2005 
Included any version QFT®   Only examined TST 
Included T-SPOT®.TB   Studies including only children 




  Inclusion criteria included studies published in English conducted in low or 
medium TB incidence settings from 2005 to present with relevant information to IGRA 
testing in healthcare workers including QFT®, QFT®-TB Gold, QFT®-GIT, or T-
SPOT®.TB. Studies were excluded that were conducted primarily in high TB incidence 
settings, did not include healthcare workers, were published in other languages, and those 
that were primarily about children or immune compromised patients (see table 5). The 
Centers for Disease Control updated guidelines were examined first to determine if 
utilization of Interferon Gamma Release Assays (IGRA) would meet required regulations 
before proceeding with the PICOT and literature search (Mazurek et al., 2010). Initially 
this author tried to limit articles to 5 years but did not find the required number of 
relevant articles. Since the QuantiFERON®-TB Gold was developed in 2005 and the 
CDC guidelines were written in 2005, articles were limited to those published in 2005 to 
present with focus on newer articles. The main inclusion articles of interest were studies 
that examined baseline IGRA testing of healthcare workers. Articles were included that 
examined IGRA alone with single or multiple retests, or IGRA with Tuberculosis skin 
test (TST) conducted separately or simultaneous. Studies that only examined non-
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healthcare workers were excluded unless this was a small portion of a larger study. 
Studies were included that examined IGRAs in low or moderate incidence countries since 
the setting for this project is in a low to medium TB risk setting. Studies that looked at 
IGRAs in high-incidence settings or countries were excluded unless they were part of a 
larger study that also included low-incidence setting. Articles on cost-effectiveness of 
IGRAs were also included in order to examine financial feasibility for the project. There 
were not many articles directly related to new hire tuberculosis screening time and 
compliance, but two specific ones were found. Due to the concern regarding false-
positives and at the direction of DHEC, studies regarding QFT®-GIT cutoff values and 
retesting were included (see Table 2.2). Overall, there was good evidence to continue on 
with the PICOT question and study (see Appendices A for full evidence table).  
Literature Analysis 
 Twenty-three studies were included in the review of the literature. The articles 
were classified into levels I through IV according to John Hopkins Research and Non-
Research evidence appraisal tools (Dearholt & Dang, 2012). Level I includes 
experimental studies, II quasi-experimental, III Non-experimental, IV clinical practice 
guidelines, consensus or position statements, and level V literature review, expert 
opinion, community standard, clinician experience, and consumer preference (see 
Appendices B for level and quality guide). Of the 23 articles analyzed there were four 
level II articles, seven level III, two level IV, and 10 level V (see Table 2.3). Quality of 
the articles were also analyzed as shown in table 5 according to John Hopkins appraisal 
tools with ratings of A- high quality, B- Good quality, and C- Low Quality (Dearholt & 
Dang, 2014). All of the studies were conducted in the United States with the exception of 
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two in Germany that report that the study was conducted in low incidence settings (Diel, 
Loddenkemper, Meywald-Walter, Gottschalk, & Nienhaus, 2009; Schablon, Nienhaus, 
Ringshausen, Preisser, & Peters, 2014). Most of the studies focused on healthcare 
workers with the exception of 4 studies that included healthcare workers as well as other 
groups such as close contacts but all were published in English (Banaei, Gaur, & Pai, 
2016; Diel et al., 2009; Pai, Zwerling, & Menzies, 2008; Rangaka et al., 2012). The 23 
articles were published by 18 different journals or sources (see table 2.4). The articles 
reviewed were classified according to type of study which includes quality improvement, 
clinical practice guidelines, quasi-experimental, systematic review, financial, program 
evaluation, expert opinion/literature review, and case report (see table 2.5). 
Table 2.3 
Quality Ratings per evidence level 
 
# of Articles in Quality Rating 
Level   A-High B-Good C-Low 
II   1  3  0 
III   3  4  0 
IV   2  0  0 














American Journal of Respiratory Critical Care Medicine 2 
Annals of Internal Medicine 1 
Archives of Internal Medicine 1 
BMC Health Services Research 1 
Chest 2 
Infection Control & Hospital Epidemiology 1 
Journal of American College Health 1 
Journal of Clinical Microbiology 1 
Journal of Hospital Infection 1 
Journal of Occupational & Environmental Medicine 1 
Journal of Occupational Medicine & Toxicology 1 
Lab Medicine 1 
Lancet Infectious Disease 1 
MMWR 2 
PLoS One 1 
Qiagen 2 
Thorax 1 





Categories of Articles   Total 
 
Case Report    1 
Clinical Practice Guidelines  2 
Correlational    1 
Expert Opinion/Lit. review  3 
Financial    1 
Program Evaluation   2 
Quality Improvement   3 
Quasi-Experimental   4 
Systemic Review   6 
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Evidence level II, high quality (A) articles. 
  A longitudinal study of healthcare workers at four organizations undergoing 
tuberculosis screening from February 2008 through march 2011 was conducted (Dorman 
et al., 2014). The purpose of this study was to assess the performance of IGRAs for serial 
testing of healthcare workers compared to tuberculin skin test (TST). The sample 
included 2,563 healthcare workers in Denver, Colorado; Houston, Texas; Baltimore, 
Maryland; and New York City. Healthcare workers with a history of TB, TST within the 
past 6 months, and those with history of anaphylactic reactions to TST reagents were 
excluded from the study. Initially participants were interviewed regarding demographics, 
occupations, TB exposure, history of LTBI and BCG status. Then blood was drawn for 
T-SPOT®.TB and QFT® followed immediately by TST. Participants had a second TST 
in 1-3 weeks if they did not have another TST in the past 12 months. Participants had 
repeat interview, QFT®, T-SPOT®.TB and TST at 6, 12, and 18 months. Those with a 
positive TST were asked to have a repeat TST. There was a sub-study wherein 
participants had blood drawn two weeks apart without a TST in-between and by drawing 
two sets during a single blood draw. It is important to note that mid-study, participants 
had repeat ELISA testing for all positive tests because there was a higher than expected 
rate of conversion. Another sub-study was conducted in which participants with baseline 
negative IGRAs had repeat IGRA in 7-21 days. Statistical analysis included K coefficient 
for agreement, two-proportion Z-test for independent proportions and McNemar’s test for 
dependent proportions. Multiple comparisons were assessed by Holm-Bonferroni method 
and mean changes were compared by t test. Linear mixed-effects models were used and 
confirmed by residual plots. SAS 9.2 was used for calculations. Results show a 6.1% 
   
26 
 
(138 of 2,263) conversion rate for QFT®-GIT, 8.3% (177 out of 2,137) conversion for T-
SPOT®.TB, and 0.9% (21 out of 2,293) for TST. There was a statistically significant 
difference in conversion rate of QFT®-GIT compared to TST (p<0.001). Baseline testing 
results showed 125 positive TSTs (5.2%), 118 positive QFT®-GIT (4.9%) and 144 
positive T-SPOT®.TB (6.0%). The rate of positives in the IGRA groups was not 
significantly higher than the TST groups. Agreement of test results for those with triple 
positives was high with agreement between TST and QFT®-GIT 93.2%, 91.2% for TST 
and T-SPOT®.TB, and 93.8% between QFT®-GIT and T-SPOT®.TB (95% CI for all 
comparisons). There was a higher rate of baseline positive TST and negative IGRAs in 
BCG vaccinated participants (odds ratio 33.4). There was a 53.7% reversion of baseline 
positive TSTs in 29 out of 54 participants. Likewise, there was baseline reversion from 
positive to negative for QFT®-GIT of 56.8% (67 of 118) and 63.9% for T-SPOT®.TB 
(92 of 144) without statistically significant differences in comparison between the groups. 
Those with higher baseline values for QFT®s had lower rates of reversions but there was 
no difference in the T-SPOT®.TB group. Test conversions during this study were 0.9% 
for TST, 6.1% QFT®-GIT, and 8.3% for T-SPOT®.TB which was significant for TST vs 
QFT®-GIT and for T-SPOT®.TB (p<0.001) but no significant difference between 
QFT®-GIT and T-SPOT®.TB. When converters were retested in 6 months, 76.4% (81 of 
106) QFT®-GIT positive tests reverted and 77.1% (91 of 118) of T-SPOT®.TB. It is 
important to note that not one participant converted in all three tests at once and there was 
no association with TB exposure for any of the conversions. In the sub study that was 
retested in 2 weeks, 7.5% of QFT®-GITs changed from negative to positive and 8.1% for 
T-SPOT®.TB. In the positive testes, 33.3% and 52.6% reverted for QFT®-GIT and T-
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SPOT®.TB respectively. In the sub study that had two sets of blood drawn in one visit, 
there were discordant results in 5.8% for QFT®-GIT and 6.5% for T-SPOT®.TB (p=.39). 
When a subset of samples was retested by ELISA in 8 days, all negatives remained 
negative, but 27 out of 114 positives turned negative. An intervening TST boosted 
QFT®-GIT in 9.1% and 11.3% for T-SPOT®.TB and those with baseline positive TST a 
boosting affect. The authors conclude that conversions of IGRAs over 18 months 
occurred 6-9 times more often than TST which demonstrates false-positives and a need 
for retesting of converters. The authors did not feel that changing the cut point would be 
helpful since this only attributed to 15-18% of conversions in this study (Dorman et al., 
2014). 
 The prospective study by Dorman et al. (2014) is a level II comparative study, 
quality A high  study. This is an example of a prospective comparison study of which 
there are few for IGRAs. The authors analyzed several conversion factors by statistical 
methods. The sample size was sufficiently large and spanned different areas of the US 
but each were in larger metropolitan areas. The authors report the limitations of limited 
generalizability to groups with immunosuppression and limited generalizability for other 
higher incidence countries. There was also some attrition in the TST repeat groups 
(Dorman et al., 2014). This study was very thorough and has good applicability to this 
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Evidence level II, Good quality (B) articles. 
 The Switch study was conducted to determine what cost an IGRA would need to 
be in order to cost less overall than the tuberculin skin test for health care employees 
(Wrighton-Smith, Sneed, Humphreys, Tao, & Bernacki, 2012). All of the actual costs for 
materials and employee health staff labor costs involved with tuberculosis screening were 
gathered from a large healthcare facility’s finance records. The setting was John Hopkins 
in Baltimore, Maryland that screens about 18,000 employees annually with the TST. 
Secondarily, 393 random employee encounters were selected for time motion study to 
measure the time it takes to complete each step with the TST including data entry as well 
as time for the IGRA lab draw as well as how much time away from work the employee 
had to take for testing. This study also randomly invited new hire and annual employees 
to participate in parallel testing of T-SPOT®.TB and TST with a total sample of 750 (473 
annual, 270 new hires). Of the 113 employees (69 foreign born) with a previous history 
of positive TST, two thirds had negative IGRA. The nonreturn rate for TST was 10%, 
while only 0.4% of IGRA results were unavailable. The IGRA test also showed a lower 
rate of positive results than the TST in new hires. Questionnaires completed by 
participants revealed that 62.3% preferred the IGRA to the TST. The cost model revealed 
that when considering non return rates, the average cost for TST for annuals was $73.20 
and $90.80 per new hires. The IGRA costs overall $78.05 per annual screening when 
adding in labor and supplies, and $64.47 for new hires. The IGRA would save money if 
the test costs $54.83 or less per test for each new or current employee. A sensitivity 
analysis was also conducted to determine which of 38 variables had the most effect on 
the cost model. None of the variables had much effect beyond 0.75 cent except for labor 
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cost. Labor costs would impact the overall cost due to higher costs for time off work. If 
employees made 20% higher salaries, then IGRA would save money if it was $61.16 per 
test (p value not provided). The sensitivity analysis of variables was shown in a bar graph 
and statistical significance was not revealed. In conclusion, the authors report that the 
IGRA saves money and improves compliance rates for health care employee tuberculosis 
screening (Wrighton-Smith et al., 2012). 
 This Switch study was rated level II and quality B. The strengths of this study 
include that the study did have some elements of random selection and it did a parallel 
comparison of the TST and T-SPOT®.TB. The study also supports the conclusion that 
non-return rates for the TST affect cost. There may be potential bias in this study since 
the manufacturer of T-SPOT®.TB, Oxford Immune provided the test free of charge and 
provided John Hopkins a grant of $49,300 for the study (Wrighton-Smith et al., 2012). 
The salaries had to be weighted and estimated to give an estimate of the average hourly 
wage. This could have skewed the results. A more accurate direct measure would have 
been to use the exact salary of each participant. The authors report the limitation that the 
study considered the TST and IGRA to be equally accurate. Descriptive statistics were 
described, rather than statistically significant testing. This is probably not necessary for 
the cost result, but would be important to ascertain for parallel testing of results. Overall, 
this is a good study to support this project.  
 Cummings et al. (2009) conducted a study of newly hired healthcare workers at 
West Virginia University prospectively comparing the tuberculin skin test and QFT®-
GIT. A convenience sample of 182 out of 266 invited new hires from June 2007 to 
February 2008 was obtained by offering 2 QFT®-GITs to all new hires who were having 
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a TST. The QFT®-GIT was drawn first, followed by the first TST up to 3 weeks later, 
followed by a second QFT®-GIT and second TST if needed 1 week later. A unique 
feature of this study was that any indeterminate or positive QFT®-GIT was retested in 
the lab by ELISA. If the positive results agreed, then the result was confirmed. If the 
results did not agree, a third test was conducted and the mean of the values was used. In 
order to determine specificity, the study assumed that participants who had no risk factors 
for TB did not have latent TB. The study used mixed-model repeated measure analysis of 
variance (ANOVA) to compare results of first and second QFT®-GIT results and timing 
of TST was considered as a variant. The sample included 96% born in the US, 93% 
without BCG vaccination, and 62% having no risk factors reported for TB. For initial 
testing, the TST and QFT®-GIT had 96% agreement of negative results (both results 
were negative) but no agreement on positive results (none had both positive TST and 
QFT®). It was determined that specificity for the TST was 99% and QFT®-GIT 98% for 
healthcare workers that reported no risk factors. Eighty-five participants completed the 
second blood test and out of these two of the participants with initial negative QFT®-GIT 
results had subsequent positive results. The authors considered both blood test results and 
found that 4 had positive blood tests but negative TST, while 3 had positive TSTs but 
negative QFT®-GIT results. Only one participant had both a positive QFT®-GIT and 
TST. Sixteen indeterminate results were repeated in the lab by ELISA and 11 remained 
indeterminate while 5 were negative. The study found that employees with diabetes or 
who were on immunosuppressive therapy had greater odds of having an indeterminate 
result (rate 6.8, 95% confidence interval). Out of the 5 positive results, 2 were confirmed 
positive. This study did not find any statistically significant difference between the first 
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and second QFT®-GIT results. The INFƴ result for participants that had only 1 TST 
showed a mean increase of 0.02 which was statistically different (p=.04). The authors 
conclude that overall agreement and specificity for the TST and QFT®-GIT was good 
due to the fact that there was a high rate of negative results, but positive results did not 
agree. Retesting of samples in the lab may improve diagnostics due to the reversion of 
follow up testing. There was a small boost in IFN-ƴ results from the TST which may 
limit testing. Immune status of participants should also be considered due to increase in 
indeterminate results. The authors state that the QFT®-GIT may be beneficial due to 
fewer visits required for QFT®-GIT as compared to multiple visits for the TST 
(Cummings et al., 2009). 
 This study by Cummings et al. (2009) is level II with rating of good quality. The 
study is good in that it compared both QFT®-GIT and TST tests and included statistical 
analysis. The authors have clear discussion of the results, but do not assert which testing 
is recommended. However, the study had important findings to consider when 
determining whether to retest employees when QFT®-GIT are positive or indeterminate. 
This setting is low- incidence which is relevant to this project, but would limit 
generalizability to other settings. A limitation is that the study lacks randomization and 
only 47% returned for the second blood rest resulting in attrition bias (Cummings et al., 
2009). The authors assumed that employees without risk factors for tuberculosis did not 
have LTBI which could have skewed results. The sample included 96% United States 
born and 93% did not have BCG vaccination which could limit generalizability to other 
countries (Cummings et al., 2009).   
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 Diel, Loddenkemper, Maywald-Walter, Gottschalk, and Nienhaus (2009) 
conducted a study to assess agreement between the QFT® and T-SPOT®.TB in 
comparison to people with positive TSTs who had recently been exposed to tuberculosis. 
The sample included 2,004 people who were close contacts of patients with culture 
confirmed tuberculosis, which were reported to the Hamburg Public health department 
from December 2006 through February 2008. Six people were excluded from the study 
because they had already had contact investigations, and seven did not follow up for 
testing. Eight hundred and forty-two contacts tested positive by TST and had subsequent 
QFT® and T-SPOT®.TB testing. Twenty- two were eliminated because the T-
SPOT®.TB could not isolate sufficient lymphocytes. Results were indeterminate for 7 T-
SPOT®.TB and 1 QFT®. The final sample was 812 TST positive contacts who were 
exposed to 123 tuberculosis patients. The results revealed 245 (30.2%) positive QFT®s 
and 233 (28.7%) positive T-SPOT®.TB. The rate of negative IGRA results significantly 
increased in the BCG vaccinated groups with 140 negative T-SPOT®.TB (versus 93 
positive) and 146 negative QFT®s (versus 99 positive) (p<0.0001). Statistical analysis 
revealed high agreement between the QFT® and T-SPOT®.TB with k value of 0.852, 
95% confidence interval. Furthermore, QFT® and T-SPOT®.TB were more statistically 
likely to be positive if the patient coughed in the presence of the contact (p<0.0001 for 
each). There was also a statistically higher rate of IGRA positive results for those with 
higher exposure time (p<0.0001) and those with contact with AFB positive patients 
(p<0.0001). Those with exposure >40 hrs. to AFB positive patients had a 6 times higher 
positive rate than those with < 8 hours of exposure and twice as likely in the AFB smear 
negative sources. It appeared that higher cutoffs for TST positive results showed greater 
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association with positive IGRAs. Those with TST result of >15 mm had 68.3% positive 
QFT® and 87% for T-SPOT®.TB. However, this agreement decreased to 56.7% and 
54.4% for patients with TST positive results of 11-15 mm and decreased further to 14.2% 
and 12.9% for those with TST of 6-10 mm. Multiple regression analysis showed a 
statistically significant relationship between increase age (p=.003), and foreign birth 
(p<0.001), source AFB-positive contacts (p<0.001) and positive QFT® and T-
SPOT®.TB results. Overall, the QFT® and T-SPOT®.TB had good agreement of 93.9% 
and were associated with increasing exposure risk factors. Metanalysis revealed the 
QFT® to be more specific for active TB than the T-SPOT®.TB but less sensitive, 
however in actuality there were more positive QFT®s found than T-SPOT®.TB. 
Specificity of the TST was poor (64.5%) for those with TST cutoff of >5 mm if you 
consider that patients with positive results to both QFT® and T-SPOT®.TB had true 
infection. The authors conclude that the QFT® or T-SPOT®.TB is more accurate 
indicators of LTBI than TST and  utilization would decrease the number of patients with 
suspected LTBI by 70% (Diel et al., 2009). 
 The article by Diel et al. (2009) is rated level II, good quality. There is excellent 
prospective comparison of the TST and QFT® and T-SPOT®.TB. Not many studies have 
conducted these analyses with statistically significant results. This was a convenience 
sample which can lead to some selection bias. There was just a small attrition in this 
study. Multiple statistical tests were applied which result in statistically significant results 
by chance (Melnyk & Fineout-Overholt, 2015). This article is relevant to this project in 
that it shows that QFT® is associated with greater likelihood of exposure to tuberculosis.  
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Evidence level III, high quality (A) articles. 
Schablon, Nienhaus, Ringshausen, Preisser, and Peters (2014) performed a large 
scale study of serial QuantiFERON® Gold in Tube (QFT®) tests on 3,823 healthcare 
workers in Germany. Participants included a convenience sample selected by 
occupational health physicians from 32 different hospitals, nursing homes and out-patient 
centers from 2006 through 2013. Each participant signed a written informed consent and 
physicians collected information regarding age, gender, reason for the test, exposure to 
TB, work history, history of TB, birth country, and tuberculosis screening results. 
Statistical analyses were performed by SPSS version 21 and included Chi-square, 
adjusted odds ratios, 95% confidence intervals, and logistic regression models. At 
baseline, there were 318 positive QFT®s (> 0.25 IU/ml) which is 8.3% of the sample. 
There were four variables found to be associated with positive QFT®s including age > 55 
with odds ratio 6.89 (95% CI), foreign birth odds ratio 2.39 (95% CI), personal or family 
history of TB with odds ratio 6.23, and place of work. Interestingly, there was no 
association with job title (RN versus MD, etc.) or with the reason for the testing 
(screening versus contact investigation). Out of the sample, 817 had repeat QFT® testing 
from 7 days to 48.6 months apart. The amount of time between testing had no difference 
in conversion, reversion, or results that did not change. 97.2% of those with negative 
baseline tests had consistently negative QFT® results (721 out of 742) and 62.5% were 
consistently positive (47 of 75). The odds of remaining positive increased from 2% to 
18% for those over 55 years of age. Age did not appear to affect conversion or reversion 
rates. Those who were foreign born outside of Germany had higher reversions rates of 
7.8% versus 2.7% German born. Conversions on serial testing after baseline occurred in 
   
35 
 
2.8% (21 out of 742) and reversion rate of 37.3% (28 out of 75). If the definition of 
QFT® result was changed to a borderline zone of 0.2 to <0.7 IU/ml, then conversions 
would decrease to 1.1% and reversions to 18.8%. If the definition of conversion was 
changed to 1.0 or 3.0, then conversion rates decreased even further to 1.0% or 0.4% 
respectively and the reversion rate changed to 18.6% or 11.1%. The authors conclude that 
a borderline interpretation zone of 0.35 to 0.7 or 1.0 IU/ml would be safe and reduce the 
number of chest x-rays for healthcare workers without symptoms of TB in countries with 
low TB incidence (Schablon et al., 2014). 
 This study by Schablon et al. (2014) is a level III correlational, quality B Good 
study. The authors discuss the limitations of using a convenience sample with selection 
bias. The occupational health physicians did not have a strict study protocol for schedules 
of retesting or selection of groups to test (Schablon et al., 2014). There appears to be a 
preconceived bias by the authors that there should be a borderline testing zone, however 
it does not appear that the authors directed the physicians to retest participants in this 
zone. There was no specific inclusion or exclusion criteria for participant selection to 
control for any variables. The sample size was sufficiently large at 3,823. 
Generalizability to US healthcare workers could be limited since this study was 
conducted in Germany and authors report that from literature there is a historical positive 
rate of TSTs to be 24-50% in healthcare workers. This would not be the general result 
that is found in the US. Furthermore, 45.5% of participants had BCG which did not affect 
the odds ratio for positive QFT®s (Schablon et al., 2014). This high rate of BCG 
vaccination might not be found in the US. It would be helpful to know the number of 
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foreign born US participants in this study. A comparison with TST would strengthen this 
study. 
 Lamberti et al. (2015) conducted a system review of the literature with meta-
analysis with the purpose of reviewing healthcare worker screening with TST and QFT® 
test agreement and association with BCG vaccination and TB incidence. The authors 
searched PubMed for articles from January 2004 through October 17, 2013 with 
combination of search words “workers”, “tuberculosis”, “TB infection”, “TB disease”, 
“TB”, “tuberculin skin test”, “Tuberculin skin testing”, and “quantiferon”. The Preferred 
Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) was utilized for 
the review and meta-analysis. Studies included were cross-sectional or longitudinal 
articles about screening of healthcare workers with TST and QFT®, and comparison of 
the tests as well as those with vaccination information. Studies were excluded that were 
case reports and those that were about patients with immune system diseases or HIV. 
Twenty-nine studies were chosen out of 1,430 abstracts. The authors considered the 
QFT®-TB Gold and the QFT®-GIT to be QFT® for purposes of analysis. Cohen’s k was 
used with a confidence interval of 95% calculated. Meta-regression was used to examine 
the covariates. The selected articles included 10 studies in low TB incidence settings, 7 
intermediate and 7 high incidence settings. Studies were excluded that did not define a 
positive PPD at cutoff of 10 mm. The sample size was 10,314 with patients with 
indeterminate results being excluded. Results regarding agreement between the tests 
showed that 6,893 tests agreed for TST and QFT®, while 3,421 did not. TST positive and 
QFT® negative occurred four times more often than TST negative and QFT® positive. 
The Cohen’s K for agreement between the TST and QFT® overall was 0.28 with 95% 
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Confidence Interval which the authors report is low and shows that 33% of the time the 
tests do not agree. However, this improved to 0.38 for high incidence settings while 
intermediate was 0.19 and low incidence 0.25 Cohen’s k. The intermediate group had the 
worst agreement and was significantly different than the high incidence (p=0.041). 
However, the intermediate group had the highest BCG vaccination rate. When the sample 
was divided by low and high BCG vaccination rates, the group of studies with the lower 
rate (15 studies) had a Cohen’s k of 0.34 and the higher group (9 studies) was 0.17. The 
authors conclude that TST should be used in areas with low vaccination rates or high 
incidence of TB, while QFT® is helpful in settings with high incidence of TB. Providers 
should consider that the QFT® higher specificity for mycobacterium tuberculosis may be 
causing the differences in test results because the TST reacts to nonspecific antigens 
(Lamberti et al., 2015). 
 The systematic literature review by Lamberti et al. (2015) is a level II study with a 
quality rating of A High. This study applied statistical analyses to multiple articles to 
generate new statistics. A table is provided with the variables of interest for each study. 
The sample size was very large. The review included articles dated to 2004, but all 
studies were relevant to QFT® testing in healthcare workers. One limitation is assuming 
that the TST which measures nonspecific antigens is a valid indicator of LTBI when 
comparing agreement with QFT® which tests specific mycobacterium antigens. 
Therefore, the QFT® should reduce false-positives which would result in discordant 
agreement between the tests. Another limitation of the review was the combined testing 
of the QFT®-G and QFT®-GIT. It would be beneficial to examine whether there was a 
difference between the QFT®-G and QFT®-GIT improved testing.  
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 Zwerling et al. (2012) completed as systematic review of the literature regarding 
IGRAs for healthcare worker screening. The authors searched PubMed, Embase, Biosis 
and Web of Science for all articles up through 2010 and included sources from 
conferences, article references, and references from experts and test manufacturers. A 
total of 50 articles were reviewed with 44 that examined LTBI prevalence and incidents, 
agreement of IGRA results or agreement between IGRA and TST. Three of the studies 
were included regarding cost-effectiveness and three on feasibility. Of the 44 main 
studies, 35 studied QFT® only, 3 T-SPOT®.TB only and 6 studied both. Five of the 
studies were conducted in high incidence settings. The total sample across the studies was 
11,963 healthcare workers. Fisher exact 95% confidence interval was calculated for 
prevalence estimates. Three cross sectional studies from in India, Russia and Vietnam 
were included, but the Russian study did not perform TST. The India and Vietnam 
studies showed a high positive rates for IGRA in healthcare workers of 40-60%. The rate 
of IGRA positives was only slightly lower than TST positive in the two studies. The 
prevalence between the TST and IGRA was only statistically significant (statistic not 
provided) in the Vietnam study which had a lower BCG vaccination rate of 37.3% 
compared to 71% in the India study. Thirty-one of the studies were from low or 
intermediate risk settings. Out of 25 studies, 24 showed lower prevalence of positive 
QFT® or T-SPOT®.TB compared to TST with 17 statistically significant (p value not 
provided). There did not appear to be an association between BCG vaccination and 
higher prevalence of positive TST or difference between the tests. Agreement between 
the TST and IGRA was weak with more common TST positive and IGRA negative 
results with k values from 0.05 to 0.56 with agreement improving if TST cutoff was 
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increased to 15 mm. in 14 studies in low incidence countries, there was an association 
between positive IGRA results and occupational risk factors for TB such as working in 
high risk TB units, working in TB clinics or geriatric areas and longer employment 
duration with two studies not finding this association. Four studies showed relationship 
between foreign birth or history of living in high TB incidence country and positive 
QFT® results with 3 showing correlation with TST positive. One study did not find this 
association with foreign birth but it was the only study that used T-SPOT®.TB. Two 
studies in high incidence settings showed IGRA conversion rates of 11.6% and 21%. 
Only four studies examined conversion rates in low incidence settings and ranged from 
1.8 to 14%. Three studies showed reversion rates for IGRAs to be 40-52.9%. Two more 
recent studies showed that conversion and reversion rates were more stable when the 
IGRA results were higher than those close to the cutoff. The authors concluded that use 
of IGRAs for baseline would result in lower positive rates and few treated for LTBI, 
however conversions for serial testing may result in healthcare workers taking 
preventative medications on subsequent testing. The authors conclude that guidelines for 
serial testing of IGRAs should be reviewed due to issues with conversions and reversions.  
 The study by Zwerling et al. (2012) is a level II systematic review that is rated A 
high quality. The search strategy was comprehensive and the sample size large. 
Characteristics of each study are displayed in tables with an online supplement for 
review. The authors report limitations of the study including lack of reporting of HIV 
prevalence in the studies, inherent publication bias, and a lack of evidence at the highest 
hierarchy. A limitation was noted in the review of all studies that combined QFT®s 
together as one test methodology. The review included studies from different countries 
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which could limit generalizability to US populations. The study would have been 
strengthened by meta analysis. Overall, this article is high quality and relevant to this 
project.  
 Rangaka et al. (2012) conducted a systematic literature review with meta-analysis 
to assess whether IGRAs can predict the development of active TB compared to TST. 
This review included 15 studies found through search of PubMed, Embase, Biosis, Web 
of Science, bibliographies from other reviews, and expert recommendations. Studies 
included longitudinal studies of adults or children who did not have active TB at the 
study onset with the primary objective of predictability of IGRAs for TB by ELISA, 
ILISPOT, commercial or noncommercial assays. Statistical analysis included Newcastle-
Ottawa quality assessment scale, incidence rate ratios, calculated risk ratios, 
DerSimonian and Laird random-effects with 95% CI. Seven of the reviewed studies 
showed a higher rate of positive IGRAs at baseline for those that developed TB (n=9,530, 
IRR 2·10, 95% CI). In five studies there was no statistically significant difference 
between the progression to active TB for people with TST positive versus IGRA positive 
results (IRR 2·11, 95% CI). Studies that used ELISPOT showed a sensitivity of 72% 
(95% CI) for developing active TB and specificity of 50% with TST sensitivity of 72% 
and specificity of 41%. The risk for developing active TB in positive IGRA people was 
low. The authors concluded that the association between IGRAs and active TB 
development is weak to moderate and no test is available that has high prognostic value, 
and therefore, decisions regarding testing should be based on logistics, population type, 
cost and patient preference (Rangaka et al., 2012). 
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 The study by Rangaka et al. (2012) is a level III systematic review with meta-
analysis high quality. The study had a very large sample size. The application of 
statistical analyses provides value and strength to the study although the article is very 
technical and difficult to understand. The authors noted that most of the reviewed studies 
had bias by not accounting for risk factors for TB, and did not fully answer whether 
IGRAs are predictive of TB. The authors also note that most studies were not in high 
income countries and most had industry involvement (Rangaka et al., 2012).  
 Evidence level III, good quality (B) articles. 
 Swindells, Aliyu, Enoch, and Abubakar (2009), conducted a literature review of  
82 articles related to healthcare workers and interferon-gamma release assays. PubMed 
was used to find articles published from 1990 through 2008 with the combination of 
search words health care, health care worker, doctors, nurse, medical staff, tuberculosis, 
TB, quantiferon, elispot, IFN, interferon, IFNƴ assays, t cell assays, ESAT-6, CFP10, or 
rd1 antigens. The results were published in narrative and no meta-analysis was 
conducted. A total of 22 articles met the inclusion criteria with 2 about T-SPOT®.TB and 
20 QFT® articles. Out of 11 articles, 9 found that the TST and QFT® results did not have 
good agreement while two found good agreement in high incidence countries (CI 95%). 
The studies that were examined regarding healthcare worker and BCG vaccination status 
had varied results. Two of the studies found agreement between TST and QFT® in those 
without BCG vaccination (kappa 0.676, kappa 0.649) but poor agreement in BCG 
vaccinated (Kappa 0.090 and 0.029). But two studies did not find any difference in 
results according to BCG status (84.2% concordance without BCG and 80.2% with 
BCG). Three of the studies did find that positive QFT®s was more closely related to 
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increasing TB exposure for healthcare workers (p value not provided).  Another reviewed 
study also found that the QFT® was more likely to be positive for healthcare workers 
that were older and had worked longer in health care. Likewise, a Swiss study reviewed 
showed that healthcare workers in higher risk departments were more likely to have a 
positive QFT® (p= 0.03). One Italian study did not agree with this assessment and did 
not find any correlation between professional category and QFT® result (p value not 
provided). Studies that examined contact investigations found that positive QFT®s were 
more likely associated with exposure than positive TSTs (p < 0.05). When examining 
articles regarding conversions/reversions, there was one that showed a 24% QFT® 
reversion rate, one showed good QFT® reproducibility, and one that reported a 
significant increase in QFT® results in repeat testing over time (CI 95%). The authors 
reported that overall there was poor agreement between the TST and QFT® in healthcare 
workers in high incidence countries, however this discordance most likely is due to false 
positive TSTs in BCG vaccinated individuals. The authors report that the QFT® was a 
good marker of TB exposure in contact investigations. It was concluded that IGRAs are 
important to screening and prevention of tuberculosis for healthcare workers (Swindells 
et al., 2009). 
 The study by Swindells et al. (2009), is a level III systematic review of the 
literature rated good. The literature review used a reputable database (PubMed) and had 
clear criteria for inclusions and exclusion. However, the reviewed articles were published 
within the past 18 years which is longer than recommended. This long period of time may 
have been necessary due to limited research regarding QuantiFERONs® since the test 
itself was fairly new at the time of publication. The authors published results in Euros and 
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did not report p values or confidence intervals. Several assumptions were made regarding 
specificity and sensitivity of the TST and QFT®. The authors did not specify which 
QFT® was used in the reviewed studies and QFT®s only became approved in 2001. 
Different types of QFT® could have altered the results since newer versions of the test 
are considered to be more accurate. The authors did not discuss the limitations of the 
articles reviewed. The authors mentioned that there were only 2 studies that assessed the 
T-SPOT®.TB and therefore there was not adequate evidence for its use in healthcare 
workers at the time. Another limitation was that the review included articles published in 
different countries which may have different TB incidence rates. Overall this was a good 
study, but would have been strengthened by conducting some form of meta analysis. 
 Nienhaus, Schablong, Costa, and Diel (2011) conducted a systematic review of 
the literature to evaluated cost effectiveness of utilizing IGRAs to replace TST in 
tuberculosis screening. The authors searched Medline and Embase for search terms cost, 
interferon, and tuberculosis for articles in English and German. 76 studies were identified 
and narrowed down to 13 articles that met inclusion criteria of studies regarding cost, 
included high risk groups such as healthcare workers, immigrants, contacts, included TST 
and/or IGRA. In five cost analysis studies, two found the QFT®-GIT to be less costly 
than TST only, and in three studies the QFT® after positive TST was less costly than 
IGRA only. In all five cost analysis studies, the TST only method costs more than IGRA 
alone. Eight cost effectiveness studies were reviewed with one study examining TST only 
versus IGRA and seven studies comparing TST only, IGRA after TST, and IGRA only 
methods. One of these examined T-SPOT®.TB and one examined both T-SPOT®.TB 
and QFT® (4 QFT®-G, 1 QFT®-G and QFT®-IT, 3 QFT®-GIT). In all cost-
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effectiveness studies, the TST only strategy was found to be the most expensive method 
of tuberculosis screening. In four of the studies, IGRA after TST was the least expensive 
and in two the IGRA only testing was least expensive. The authors conclude that there is 
strong evidence that IGRAs are cost-effective for tuberculosis screening in high risk 
healthcare workers, immigrants, close contacts, or those from high incidence countries. 
Cost savings is found in less frequency of chest x-rays and less preventive therapy for 
LTBI. The IGRA only strategy would be the least expensive if it is proven to predict 
progression to active TB more accurately, however more studies are needed to prove this 
assumption (Nienhaus et al., 2011). 
 The study by Nienhaus et al. (2013) is a level III systematic review rated B good 
quality. This study used a comprehensive search strategy with clear inclusion and 
exclusion criteria and followed the prisma guidelines. The article lists the different 
articles in tables for a clear view of differences. The authors discuss the limitation of the 
studies lacking consistency in assumptions regarding test parameters and specificity, 
progression rates, and different models for cost analysis. While the studies all targeted 
high risk groups such as healthcare workers and immigrants, the studies were in different 
countries and therefore, cost ratios had to be calculated (Nienhaus et al., 2011). This 
could limit generalizability of the conclusions. This study would be strengthened by 
applying meta analysis but overall it is a good study to support cost savings for use of 
IGRAs.  
 Pai, Zwerling and Menzies  (2008) conducted a meta-analysis of 38 studies 
examining sensitivity and specificity of QuantiFERON®-TB God, QuantiFERON®-TB 
Gold IN-Tube, and T-SPOT®.TB. This is an update to a previous study adding 20 newer 
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studies with stricter inclusions criteria compared to the previous study. Eight of the 
previous studies were excluded due to noncommercial assays, fewer than 10 participants, 
articles that only studied immune compromised patients, or that used an older antigen for 
testing. The authors used PubMed to search for articles published through March 2008. 
Studies were included that assessed sensitivity by microbiologically confirmed cases of 
tuberculosis (by culture). Studies were also included that assessed specificity by 
including samples of healthy low- risk people without tuberculosis exposure. Studies with 
fewer than 10 participants were excluded from the review. The statistical method 
included a calculation of sensitivity or specificity with 95% confidence intervals and 
displayed results in forest plots. MetaDiSc software was used for fixed-effects meta-
analysis which corrected for variability between studies. Chi-square and I2 tests were 
used to test heterogeneity. This analysis included 22 studies of QFT® with 1369 
participants and 13 T-SPOT®.TB studies with 726 sample size. Three of the QFT® 
studies were from high incidence countries, while none of the T-SPOT®.TB studies 
were.  The results showed pooled sensitivity for all QFT® studies to be 76% (95% CI). 
For each study investigating QFT®, sensitivity of the QFT®-TB Gold was 78% (CI 73-
82%), QFT®-TB GIT 70% (CI 63-78%), and T-SPOT®.TB was 90% (CI 86-93%). Six 
out of seven studies found that T-SPOT®.TB had higher sensitivity than QFT® (3-25% 
difference) while one showed equal sensitivity between the tests (CI 95%, p value not 
specified). There were 16 studies from low or incidence countries that examined 
specificity of QFT® with 8 of them including BCG vaccinated and 8 non vaccinated with 
a sample of 1624 participants. There were 2 studies that examined specificity for T-
SPOT®.TB and 4 that used ELISpot with a sample of 290. Specificity for all QFT® was 
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98% (CI 96-99%), QFT® non-BCG was 99% (CI 98-100%), and 96% (CI94-98%) for 
BCG vaccinated. T-SPOT®.TB and TB/ELISpot specificity was 93% (CI86-100%) 
overall with T-SPOT®.TB alone being 87% (CI 80-92%). T-SPOT®.TB sensitivity in 
relation to BCG was not reported, but one study included BCG vaccinated participants. 
TST sensitivity from 20 studies was 77% (CI 71-82%) and specificity in non-BCG 
vaccinated in 6 studies of 97% (CI 95-99%). Specificity for TST in BCG vaccinated 
participants was low. The authors concluded that IGRAs have excellent specificity that is 
not influenced by BCG vaccination status particularly for QFT®s but there are few 
studies on T-SPOT®.TB. TSTs were found to have high specificity for those not 
vaccinated with BCG but specificity was variable for BCG vaccinated participants (Pai et 
al., 2008). 
 This article by Pai et al. (2008) is a B good quality level III systematic review 
with meta-analysis. The authors list the limitation that most of the studies examined were 
small and the studies had different cutoffs for testing results. The authors also report that 
studies were not included that examined TST alone which could alter the TST analysis. 
The authors also report that interpretation of the usefulness of sensitivity and specificity 
is limited since there is no gold standard for latent tuberculosis diagnosis. Not all of the 
studies reported sensitivity and specificity. The authors caution that results regarding T-
SPOT®.TB should be carefully interpreted since there were few studies. The authors 
clearly discussed limitations of their studies which is important for readers to ascertain 
strength. The analyses included scatter plots in the appendix with information about each 
article’s sensitivity/specificity results as well as tables comparing BCG vaccinated versus 
non-vaccinated (Pai et al., 2008). This improves this studies validity. The meta analysis 
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rather than just systematic review is a strength of this study. The results of this study are 
comparable to many other articles found in this review of the literature and contribute to 
considerations for policies and procedures for the project.  
 Evidence level IV, high quality (A) articles. 
 Jensen, Lambert, Iademarco, and Ridzon (2006), published recommendations for 
preventing tuberculosis in healthcare settings. These are the recommendations that are 
approved by the CDC and that DHEC require to be followed. This article is 141 pages 
long and the aspects that pertain to this project will be summarized for brevity. This 
article discusses healthcare workers that should be screened, epidemiology and 
transmission of tuberculosis. The authors report that tuberculosis may be transmitted in 
healthcare settings and healthcare workers are at risk. Therefore, healthcare facilities 
should implement infection control measures. The article describes in detail the infection 
control measures including administrative controls, environmental controls, and 
respiratory protection controls in detail (Jensen et al., 2006). 
The article outlines methods for determining risk level in health care settings and 
describes the required screening for low, medium and healthcare workers with potential 
ongoing transmission settings (Jensen et al., 2006). According to recommendations, 
healthcare workers in low risk settings should receive two step tuberculosis skin testing 
on hire or a single blood assay. Those with positive tests should have a chest x-ray to rule 
out TB. Healthcare workers in medium risk settings should have the same baseline 
screening but should have annual TB screening. Baseline testing with a single blood 
assay is acceptable. Facilities should complete only one test without overlapping the 
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blood test and TST except for a trial period of evaluation for 1-2 years. The article 
reviews care of patients with TB and managing exposures. Proper TST procedures 
include first step followed by a trained designated reader in 48-72 hours. The second step 
should be placed in 1-3 weeks and read in 48-72 hours. If a patient does not return for 
reading within 72 hours and the result is negative, the test must be repeated. Positive 
results can be read up to 7 days after placement. The second step is necessary because an 
initial TST may be falsely negative while the second step boosts a person with LTBI’s 
ability to react to the TST with subsequent positive test. Healthcare workers must have a 
trained health care professional to read the TST result. Reading is determined by 
measuring mm of induration perpendicular to the forearm. The QFT®-G blood assay for 
mycobacterium tuberculosis (BAMT) is reported as an alternative to the TST and this 
article reports that the test reacts to two specific proteins found in mycobacterium 
tuberculosis “(M. tuberculosis, M. Bovis, M. africanum, M. microti, M. canetti, M. 
caprae, and M. pinnipedii)” but not to m. bovis found in BCG vaccine. The blood test 
interpretation is less subjective than the TST, may be more cost effective, efficient, and 
eliminate two step testing. The TST is subject to variability in placement and reading but 
healthcare professional TST administration training can help overcome these barriers. 
The authors report that the likelihood that a positive TST represents TB infection in low 
risk settings is low but the specificity improves in higher prevalence settings. The authors 
report that one single negative BAMT is all that is needed to determine if a healthcare 
worker is not infected with tuberculosis. Conditions that reduce immune function could 
reduce the predictive value of a negative BAMT or TST (Jensen et al., 2006). BAMTs 
may result in indeterminate results if the IFN-ƴ antigen response is low or if the antigen 
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response is not at least 50% of the Nil (Jensen et al., 2006). Some reasons for 
indeterminate BAMT results include low immune response, improper storage or transport 
of blood, lab error, or other illness in the healthcare workers. BAMTs or TSTs should be 
completed within 10 days of hire for baseline screening (Jensen et al., 2006). Healthcare 
workers with positive blood assays or positive TSTs should be referred for healthcare 
evaluation and testing (Jensen et al., 2006). Treatment options for healthcare workers 
with positive test results should be guided by considering test results, epidemiologic 
factors, risk factors and by diagnostics including chest x-ray or bacteriology, and 
histology (Jensen et al., 2006). 
Prior to making any changes in tuberculosis screening in healthcare settings, the 
Centers for Disease Control and Prevention recommendations must be reviewed and 
followed. Therefore, this was the first resource reviewed prior to considering this project. 
While the date of publication is 2006, this article had to be included as it is still the most 
current guidelines with the addendum on IGRAs published in 2010. There is clearly 
expert input in the article including CDC, experts in TB and infection control as well as 
experts in respiratory protection and occupational health (Jensen et al., 2006). A list of 
departments for which the experts come from are given, however a specific list of who 
these experts are is revealed. There is a comprehensive list of 487 references is given. 
The authors did not specify their method of obtaining the references for review. Overall, 
Jensen et al. (2006) is rated a high quality A level IV study of clinical practice guidelines.  
 The literature search revealed that the CDC gathered a group of experts and 
published an article in 2010 regarding guidelines for IGRAs (Mazurek et al., 2010). This 
group of experts reviewed 96 out of 152 articles published through 2008 which examined 
   
50 
 
agreement between QFT®-GIT and T-SPOT®.TB or with TST, sensitivity or specificity 
of QFT®-GIT or T-SPOT®.TB, QFT®-GIT and T-SPOT®.TB in relation to TB risk, 
and use of QFT®-GIT or T-SPOT®.TB in contact investigations. The authors searched 
PubMed as well articles from the test manufacturers. The purpose was to provide 
guidance for use of IGRAs for tuberculosis diagnosis for healthcare providers, public 
officials, and laboratory workers. The result is a lengthy article with discussion of the 
strengths and limitations of QFT®-GIT and T-SPOT®.TB. The review of articles by the 
authors showed varying results regarding sensitivity of the QFT®-GIT and T-
SPOT®.TB, however, in general sensitivity is similar to the TST. Pooled QFT®-GIT 
sensitivity was reported as 81-83%. Out of 11 studies that examined confirmed active 
tuberculosis patients, six studies showed no statistically significant difference between 
QFT®-GIT and TST, three showed greater sensitivity for TST, and two showed greater 
sensitivity for QFT®-GIT (p<0.01). Pooled T-SPOT®.TB sensitivity was about 90-91%. 
Pooled QFT®-GIT specificity for those not likely to have TB was 99% and for TST 85%, 
and 86% for T-SPOT®.TB. The authors caution that the reviewed articles for specificity 
have varied risk for infection and test methods and interpretation may vary. Tables are 
available in this article listing the p values for each study by country. The articles which 
the experts reviewed showed varied results with regards to agreement among tests due to 
differences in test interpretation criteria, estimates of exposure, BCG status, TST status, 
and coexisting conditions. The review did reveal that in contact investigations, positive 
IGRAs were more strongly associated with recent exposure and longer duration of 
exposure or infectiousness as compared to the TST. Therefore, IGRAs may be better at 
detecting more recent infection with TB than the TST. There have been few studies to 
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examine whether IGRAs will predict development from LTBI to active TB. However, a 
few have reported that the QFT®-GIT performed better than TST at predicting 
conversion to active TB. There is limited data regarding using QFT®-GIT for 
immunocompromised persons, but two found that QFT®-GIT sensitivity was 81-88%. 
Further study is recommended for all aspects of IGRA use. The authors suggest that 
ultimately the organization should consider logistical factors such as single visits for 
IGRAs, quicker results and less error with reading of results, and cost factors (Mazurek et 
al., 2010). 
Mazurek et al. (2010) gives guidelines for general use of IGRAs and approve use 
for surveillance. It is recommended that quantitative and qualitative results be utilized. It 
is recommended that organizations evaluate cost, availability, and benefits of each test in 
order to choose which test to implement as studies vary as to which test is better 
regarding sensitivity and specificity. IGRAs are preferred for individuals who have a low 
rate of return for TST reading and for those who have received a BCG vaccine. An IGRA 
or TST may be used without preference for contact investigations and period screening 
for occupational exposure. It is mentioned that repeat of an IGRA may be useful if the 
result is indeterminate or borderline. After testing, a person with a positive IGRA should 
be assessed for likelihood of active TB versus LTBI based on risks, exam, history, chest 
x-ray and symptom assessment. A single positive IGRA should not be used as reliable 
evidence that someone has tuberculosis as false-positives do occur (Mazurek et al., 
2010). Overall, use of IGRAs are acceptable and approved by the CDC for tuberculosis 
screening in healthcare workers.   
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Evidence level V, high quality (A) articles.  
 A study comparing the cost-effectiveness of the QFT®-G, QFT®-GIT, and the 
TST for new health care workers was conducted based on data from the Veterans 
Healthcare Administration in 2007 (dePerio, Tsevat, Roselle, Kralovic, & Eckman, 
2009). The study conducted a Markov stat-transition decision analytic model and 
measured quality adjusted life years (QALYs) in relation to direct costs, missed work 
time and probabilities. A hypothetical sample of 35-year old RNs was used for this study. 
The analysis ran decisions for those with and without BCG vaccination, those with and 
without LTBI. The study also accounted for those that fail to return for TST readings. 
Also, analyzed was whether isoniazid treatment might be indicated for 9 months and 
whether medication induced hepatitis might develop as a result of INH treatment. Direct 
and indirect costs were considered, including costs for conducting the tests missed time 
from work. Sensitivity analysis was conducted to examine all probabilities and changes 
in age. Final results indicated that for all models IGRAs were less expensive than TSTS. 
According to the sensitivity analyses, the IGRAs were less costly as long as tests were 
conducted in batches of at least 12 for non BCG vaccinated and at least 4 for BCG 
vaccinated. For batch QFT® testing, in order to cost less than the TST, the cost for the 
QFT®-G should be $32 or less and for the QFT®-GIT $36 or less. The authors 
demonstrated that the IGRAs were less costly than TST 100% of the time, but the rate of 
LTBI did not change this result. It is concluded that the QFT®-GIT is less costly than the 
QFT®-G if it is more sensitive. The authors conclude that the QFT®-G or the QFT®-
GIT can lower costs in comparison to the TST for tuberculosis screening of new 
healthcare workers and have “superior clinical outcomes” (dePerio et al., 2009). 
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 The study by de Perio (2009) is level V Financial evaluation with a quality rating 
of high. This study analyzed multiple hypothetical variables to assess cost of QFT®s in 
comparison to TST and the results were very clear that the IGRAs were less costly. 
Limiting the age to 35 could have skewed the results, however the authors did vary the 
age in some of the models and there were no changes in the result. The figures for salary 
could vary by institutions which could change the outcome of this study. The study also 
only considered RN salary which is the largest employed group in the hospital, however 
this could have skewed the results by not considering lower and higher paid staff. It is 
important to note that this study was published in 2009 and the salary and costs for 
testing would be considerably higher today. The authors mention the limitation that 
decision analyses are dependent on quality and accuracy of the model parameters. The 
authors attempted to use pooed data from multiple studies to help overcome this. 
However, readers need to understand QALYs definitions. The study could be 
strengthened by including decisions regarding cost of subsequent annual TST testing as 
well as analyzing actual versus hypothetical data.  
 An article by Banaei, Gaur, and Pai (2016) discuss the literature regarding 
variability for IGRA results and  recommendations. According to the authors, studies 
have shown some issues with reproducibility and conversion rates with respect to 
variability. Factors that contribute to this variability including pre-analytical, post-
analytical, manufacturing, and immunological problems. A pre-analytical source of 
variability is timing of the blood draw since QFT®-GIT results tend to be higher when 
blood is drawn in the evening rather than morning. Also, if the blood collection tube and 
the skin is not properly disinfected, there can be contamination causing 
   
54 
 
immunomodulatory response from bacteria. If the blood is not drawn in the correct order 
of nil, antigen, and then mitogen tubes, then there could be contamination of the antigen 
tube from the mitogen giving a false-positive or from the nil tube with mitogen causing 
false-negative. The volume of blood and vigorous shaking can affect results as well. The 
higher volume of blood can result in false-negatives. Excess shaking can cause increased 
IFN-ƴ response and false- positive or negatives depending on whether it was the nil or 
antigen tube shaken too much. The authors report that literature shows that delay in 
incubation can cause false negative or indeterminate results due to reduction in mitogen 
response for QFT®-GIT. For T-SPOT®.TB, indeterminate results are more common in 
fall and winter perhaps due to lower temperature during transport of the blood. Longer 
incubation does not appear to affect results. Analytical sources of variability can be due 
to pipetting that is not precise, errors with centrifugation, washing steps and operator 
incorrect measurements.  The authors report that studies have shown variability in results 
of +0.6 overall and a variability of + 0.24 IU/ml for those with initial results close to 
cutoff levels. Post-analytical errors can be the result of error in clerical data entry. 
Manufacturing errors can be due to faulty antigen tubes or bacterial contamination 
causing false-positive or faulty mitogen tubes causing indeterminates. Immunological 
variability may be due to boosting from TST causing conversions. Contamination from 
microorganisms on skin or in the environment can cause microbe-associated molecular 
patterns that increase the TB response. Staphylococcus aureus contamination in the 
antigen tube can cause increase in false-positive results. Recommendations to reduce 
variability include: proper disinfection, correct collection tube order, standardize order of 
blood draws standardize filling of tubes to 1 ml, gentle shaking of QFT®-GIT tubes, 
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prompt incubation, use of automated instruments, quality assurance equipment 
calibrations, and draw blood within 72 hours of TST placement (Banaei et al., 2016). 
 The article by Banaei et al. (2016) is a level V, high quality expert opinion with 
some literature review. Recommendations are very clear and helpful for policy and 
procedures for QFT®-GIT implementation. References are comprehensive and recent. 
This article was not primarily a literature review, but did discuss the literature. The article 
did not discuss the limitations of the articles presented in the expert review. Overall, this 
is an excellent article which provides clear guidance to avoid variability in IGRA results. 
 
 Evidence level V, good quality (B) articles. 
 Weddle, Hamilton, Potthoff, Rivera, and Jackson (2014), conducted a study with 
the purpose of determining performance of the QFT®-GIT in healthcare employees in a 
children’s hospital setting determined to be in a low TB incidence. Secondly, the study 
examined whether repeat testing of positive QFT®s was useful to determine TB 
infection. The study utilized occupational health records to retrospectively review 758 
employees screened for TB in 2010-2011. Out of 47 who had positive QFT®s, 34 had 
repeat testing with 64.7% (22) positive on repeat and 35.5% (12) negative on repeat. The 
mean QFT® result of those who had positive repeat testing was 1.19 and 0.92 on initial 
testing. The initial mean and median of negative repeat testers was 0.61 and 0.5. This 
revealed that the negative repeat individuals had a statistically significant (p=.01) lower 
IFNƴ results than those with positive results. The authors did not reveal which statistical 
test was used to compute the findings. There was no statistically significant difference in 
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reported risk factors between the repeat negative and repeat positive groups (p=.86). Out 
of the 707 negative QFT® employees, 37.9% had risk factors for TB and 36.2% of the 
positive QFT® individuals had risk factors for TB. The authors conclude that the QFT®-
GIT is useful for tuberculosis screening in healthcare workers, however false positive 
may occur when results are less than 1IU/ml and repeat testing should be considered 
(Weddle et al., 2014). 
 Overall, this study is level V quality improvement with a quality rating of good. 
While statistical analyses were conducted, the authors did not reveal which tests were 
employed. The authors give a clear discussion of implications for repeat testing. 
However, the authors do not discuss the results of the risk stratification. This study would 
have been strengthened by a larger sample of positive repeaters. Comparing 707 negative 
employees to 47 positive employees may have skewed results unless this was adjusted for 
in the statistical analysis. This study is important to consider when designing policies and 
procedures for repeat testing.  
 Foster-Chang, Manning, and Chandler (2014), conducted a study at the Veteran’s 
Administration health care facility to determine if an IGRA was acceptable in lieu of the 
TB skin test to improve processes for pre-placement assessments. This medical center 
employees 3,500 with 64% in the 41-60 age group. It was reported that many employees 
were foreign born and had BCG vaccination but the total number or percent was not 
given. This study included a convenience sample of 100 new employees hired from 
March 19 through May 30,2013 who were asked to have a T-SPOT®.TB instead of the 
TST during pre-placement assessment. Data from this group was compared to 
retrospective electronic chart review of 100 new employees who had the TST in the 
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previous time periods of 2011 and 100 new employees in 2012. The study examined 
compliance with completing the entire pre-placement process within 14 days. 
Compliance in the T-SPOT®.TB group was 97% while compliance in the PPD group 
was 77%. Chi-square goodness of fit tests showed statistically significant difference 
between the TST group and the T-SPOT®.TB group compliance rates with p <.001 for 
2012 compared to 2013 and p < .0001 for 2011 compared to 2013. The study also 
reviewed the clearance for work time defined as the time from pre-placement assessment 
to provider signed clearance to start work. The average clearance for work time for the T-
SPOT®.TB group was 5.91 days while the average for the TST groups was 12.67 in 2011 
and 13.18 in 2012. There was statistically significant difference in clearance time by 
Kruskal-Wallis equality of populations rank test between the T-SPOT®.TB and the TST 
groups regardless of whether the employee in the TST group brought prior TB 
documentation (p <.001, 95% confidence interval, Chi-square 30.981) or did not (p<.001, 
95% confidence interval, chi-square 28.479). Cost comparison for the IGRA with cost of 
TST process was $78.53 per person versus $47.02 per person in the T-SPOT®.TB group 
(Foster-Chang et al., 2014). No statistical analyses were conducted for the cost estimates. 
The authors conclude that IGRAs are acceptable in place of the TST for new employees 
and will improve tuberculosis screening processes (Foster-Chang et al., 2014).  
The strengths of this article by Foster-Chang et al. (2014) included good precision 
with results that were statistically significant for compliance and screening time with 
adequate sample size of 300. Another strength of the study is that the purpose and design 
are closely related to the PICOT questions for this project, however the authors used the 
T-SPOT®.TB rather than QuantiFERON®-TB Gold In-Tube-Test. External validity is 
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good in that conclusions can be applied to similar healthcare settings, however the fact 
that the sample may have a higher percentage of foreign born employees who may have 
received BCG vaccination could affect the generalizability. For construct validity, other 
facilities might interpret clearance time different than this organization. One weakness is 
that the authors admit that reliability could have been affected due to the physician signed 
clearance with impending vacation plans, a chart for a T-SPOT®.TB employee was 
misplaced and discovered 21 days later, and two employees chose not to have blood 
drawn on date of pre-placement assessment, returning 2 weeks later (Foster-Chang et al., 
2014). These factors could have affected the results causing increase in clearance time 
and reduction in compliance. Furthermore, data from misplaced charts were probably not 
readily available for data analysis of the TST groups. This study was not a controlled 
experiment which affects internal validity. Investigators may have also had bias due to 
the expected reduction in clearance times at the start of the study. A strength in the 
internal validity is that the T-SPOT®.TB group had no attrition. Overall the evidence 
level for this study is V quality improvement with quality rating of B Good. This article 
supports that implementation of an IGRA is acceptable for new healthcare employees.   
Gonzalez and Conlon (2013) described how their organization developed a needs 
assessment to determine which tuberculosis surveillance program would meet the needs 
of the facility. The hospital is described as moderate sized and has 4,300 employees with 
a low risk assessment per CDC guidelines. Approximately 25% of the employees had 
previous BCG vaccination. TB screening is conducted by TST annually for those without 
previous BCG vaccination or previous positive. This organization was originally 
exempting pregnant employees from screening and conducted annual symptom 
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assessments. The organization also conducted an annual symptom review and a chest x-
ray every 5 years for those with a history of positive TST. The authors admit that these 
practices were outdated and did not meet current CDC guidelines as pregnant women do 
not need to be excluded and an x-ray every 5 years is not necessary. New employees 
were screened with two-step TST. The organization developed a 12 item table comparing 
the attributes of the TST, QFT®-GIT, and the T-SPOT®.TB. The organization 
eliminated the T-SPOT®.TB as an option due to the lack of on-site lab testing and the 
time limitations for the specimens. The authors’ literature review revealed that QFT® and 
TST had comparable sensitivity and specificity when BCG vaccinated people are not 
included in the TST data. The authors were concerned about the report reversion rates 
with the QFT® and the laboratory preparation and incubation time. The organizations lab 
did not conduct testing on the weekend which would limit QFT® testing due to the 16-
hour time limit for processing. The QFT® can be conducted in one visit which saves 
money in lost productivity. Ultimately the organization chose to continue two step TSTs 
for new hires without BCG vaccination and for annual testing. The organization chose 
QFT® for BCG vaccinated new hires but only a symptom assessment for annuals. The 
organization will utilize QFT® additionally for exposures, pregnant employees and 
immunocompromised employees. This article provides an example of how organizations 
should consider all of the variables when deciding on which tuberculosis screening test to 
implement (Gonzalez & Conlon, 2013). 
The article by Gonzalez and Conlon (2013) is a level V Organizational 
Experience/Quality Improvement quality B good article. This is a non-research article 
that provides useful information to consider when choosing a tuberculosis screening tool. 
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The article had a small amount of literature included but certainly is not comprehensive. 
The decisions in this tool cannot be generalized but the techniques for decision making 
can be applied. A concern, is that they continue to exclude pregnant workers from their 
standard TST, rather choosing to use the QFT® demonstrates an improvement in 
standards. Decision making for tuberculosis screening is certainly complex and unique 
for each organization due to multiple variables such as demographics and geographics. 
Veeser, Smith, Handay, and Martin (Veeser, Smith, Handy, & Martin, 2007) 
evaluated the results, acceptability and costs for QFT®-G implementation at the 
University of Tennessee Health Science Center at Memphis. There are approximately 
2,200 students and 6,000 direct patient care employees that are screened for tuberculosis. 
The authors conducted a retrospective chart review for those that were screened for 
tuberculosis with QFT®-G from June 2005 through August 2006 through University 
Health Services (UHS). The organization began using the QFT®-G in 2005 for special 
groups included those that reported a history of positive TST but did not have 
documentation from the health department, those with questionable history of positive 
TST, people who had been BCG vaccinated and those that tested positive by TST at 
UHS. The sample size was 109 including 55 employees and 54 students. Out of the 
sample, 84 had negative QFT®-G, 10 positive and 5 indeterminate. Out of the 10 positive 
results, 7 were students who had BCG vaccination and 1 that reported a history of 
undocumented positive TST. One was an employee that had documented past positive 
TST and one employee had history of undocumented positive TST. The 5 people that had 
indeterminate results were tested a second time and had indeterminate results again. One 
case study is discussed in which one employee had a positive TST after years of negative 
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testing and was referred for treatment. The authors state she was tested with bot methods 
but do not report if the QFT®-G was positive. There were 3 people who had a past +TST 
but negative QFT®-G result. The authors state that this may have been due to improper 
readings, or thimerosal reactions. The authors conclude that the QFT®-G is acceptable 
and provides operational improvements. The authors report that phlebotomy was 
acceptable to the patients. At this facility the QFT®-G costs $62.60 and the TST is $9.79 
but report that patient time requirements could make the QFT®-G cost effective. The 
authors report that the cost of one false-positive TST would be $445 to $1,195 for chest 
X-ray, office visits, lab monitoring, and medications. In this organization implementation 
of the QFT®-G was successfully implemented for specific groups (Veeser et al., 2007). 
The study by Veeser et al. (2007) is a level V program evaluation rate B good 
quality. This study had clear recommendations and clearly described the program. 
However, there was no attempt to complete statistical analyses of the results. The sample 
lacked randomization, and there was not control for extraneous variables. The 
conclusions regarding the past positive TST but negative QFT®-G is presumptive and 
not objective. The conclusions regarding acceptability of phlebotomy is not verified by 
any objective information that is provided in the article. Logistical improvements were 
discussed but this conclusion would have been improved by tracking objective data. This 
study could be strengthened by including statistical analysis and further measures of 
logistical improvement and acceptability surveys for the patients.  
Slater, Welland, Pai, Parsonnet and Banaei (2013) conducted a retrospective study 
to examine the reproducibility of QFT® in healthcare workers at Stanford University 
Medical Center (SUMC). SUMC has 10,000 employees and averages 14 cases of TB per 
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year between 2006 and 2011. The TST conversion rate in 2006 was 0.4%. SUMC screens 
employees for TB annually and in 2006 began using the QFT®-G for screening and 
changed to QFT®-GIT in 2008. SUMC clinic screened all employees with QFT® 
regardless of previous history of LTBI or positive results. Anyone who had a conversion 
was retested in 6 weeks. The study period was from June 1, 2008 through July 31, 2010 
and the sample size was 9,153 healthcare workers who had at least 2 QFT®s. Data was 
obtained from lab databases and no information was obtained regarding previous test 
results or risk factors. Statistical analysis included independent group t test for 
comparison of variables, ȥ for proportions, linear regression, and kappa statistic 
performed using Stata. The results showed that when those with initial positive QFT®s 
(1,223) were retested 67.5% (n=828) remained positive. When employees who had 
negative initial QFT®s (8,277) were retested, 4.4% (361) converted to positive. There 
was a statistically significant (p< .001) increase in conversions and reversions in groups 
that had results between 0.35 and 1.0 IU/ml compared to those who were persistently 
positive. Three hundred and sixty-one healthcare workers that converted to positive and 
retested 262 (72.3%) retested within 60 days and reverted to negative, and 38 people 
tested negative after 60 days, while 11.1% (40) failed to retest. Twelve out of 16 
Healthcare workers who received a second repeat test reverted to negative. If the cutoff 
for positive results was changed to 1.0 IU/ml, 67% of discordant results would be 
eliminated, however 33.7% of the persistent positive results would have been missed. In 
order to obtain the same 0.4% conversion result as with the TST, the cutoff for QFT® 
would have to be 5.3. The authors conclude that QFT® cutoff values result in increased 
conversion rates and conversions suggest false-positive results (Slater et al., 2013). 
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The article by Slater et al. (2013) is a level V organizational experience, quality 
good study. The authors discuss the limitations of a lack of gold standard, the lack of 
information regarding TB risk factors for this study, and intervals between retests were 
not standardized. The authors also mention the limitation of possible changes in lab 
practices over the years (Slater et al., 2013). This study did include a large sample size 
which improves validity. There was some attrition bias as 11.1% of positive testers did 
not follow up for repeat testing. There was no randomization for this study. The authors 
did not do any comparison for the QFT®-G versus the QFT®-GIT which might have 
provided some helpful information. Information regarding previous BCG vaccination 
status and risk factors would have improved interpretation of results.  
Loddenkemper, Diel, and Nienhaus (2012) wrote an expert opinion article that 
discuss a few studies. The authors report that the specificity of IGRAs is well established 
and sensitivity for diagnosis of active TB is higher than with the TST. IGRAs are useful 
for identifying who will benefit from preventive treatment, however research on the 
positive predictive value is still small. The few studies that have examined serial IGRA 
testing have found high reversion rates for positive IGRAs and simple negative or 
positive result interpretation can overestimate reversion and conversions. Some studies 
have suggested using a gray interpretation zone of 0.35 to 1.0 IU/ml, but that figure has 
not been validated. The authors conclude that positive IGRAs should be repeated for 
routine screening of healthcare workers. Chest x-rays are not needed if healthcare 
workers with positive IGRAs are asymptomatic and the IGRA reverts (Loddenkemper et 
al., 2012).  
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This article by Loddenkemper et al. (2012) is a level V Expert opinion, quality B 
article. The article is short but contains 13 references. It is too short to discuss all the 
limitations of the studies mentioned. The authors appear to be experts from German 
Central Committee Against TB, Department of Pulmonary Medicine Medical School and 
a physician from University Medical Center Hamburg-Eppendorf as well as being 
authors of other articles reviewed in this literature review (Loddenkemper et al., 2012). 
The conclusions would be more credible if the authors were able to specify frequency for 
when IGRA results should be repeated, but as they state, there is no validated 
recommendations at this time (Loddenkemper et al., 2012).  
Nienhaus (2013) provides expert opinion and a short literature review regarding 
use of QuantiFERON®-TB Gold (QFT®) in healthcare workers. This article discusses 
the risk for tuberculosis in healthcare workers which is still a concern globally. Ongoing 
screening for TB is essential for TB control. The advantages of IGRAs include one visit, 
clearer interpretation, results are not affected by BCG vaccination, and objective results. 
The authors report that studies show that IGRAS have superior specificity in comparison 
to TST in low incidence countries with QFT® offering the highest specificity of 99.2%. 
Utilization of QFT®s would reduce the number of chest x-rays by 25 to 98% as shown in 
a head to head comparison (Nienhaus, 2013). The author reports that QFT® can predict 
the development of active TB better than TST and reduce the number of patients needing 
chemotherapy. QFT® results should not be compared to TST or Elispot due to different 
cutoff levels and methods as well as the TST has non-return rates and Elispot invalid 
results are usually not published. The author reports that studies have shown IGRAs to 
improve cost-effectiveness. The article reviews the criteria for interpreting negative and 
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positive with a flowchart. If TB Antigen Minus Nil is > 0.35 IU/ml and that result is > 
25% of the Nil value and the Nil is < 8.0 IU/ml, then the result is positive. Healthcare 
workers are usually more accepting of taking medications for positive IGRA results 
versus TST results. The author discusses that studies show that healthcare workers do 
have a higher rate of reversion from positive to negative IGRA results, and therefore, 
should have retesting if positive and TB is not suspected. Some studies have suggested a 
borderline retesting zone of 0.35 to 1.0 IU/ml but the FDA has not approved a change in 
cut off (Nienhaus, 2013).  
The article be Nienhaus (2013) is  level V expert opinion/literature review quality 
B good. Recommendations and review are clear and concise. This article is published by 
QIAGEN® which is a limitation that could introduce bias. The number of references is 
large at 63. The number of articles discussed in depth is smaller at 10. The article does 
not review limitations of articles but the main purpose of the article is expert opinion. 
Expert opinion is evidence since the author is a Professor and occupational physician in 
Germany and has written several other studies on QFT® testing. Overall, this article is 
useful for providing guidance for QFT® testing in employees.  
Graban and Filby (2015) discussed a case study of a ‘lean’ process applied to a 
healthcare facility’s evaluation for utilizing the QuantiFERON®-TB Gold test for 
tuberculosis screening of new hires. ‘Lean’ processes aim to improve work flows, reduce 
delays and other barriers to completion of work. The health system has 5,000 employees 
and hires about 1,000 new employees annually with an employee turnover rate of 15-
20%. The system currently uses a 2 step TST process for new hire screening requiring 
four different visits for each new hire. According to data, new hires do not follow up for 
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TST readings which delays onboarding. This further contributes to the need for 
temporary staffing or locum tenens and additional recruitment efforts to fill employee 
vacancies. The organization has a goal of completing onboarding within 30 days and the 
2 step process can delay this. The one step QFT® can reduce ‘waste of transportation’ in 
‘lean’ terminology which means it reduces the number of visits improving efficiency. If 
the QFT® has a false positive rate that is less than TST then there may be a reduction in 
‘waste of defects’. QFT® results are reported within 1-3 days which can reduce 
tuberculosis clearance by 7-9 days. Reduction in Chest X-rays and medications for false-
positive can also reduce waste. More objective results reduce waste. Reduction in ‘over-
processing’ and ‘talent’ occurs when staff do not have to spend time following up on new 
hires who don’t return for TST readings. QFT®s may reduce costs by reducing, and 
therefore, reduce temporary staffing or locum tenens needs. The authors conclude that 
QFT® testing of new hires for screening can reduce waste (Graban & Filby, 2015). 
The article by Graban and Filby (2015) is a Good B quality level V case report. 
This article reviews how ‘lean’ business principles can be applied to QFT® for new hires, 
but does not report any actual statistical results. This would add value and validity to this 
article. This article was published by QUIAGEN which could result in bias. There were 
only 6 references for this article which is small limiting validity. This article has good 
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Synthesis of Literature 
 Tuberculosis screening process. 
 Studies suggest that organizations should conduct a needs assessment prior to 
selection and implementation of IGRAs (Gonzalez & Conlon, 2013; Graban & Filby, 
2015). The first step in the needs assessment is to make sure that the tuberculosis 
screening method meets regulatory requirements. The Federal Drug Administration 
(FDA) and the CDC has approved IGRA’s for screening of workers who may have 
occupational exposure to tuberculosis (Jensen et al., 2006; Mazurek et al., 2010).  Studies 
show that organizations should choose the appropriate test based on availability, costs, 
logistics, population TB risk, BCG Vaccine status, staffing, and organization resources 
(Gonzalez & Conlon, 2013; Graban & Filby, 2015; Lamberti et al., 2015; Mazurek et al., 
2010; Rangaka et al., 2012). Healthcare employee health offices should examine current 
processes and any impact the change would make to the organization. After impact to the 
organization has been identified, the organization can then individualize the test selection 
and process plan (Gonzalez & Conlon, 2013).  
 Logistics and adherence of utilizing IGRAs in place of TB skin tests should be 
considered (Foster-Chang et al., 2014; Gonzalez & Conlon, 2013; Graban & Filby, 2015; 
Mazurek et al., 2010; Rangaka et al., 2012). IGRAs do have the advantage of one single 
visit rather than 4 visits for two step TB skin tests. Studies report that IGRAs improve 
compliance and expedite completion of tuberculosis screening (Cummings et al., 2009; 
Foster-Chang et al., 2014; Graban & Filby, 2015; Mazurek et al., 2010). Lean processes 
applied to analyzing logistical processes for tuberculosis screening and can help with 
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improving flow, work time, and efficiency. The required four visits for tuberculosis 
screening is inconvenient to new hires and can result in noncompliance and hiring delays. 
Hiring delays can result in further understaffing which can lead to stress and increased 
turnover and costs due to temporary agency staffing. One study showed that onboarding 
of associates in an organization with 5,000 employees with a 15-20% turnover rate rarely 
resulted in meeting the onboarding goal of completion in less than 30 days. The QFT® 
presents a possible contributing solution for reduction in onboarding time since results 
can be received within 1-3 days and the candidate can be cleared 7-9 days sooner than 
with the 2 step TST (Graban & Filby, 2015).  Studies have shown that use of IGRA’s can 
indeed increase compliance, reduce tuberculosis screening time and improve compliance 
(Foster-Chang et al., 2014; Veeser et al., 2007; Wrighton-Smith et al., 2012). Veeser, 
Smith, and Martin (2007), successfully implemented QFT®-TB Gold tests for students 
and employees of a health science college and saw improved completion rates.  Likewise, 
Wrighton-Smith et al. (2012) conducted parallel testing of healthcare workers at a large 
healthcare system and reports  that only 0.4% of IGRA test results were unavailable in 
comparison to the typical rates of noncompliance with TST follow up to be 20%. This 
shows an improvement in tuberculosis screening compliance from 80% to 99.6% with 
utilization of IGRAs (Wrighton-Smith et al., 2012). Foster-Chang et al. (2014), revealed 
successful implementation of the T-SPOT®.TB for all new hire hospital workers. This 
study showed that use of the T-SPOT®.TB for new employees improved overall 
employee health clearance to work time from 13.18 to 5.91 days showing a reduction of 
7.27 days. Compliance with completion of the pre-placement process within 14 days also 
increased from 77% to 97% (Foster-Chang et al., 2014). This demonstrates that 
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implementation of an IGRA for new hires can significantly reducing overall onboarding 
time and improve compliance. It would be expected that the QFT®-GIT should yield 
similar results with increased compliance and reduced onboarding time. However, if 
QFT®-GIT is selected, the facility must have resources and staff to draw the blood, and 
incubate or send the specimens to a lab for incubation within 16 hours (Banaei et al., 
2016; Gonzalez & Conlon, 2013). The T-SPOT®.TB has similar process issues such as 
need to process fresh blood within 5 hours (Gonzalez & Conlon, 2013; Mazurek et al., 
2010). If procedural difficulties are overcome, IGRA results are quicker and not subject 
to reader bias which can improve efficiency in the employee health department (Graban 
& Filby, 2015; Mazurek et al., 2010)  
 Of high importance is that studies found use of IGRAs was found to be acceptable 
by patients (Foster-Chang et al., 2014; Veeser et al., 2007; Wrighton-Smith et al., 2012). 
One study administered a questionnaire to healthcare workers who were enrolled in a 
study with parallel TST and IGRA testing. This study revealed that 62.3% of participants 
preferred the IGRA and had better confidence in IGRA results (Wrighton-Smith et al., 
2012). One visit is more convenient than 2 or 4 visits for employees. Improved employee 
satisfaction with use of IGRAs can lead to reduced turnover, improved compliance, faster 
onboarding, and provide logistical benefits to employee health offices (Graban & Filby, 
2015). 
 Cost. 
 Cost-effectiveness of using an IGRA versus TST was evaluated in several studies 
and found to be cost-effective (dePerio et al., 2009; Graban & Filby, 2015; Mazurek et 
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al., 2010; Nienhaus, 2013; Nienhaus et al., 2011; Wrighton-Smith et al., 2012) The IGRA 
costs more than the TST on the surface, but savings can be found in staff time, less 
missed work time, less treatment of false positive results, and reduced turnover (Foster-
Chang et al., 2014; Graban & Filby, 2015). In a high quality financial evaluation utilizing 
a Markov state-transition decision analytic model, QFT®-TB Gold and QFT®-GIT were 
both found to be less costly and more effective than TSTs for healthcare workers 
regardless of BCG vaccination status. This study measured direct and indirect costs 
including quality-adjusted life-years (QALYs) which considers missed work time into 
costs and analysis revealed reduced costs (dePerio et al., 2009). Foster-Chang et al. 
(2014) conducted a quality improvement study in which new hires had IGRAs. When 
salaries, supplies, staff time, failure to return for TST, and monitoring of positive results 
were considered in cost analysis, there was a reduction in costs of 38% to 40% in 
comparison to the TST. Costs were reduced from $7,852.70 for 100 new employee TSTs 
in 2011 to $4,699.50 for 100 new employees with IGRA (Foster-Chang et al., 2014). 
Veeser et al. (2007) found similar results when QFT®-G was implemented for health 
science students and employees which revealed reduction in costs related to less false 
positive results and follow up. They estimated that the cost of one single false-positive 
TST to be $445 to $1,195 for chest x-rays, medications, and follow up (Veeser et al., 
2007).  
 The SWITCH study was conducted at John Hopkins Healthcare system employee 
health which screens 18,000 employees annually with the purpose of determining the 
price at which IGRA becomes less costly than TST. This study analyzed material and 
labor costs, conducted a time-motion study of 393 patients and assessed labor costs, and 
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thirdly 743 health care workers had TST and IGRA parallel testing. Material costs, 
employee health labor costs, employee labor costs, employee health staff time, and 
employee time off work were considered. When considering all these factors, switching 
to IGRA for annual as well as new hires there would be savings if the IGRA costs $54.83 
or less per test. When considering only new hires, switching to IGRA would result in 
savings if the IGRA costs $81.16 or less per test (Wrighton-Smith et al., 2012). 
 Nienhaus, et al. (2011) conducted a systematic review of 13 studies and found 
that TST’s were the most expensive method for tuberculosis screening while utilization 
of IGRAs decreased costs in all scenarios. Only two of the studies reviewed examined T-
SPOT®.TB while the other studies examined QFT®-TB gold or QFT®-GIT. Four of 
seven of these studies this review examined revealed that IGRA after positive TST was 
the least expensive. The authors concluded that there was strong evidence that IGRAs 
including QFT® or T-SPOT®.TB are cost effective in high risk groups including 
healthcare workers, high incidence country immigrants and close contact with 
tuberculosis (Nienhaus et al., 2011). Literature review by Nienhaus (2013) also revealed 
that studies that considered that TST sensitivity is well below 100% for countries with 
low incidence of TB, found that IGRA alone will improve cost-effectiveness. The 
evidence shows that screening with IGRA can be cost-effective if cost of the test is 
controlled and staff time, labor costs and adherence are considered (dePerio et al., 2009; 
Nienhaus, 2013; Nienhaus et al., 2011; Wrighton-Smith et al., 2012). 
  
 




 Several studies examined the sensitivity and specificity of IGRAs as well as 
agreement between TSTs and IGRAs with varied results. Sensitivity assessments attempt 
to determine whether positive tests results are truly positive. Assessment of sensitivity of 
IGRAs is complicated by the fact that there is no “gold standard” test to confirm culture 
negative latent tuberculosis infection (LTBI). IGRAs are indirect tests that measure 
immunologic response rather than testing for the organism. Published reports vary in test 
methods and interpretation criteria further confounding interpretation analysis of the 
literature (Mazurek et al., 2010).  Some of systematic reviews and single studies that 
were reviewed found that agreement between  TST and IGRA to be low in regards to 
sensitivity with predominance of positive TST compared to negative IGRA (Cummings 
et al., 2009; Dorman et al., 2014; Lamberti et al., 2015; Swindells et al., 2009). However, 
positive TST can likely be the result of false-positives from BCG vaccination status, 
immune factors, boosting or poor reader interpretation (Dorman et al., 2014; Lamberti et 
al., 2015; Rangaka et al., 2012; Swindells et al., 2009). Pai et al. (2008) conducted a 
meta- analysis of 20 studies and reports inconsistent results of sensitivity for IGRAs, but 
does report 70% sensitivity for QFT®-GIT. The authors do admit that the studies 
analyzed were small and had varying TST methods and cutoffs (Pai et al., 2008). 
However, Mazurek et al. (2010) report that when studies consider sensitivity of the 
QFT®-GIT in patients with active tuberculosis, the combined data show QFT®-GIT 
combined sensitivity of 81% in comparison to 70% for studies that use meta-analysis. 
Furthermore, analysis shows that when QFT®-GIT is compared to TST in culture 
positive patients, QFT®-GIT sensitivity is 83% while TST is 89% (Mazurek et al., 2010).  
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 Assessment of specificity (likelihood that a true negative test result is negative) of 
IGRAs shows more consistency in results. Specificity of IGRAs appears to be high 
(Cummings et al., 2009; Mazurek et al., 2010; Nienhaus, 2013). This high specificity is to 
be expected since IGRAs and QFT®-GITs in particular do not react with BCG 
vaccination or other nontuberculous mycobacteria (Mazurek et al., 2010). Cummings et 
al. (2009) conducted a study comparing QFT®-GIT in low risk healthcare workers with 
tuberculin skin tests and found high agreement and specificity. Two QFT®-GITs were 
offered to newly hire healthcare workers who were having TSTs. Specificity of the 
QFT®-GIT was 98% for healthcare workers without risk factors (Cummings et al., 
2009). One systematic review found that QFT® have 99% specificity in patients not 
BCG vaccinated and 96% in BCG vaccinated (Pai et al., 2008). Nienhaus (2013) reports 
that a review of the literature supports that QFT®s have superior specificity in 
comparison to TSTs especially in countries with low TB incidence. In particular, results 
of pooled studies show QFT®-GIT show specificity of 99% while TST was 85% 
(Mazurek et al., 2010). This shows a higher rate of specificity for QFT®-GIT than TST 
supporting its use in low risk areas.  
 Risk factors, BCG vaccination status and exposure risk should be considered 
when choosing testing methods. Several studies agree that IGRAs are the test of choice 
for individuals vaccinated with BCG (Foster-Chang et al., 2014; Jensen et al., 2006; 
Lamberti et al., 2015; Mazurek et al., 2010; Rangaka et al., 2012; Wrighton-Smith et al., 
2012). The CDC reports that IGRA is the preferred method for tuberculosis screening for 
individuals who have received the BCG vaccine and for those who are unlikely to return 
for follow up (Jensen et al., 2006; Mazurek et al., 2010). IGRAs have been correlated 
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with exposure risk including length of employment in healthcare, age, foreign born, and 
exposure level (Diel et al., 2009; Nienhaus, 2013; Swindells et al., 2009; Zwerling et al., 
2012). In one quasi-experimental study, close contacts of tuberculosis culture confirmed 
sources were tested with IGRAs and found that IGRAs were a better indicator of latent 
tuberculosis in relation to exposure risk in comparison to TST (Diel et al., 2009). 
Mazurek et al. (2010) had similar findings when reviewing the literature and found that 
positive IGRA results were more closely associated with greater recent exposure 
measured by exposure duration. Therefore, IGRAs should be chosen over TST in 
situations when the individual is BCG vaccinated or has high risk of exposure.  
Conversions, reversions and result cutoffs. 
Several studies examined conversion (change from negative to positive) and 
reversion (change from positive to negative) rates and discussed possible need for change 
in IGRA cutoffs (Banaei et al., 2016; Cummings et al., 2009; Dorman et al., 2014; 
Loddenkemper et al., 2012; Schablon et al., 2014; Slater et al., 2013; Weddle et al., 2014; 
Zwerling et al., 2012). This evidence will be important to consider when designing 
processes for interpretation and implementation of QFT®-GITs. Weddle et al. (2014) 
conducted repeat QFT®-GITs in healthcare employees who had positive QFT®-GITs. Of 
the 34 QFT®-GIT positive employees who had repeat testing 64.7% had positive repeat 
tests and 35.3% had negative on repeat tests. The mean result of the repeat positive 
testers was 1.19 while the mean repeat negative test results was 0.61. This article 
suggests that healthcare workers with QFT®-GIT results of 0.35 to 1 IU/ml should have 
repeat testing to avoid false-positives (Weddle et al., 2014). Zwerling et al. (2012) also 
examined four studies that addressed conversion and reversion rates in healthcare 
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workers in low incidence settings. Rates of conversions and reversion in IGRA results 
upon repeat varied in results due to different cutoff definitions. The studies had higher 
rates of conversions and reversions if a simply positive or negative cutoff was used 
(Zwerling et al., 2012). Slater et al. (2013) conducted a retrospective evaluation of 
QFT®-GIT results for 9,153 healthcare workers in relation to conversions and reversions. 
Three hundred sixty-one (4.4%) of healthcare workers with baseline negative QFT®-GIT 
converted to positive over 2 years. Of 261 healthcare workers with positive QFT®-GITs, 
169 (64.8%) reverted back to negative when retested within 60 days. This article states 
that a result cutoff of 5.3 IU/ml would result in a conversion rate of 0.4% similar to the 
institutions tradition rate of conversion (Slater et al., 2013). Dorman et al. (2014) found 
similar results when healthcare workers with QFT®-GIT test conversions were retested 6 
months later, 76.4% reverted to negative. Schlabon et al. (2014) showed a small 
conversion rate of 2.8% and reversion of 37.3% when healthcare workers were screened 
with QFT®-GIT. This study found that an interferon cutoff result of <0.2 to >0.7 IU/ml 
would decrease the conversion to 1.2% (Schablon et al., 2014). Similarly, Cummings et 
al. (2009) found that of 5 positive QFT®-GITs, only 2 were confirmed on repeat testing. 
Loddenkemper et al. (2012) also reports that a cutoff for QFT®-GIT results may be 
warranted. The author suggests a gray zone of 0.35 to 1.0 IU/ml and states that treatment 
medications should not be given for IGRA results of <0.1 IU/ml (Loddenkemper et al., 
2012). CDC recommendations agree that repeat IGRA testing with another blood sample 
may be useful if the result is borderline or invalid. However, ultimately treatment should 
be based on likelihood of infections, risk factors and symptoms (Mazurek et al., 2010). 
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Indeterminate results should also be considered when choosing IGRAs. 
Cummings et al. (2009) repeated ELISAs on the same blood sample for indeterminate 
testers. Of 16 indeterminate results due to low mitogen response, 11 (69%) remained 
indeterminate and 5 (31%) converted to negative. Healthcare workers with diabetes or 
immunosuppression had a greater odds ratio (6.8) of having a confirmed indeterminate 
result. It is also important to note that there was found to be statistically significant higher 
IFN-y concentrations in QFT®-GIT results when healthcare workers had 1 intervening 
TST regardless of the time between tests (Cummings et al., 2009).  
There are some sources of variability in lab procedures that can contribute to 
false-positive QFT®-GITs that should be considered when making recommendations. 
Sources of variability include time of day the blood is drawn, inadequate 
disinfection/contamination of tubes, vigorous shaking, blood volume, processing delays, 
and incubation issues. It is possible that contamination with bacteria can lead to higher 
IFN-y concentration. Vigorous shaking of the tubes may also lead to false positive or 
negative results. The blood should be collected in the proper order, nil, antigen, and then 
mitogen as tube contamination may be a factor in results. Incubation delays could 
potentially decrease antigen response. Processes for disinfection, tube order, and 1 ml 
blood fills should be standardized to eliminate variability. All 3 tubes should be gently 
shaken together. Processing delays should be minimized. As mentioned above TSTs can 
boost IGRAs and therefore IGRAs should be drawn within 72 hours of placement. 








 Analysis of the literature revealed pros and cons to choosing the QFT®-GIT for 
TB skin testing for new healthcare workers. There are a number of positive logistical 
factors that would provide value for employee health offices while improving cost- 
effectiveness. Since QFT®-GITs are completed in one test, new hire onboarding and 
tuberculosis clearance time should be reduced. This will also reduce the burden on 
employee health staff time spent on tuberculosis clearance activities, and enhance 
convenience to the new hire (Foster-Chang et al., 2014; Graban & Filby, 2015; Veeser et 
al., 2007). Cost analysis revealed that IGRAs are cost effective (dePerio et al., 2009; 
Foster-Chang et al., 2014; Graban & Filby, 2015; Nienhaus, 2013; Nienhaus et al., 2011). 
The QFT®-GIT has high specificity but there are some concerns about sensitivity 
(Banaei et al., 2016; Cummings et al., 2009; Dorman et al., 2014; Loddenkemper et al., 
2012; Schablon et al., 2014; Slater et al., 2013; Weddle et al., 2014; Zwerling et al., 
2012). However, sensitivity of the QFT®-GIT improves with consideration of patients 
with active tuberculosis (Mazurek et al., 2010). Some studies have shown that there can 
be issues with conversions and reversion and a borderline cutoff with retesting may be 
appropriate (Dorman et al., 2014; Loddenkemper et al., 2012; Mazurek et al., 2010; 
Schablon et al., 2014; Slater et al., 2013; Weddle et al., 2014; Zwerling et al., 2012). 
When interpreting results, the immunologic status of the patient should also be 
considered with indeterminate results (Cummings et al., 2009). Standardization of lab 
procedures can help overcome some of the variability in results (Banaei et al., 2016). 
Overall, there is good evidence to implement QFT®-GITs in new hire healthcare workers 
while considering all the interpretation factors. 




PROJECT DESIGN AND PLAN 
Introduction 
 Employee Health was faced with the dilemma of increasing volume of new hires 
coming for pre-placement assessment appointments and increasing frustration by 
management regarding delays in orientation. Employee Health management formed a 
new hire committee in Fall of 2015 to investigate the factors involved with delays in 
orientation. One factor identified that contributed to orientation delays was the amount of 
time it takes for new employees to complete the two-step TST. The literature was 
reviewed and multiple steps were taken to investigate the ability for Employee Health to 
offer an IGRA for all new hires in order to reduce the amount of time it takes to be 
cleared for orientation. In February of 2016, Employee Health implemented the QFT®-
GIT in place of the two-step TST for tuberculosis screening of all new hire employees. 
This project evaluated the success of this implementation by retrospective review of the 
data to compare the two methods of tuberculosis screening in regards to tuberculosis 
clearance time, overall onboarding time, compliance, and costs. The study utilized a 
descriptive comparative non-research design Data collection for this project was designed 
to protect the privacy of the subjects and was guided by a comprehensive framework.  
 
 





The Iowa Model of Evidence-Based Practice to Promote Quality Care (Iowa 
Model) was utilized to guide implementation of the project. This model begins with 
identification of “triggers” that are problem or knowledge focused. These triggers occur 
when the clinician questions current practices. Problem focused triggers in the Iowa 
Model include process improvement data (Melnyk & Fineout-Overholt, 2015). The initial 
process improvement problem that triggered this project was the initial question of 
whether processes for onboarding new hires could be more efficient. The demand for new 
hire appointments exceeded the available appointments in Employee Health, which led to 
delays in orientation dates. Knowledge focused triggers in the Iowa Model includes new 
research and standards. IGRAs are relatively new and represent a potentially new 
standard of care. Along with new standard of care, new research has been generated to 
assess utilization of the tests.  
Priority. 
The Iowa Model has been utilized for clinical and operational programs (Melnyk 
& Fineout-Overholt, 2015). After the triggers for change are identified, the question is 
formulated. The next step is to ask whether this is a priority for the organization (Melnyk 
& Fineout-Overholt, 2015).  The need to reevaluate onboarding practices was instigated 
by upper management which resulted in this project. The Vice-President of Human 
Resources asked this author to make this a priority for the department. According to the 
Iowa Model, if the change is a priority for the organization, then a team should be formed 
to develop and implement the change including stakeholders (Melnyk & Fineout-
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Overholt, 2015). A new hire committee was formed including managers who had 
expressed concern about onboarding delay, recruitment staff and management, education 
management, operations director and information services. Problems were discussed and 
ideas were shared for improvement in the overall onboarding process. This author 
listened to the ideas and implemented some of them and discussed why we could not 
implement others. This author knew about the QuantiFERON® lab test but also knew 
that implementation had been rejected in the past due to the high cost.  
Research and Implementation. 
The next steps in the Iowa Model include research and analysis of the literature. 
After the team agreed that utilization of the QuantiFERON® may be a good idea, this 
author began to review the literature. The next step in the Iowa Model includes asking 
whether the literature show a sufficient base for the change (Melnyk & Fineout-Overholt, 
2015). If the answer is yes, then the change should be piloted. Outcomes will be chosen, 
baseline data collected, change pilot implemented and outcomes evaluated. If the pilot 
reveals that the change is appropriate for practice, then the change should be instituted in 
practice. The structure, process and outcome data should be monitored. Last, results 
should be disseminated (Melnyk & Fineout-Overholt, 2015). The literature review did 
reveal that there was sufficient base for change in tuberculosis screening processes. 
Preliminary baseline data of implementation of the IGRA indicated that the new 
processes was increasing available appointments and appeared to be reducing onboarding 
time. This study represents a full analysis of outcomes for the IGRA implementation.   
 




 The design of this project will be evidence-based a descriptive comparative level 
III non-experimental design. Four outcomes will be measured (1) tuberculosis screening 
time for new hires, (2) overall onboarding time, (3) compliance with tuberculosis 
screening within 10 days of hire date, and (4) cost-effectiveness comparing the traditional 
two-step PPD tuberculosis screening versus screening with QFT®-GIT. 
Justification for Need 
 At the organization level, Employee Health was asked by senior management to 
improve time efficiency for TB clearance in order to onboard a larger volume new hires 
more efficiently. At the department level, Employee Health was unable to accommodate 
the volume of appointments needed to process the increased volume of new hires. 
Furthermore, Employee Health was having difficulty getting some new hires to return for 
appointments to complete the 2-step PPD skin test. This resulted in delays in orientation 
and could have led to DHEC and other regulatory agency citations or penalties. The 2-
step tuberculin skin test requires 4 visits which was inconvenient to the new hire 
employee and filled available appointments in Employee Health. Department Managers 
seeking to hire potential applicants expressed frustration with delays in orientation for 
their new hires which left the departments short staffed. Thus, management requested 
measures to improve efficiency, new hire satisfaction, and reduce costs.  Investigation of 
changes included use of interferon gamma release assays and was a priority for the 
organization. At a larger level, there is minimal research and data regarding 
implementation of interferon gamma release assays for new employees.   





Feasibility for implementation includes examination of stakeholder support 
(Melnyk & Fineout-Overholt, 2015). Leadership and stakeholder support is essential to 
success of the study. This project for implementation of QFT®-GIT and for the 
subsequent retrospective data analyses was supported by the Vice President of Human 
Resources, Recruitment Director, Director of Operations, and managers part of the new 
hire committee. Approval was obtained in January of 2016 for implementation of QFT®-
GIT beginning February 2016 for all new hires. Continued support was critical to 
ongoing success of the project and for continued implementation beyond the study. The 
Vice President of Human Resources is currently in favor in continuing with the QFT®-
GITs due to preliminary findings of a reduction in Employee Health clearance time. 
Initially, nursing staff were concerned about procedural and process difficulties with 
having only one pre-placement visit. A meeting was convened with the nursing staff to 
talk through and agree upon processes. One area that was resolved was how to provide 
follow up on all lab results since the new employee would not follow up with a second 
visit in Employee Health. It was determined that staff would mail the lab results to the 
employee’s home and call the employee for any significantly abnormal results per a 
revised protocol. Approval from risk management was obtained prior to mailing the lab 
results.  Employee Health staff were educated regarding the benefits of testing and how 
to draw the blood. Initially staff were hesitant to accept the change, but after several 
months, staff members realized the benefits of the process for the new employees and for 
themselves. They discovered that they had to spend less time trying to complete 
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tuberculosis testing and less time trying to obtain compliance with testing. Employee 
health staff now support QFT®-GITs for new employees. Meetings were initially 
convened monthly with the new hire committee and Employee Health staff in order to 
review progress and to maintain support. The Employee Health manager continued 
ongoing conversations with the microbiology lab manager to continue to problem solve 
and maintain support. Preliminary non-statistical data regarding increased volume in new 
hire visits and reduction in onboarding clearance time in Employee Health was shared 
with the VP of Human Resources and this author was asked to present the data at the 
quarterly leadership meeting.     
 Sample size and accessibility. 
Access to an adequate sample size enhances feasibility (Melnyk & Fineout-
Overholt, 2015). Adequate sample size was easily obtained since the data was collected 
retrospectively and all new hires were required to complete tuberculosis screening for 
employment. There were approximately 100-125 new hires per month in 2015 and 150-
180 in 2016.   
 Financial resources. 
Financial resources for implementation of the QFT®-GIT and for this DNP 
project was examined. While a TST only costs $4, factoring in staff time and supplies for 
four visits would cost approximately $87. The QFT®-GIT is an expensive test, however 
this author was able to negotiate a reduced price from its original price of $85 to $53 
which enhanced feasibility. This was not in the budget to implement but senior 
management believed that the extra expense would be offset by the benefits of reducing 
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onboarding time.  Although difficult to directly measure, implementation ultimately 
contributed to cost savings in the form of reduced employee health staff time, reduced 
onboarding time and subsequent reduction in locum tenens staffing. If the current high 
turnover rate slows or upper management cuts budget for the lab tests, then a more 
thorough cost benefit analysis will need to be conducted to continue with QFT®-GIT 
testing. There were no direct costs for the retrospect data collection and analyses other 
than time for this author and the secondary researcher to collect the data.   
 Time and expertise. 
Data collection for this DNP project was time consuming. One Employee Health 
staff member was enlisted to assist with collection of the data ensuring no breaches in 
HIPPA or IRB protocols. This secondary researcher completed all training requirements 
from the IRB and was added to the project committee. Utilization of QuantiFERON® is a 
new process for the author and for the organization, but knowledge barriers were 
overcome through the literature review, and utilization of resources such as consultation 
with DHEC experts and microbiology staff.  
 Legal and Ethical Implications. 
CDC and DHEC regulations in regards to tuberculosis screening were monitored 
and it was determined that QFT®-GITs were acceptable for tuberculosis screening of 
healthcare workers. There was little risk to the subjects since the data was collected 
retrospectively for the project. Measures were taken to ensure confidentiality by 
removing all identifiers from the data. 
 




Stakeholder support, sample access and size, financial, legal and ethical resources 
were substantial. An adequate sample size was easily obtained through the retrospective 
chart review. Benefits of QFT®-GIT and dissemination of results of the project will be 
provided to stakeholders including senior management, the healthcare system’s research 
council members, and Employee Health. Presentations to senior management was 
provided. Limitations such as time, knowledge barriers, and budget concerns were 
overcome.  Since findings will be important to the organization, Literature, DHEC staff, 
and laboratory management was consulted for any knowledge gaps.  
Intervention Plan 
Design. 
The design of this project was evidence-based quality improvement project that is 
descriptive comparative level III non-experimental. Data was collected retrospectively. 
Tuberculosis screening time for new hires, overall onboarding time, compliance with 
screening within 10 days of hire date, onboarding time, and costs was compared between 
the traditional two-step PPD tuberculosis screening versus screening with QFT®-GIT.  
Sample. 
 The sample included a convenience sample of all new hire employees that are 
completed pre-placement assessment at the healthcare system Employee Health in April 
and May 2015 and 2016.  
 





The healthcare system consisted of 3 acute care hospitals, a post-acute facility, 
hospice house, home health, multiple outpatient offices, and other healthcare services. 
The healthcare system Employee Health serves over 6,800 employees in addition to 
volunteers, staff providers, and contract workers. The healthcare system is state supported 
and is designated as a health professional service area and critical shortage facility. 
Employee Health staff performed pre-placement assessments including tuberculosis 
screening for all newly hired employees in the Employee Health department post offer 
but prior to orientation up until February 2016, when implementation of QFT®-GIT.  
  
Timeline 
 September 2015:  
o Formed new hire committee to review new hire processes and garner 
support from key stakeholders including: recruitment staff, education staff, 
key managers, employee relations manager and staff, outpatient office 
directors, employee health staff, and Information Services staff. 
 October through December 2015 
o Reviewed current processes and data regarding onboarding time and rate 
of new hire appointments.  
o Reviewed regulations for interferon gamma release assays 
o Compared literature regarding available types of assays 
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o Reviewed lab procedures and recommendations with healthcare system 
lab managers 
o Began literature review 
 
 January 2016 
o Negotiated price and procedures with external lab 
o Obtained permission from VP to proceed with testing 
o Reviewed process and procedures with Employee Health staff 
o Updated policies in Employee Health 
o Ordered lab supplies-QFT kits 
o Reviewed staffing needs and incubation procedures with lab 
o Completed competencies for Employee Health staff completed 
o Ongoing literature review 
 February 2016 
o Began QFT®-GIT for all new hires 
o Conducted ongoing literature review 
o Developed tracking methods for new hire log 
 March 2016 
o Contacted DHEC for recommendations and update policies to retest in 
borderline result range 
 March-May 2016 
o Testing continued for new employees 
o Completed CITI training 
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 Summer 2016 
o Planned project 
 September 2016 
o Presented poster of literature review at conference 
 Fall 2016 
o Reviewed healthcare system’s requirements for nursing research council 
o Reviewed IRB requirements for healthcare system and University of 
South Carolina 
o Reviewed new hire volumes and onboarding times 
o Completed Healthcare system CITI requirements 
 January 2017 
o Completed DNP project proposal defense 
o Presented DNP project to Nursing Research Council and obtained 
scientific reviews and approval 
o Submit IRB application to University of South Carolina and obtained 
approval 
o Received approval from healthcare system IRB. 
 February 2017 
o Completed Retrospective data collection 
o Completed data analyses  
 March 2017 
o Defend dissertation University of South Carolina 
 April 2017 
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o Final edits and submission to graduate school 
o Submission of manuscript to Association of Occupational Health 
Professionals Journal 
 September 2017 
o Potential Conference presentation 
 
Resources. 
Retrospective data was compiled in excel spreadsheets in a password protected s-
drive folder that is only accessible by the primary and secondary investigators. 
Information was obtained from the paper new hire logs and Agility electronic medical 
record. No further technology assistance was required. The QFT®-GIT cost was accepted 
mid-budget year with VP understanding that lab cost budget would exceed budget in 
fiscal year 2016.  
Evaluation Plan 
Questions/Outcomes/Evidence-based measures 
Q1. Did implementation of QFT®-GIT reduce the number of days to complete 
tuberculosis screening for new hires? 
 Retrospective data was collected from electronic and paper Employee 
Health records. This data was stored on a password protected spreadsheet 
and all identifiers were removed prior to submission for analyses.  
 Tuberculosis screening time included the number of days to complete TST 
screening from the time of placement of step 1 to reading of the 2nd step. If 
the new hire brought documentation of step 1, then only time for 
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completion of step 2 was recorded. If the new hire failed to complete a 
step and had to be replaced, then that additional time was also included in 
the number of days for clearance.  
 Tuberculosis screening clearance time for subjects who completed the 
QFT®-GIT included the date of blood draw to date the result was 
reviewed. If the QFT®-GIT needed to be repeated for borderline positive 
result, this time was included in overall screening time.  
 If any test was positive, the amount of time for result of a chest x-ray was 
also including in tuberculosis screening time. 
 Those with a previous positive TST will be included with days to 
clearance being 0 days since the symptom review was completed on the 
day of pre-placement. However, if the subject did not bring the 
documentation on day one, then the number of days it took to bring in the 
documentation was recorded.  
 Data was analyzed by simple t test. Nonparametric testing and frequency 
was completed to analyze and describe demographic variables.  
 The time for completion of DHEC evaluation for positive testers was not 
included in screening time. 
Q2. Did implementation of QFT®-GIT for new hires reduce the overall number 
of days to complete onboarding?  
 Time for onboarding include days from first appointment to completion of 
all requirements including tuberculosis screening, assessments, fit for 
duties, lab results, and review of any requested records. Completion of 
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immunizations and Hepatitis B waivers were not included because those 
are not completed until after orientation.  
 Data was analyzed by t test, and spearman correlation. 
Q3. Did implementation of QFT®-GIT improve compliance with completion of 
tuberculosis screening within 10 days of orientation? 
 Compliance included completion of both steps of the 2 step PPD 
tuberculin skin test within 10 days of orientation or completion of QFT®-
GIT results along with any required repeat results, symptom reviews, or 
chest x-rays. 
 The data was analyzed by chi-square testing. 
Q4. Was implementation of QFT®-GIT be cost-effective? 
 A simple review of associated costs with QFT versus PPD including staff 
time was reviewed. Actual average salary of employees in Employee 
Health in relation to the time it takes to complete testing and assessment 
requirements, phone calls to contact non-compliant employees, and call 
employees with results of lab testing will was considered. Cost of supplies 
will include the cost for the PPD derivative, the syringe/needle, and cost of 
lab charges for QFT®-GIT. Labor costs from missed work for the new 
hire will not be considered since the new hire is not yet working for the 
organization and current salary cannot be determined.  
 Data was collected regarding average staff salary and the amount of time 
for each step of the assessment process and was described without 
statistical analyses. 
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Data Collection Procedure 
Data was collected retrospectively from electronic medical record chart review, 
review of paper new hire logs, and by the human resources data system. Data was 
compiled in a password protected excel spreadsheet initially separated into months of the 
year. Data was collected for subjects that came to Employee Health for pre-placement 
assessments during the months of April and May of 2015 and 2016. In 2015, TST was the 
standard of care and in 2016, QFT®-GIT. Data collected in the spreadsheet included: pre-
placement date, hire date, gender, race, age at hire, job titles, dates for placement or 
reading of TSTs, dates for QFT®-GIT results, dates for Chest X-ray results, dates for 
completion of screening and overall onboarding, and whether the employee brought 
documentation of previous positive or negative TST or IGRA results. The number of 
days to complete each step were calculated manually and by excel spreadsheet. Anything 
completed on the date of first pre-placement visit was counted as zero days.  Tuberculosis 
screening time with TST was defined as the number of days from first placement of PPD 
in Employee Health to reading of second PPD. If the employee brought in documentation 
of first step PPD within previous 12 months, only the time for the one step was recorded 
for tuberculosis screening time. If the new hire employee failed to return for a reading or 
placement, the time it takes for the employee to complete the entire screening process 
was included in total screening time. The definition for tuberculosis clearance time with 
QFT®-GIT was defined as the number of days between blood draw and result including 
any repeat QFT®-GIT for borderline results of 0.25 to 1.0 IU/ml. If the new hire required 
a chest x-ray for a positive PPD or QFT®-GIT, the time to complete x-ray and receive 
result as well as completion for symptom questionnaire was included. The time for the 
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patient to complete any DHEC appointments or treatment was not included because this 
is often lengthy, unpredictable and cannot be controlled by employee health. Compliance 
with completion of tuberculosis screening within 10 days of hire date was also recorded 
as yes or no, and if the new hire failed to complete at least one TST placement/reading or 
QFT prior to orientation was recorded.   
In addition to tuberculosis screening time and compliance within screening within 
10 days of hire date, dates and time for completion of other onboarding requirements was 
recorded. Data for overall onboarding time was recorded including dates and number of 
days to complete: overall tuberculosis screening, drug screens, fit for duty examinations, 
pre-work screens, required medical records/provider notes, and any other requirements 
for orientation clearance. A simple review and comparison of costs associated with TST 
and QFT®-GIT was conducted including Employee Health staff labor costs, lab fees, 
PPD fees. Data for volunteers, and for employees who did not begin work due to 
declination of the position, positive drug screens, failed pre-work screens or fit for duties 
or those who did not start for unknown reasons were removed from the final spreadsheet 
submitted for analyses. However, the primary investigator kept notes regarding the 
number of subjects excluded and the reasons.   
Data Management and Analyses Procedures 
Once the survey data was entered into the excel spreadsheet and the identifiers 
removed the investigator in collaboration with the committee statistician, reviewed the 
data and, organized the data in the form that would be useable in SAS for analyses. Data 
analysis included both descriptive and inferential statistics using SAS 9.4. Frequency 
distribution was included for categorical variables. The continuous variable statistics 
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included measures of central tendency (mean and median) and measures of spread 
(standard deviation and range). Inferential statistics included T-test, spearman correlation, 
and nonparametric testing. P-values less than or equal to .05 were considered significant. 
A power analysis at 80% power was conducted and revealed that a sample size of 300 






The primary and secondary investigators completed CITI training for the 
University of South Carolina and for the healthcare system. After the committee 
approved the DNP proposal, the primary investigator presented the project to the 
healthcare system’s Nursing Research Council for approval. Two members of the 
committee provided scientific review of the proposal and the committee approved the 
study (see Appendices D). An application for exempt status was submitted to the 
University of South Carolina and exempt from human subjects research was obtained 
(see Appendices D). The Healthcare System IRB agreed to accept the IRB decision from 
Table 3.1 
Required sample size for Ttest analysis with 80% power,  
Different effect size, and alpha.  
Effect Size Alpha = 0.05 Alpha = 0.01 
0.2 (Small) 788 4676 
0.3 352 524 
0.4 200 296 
0.5 (Medium) 128 192 
0.60 90 134 
0.7 68 100 
0.8 (Large) 52 78 
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the University of South Carolina and approved the secondary investigator. After 
approval, the investigator began data collection. The primary and secondary investigators 
are employees of the Employee Health department and are in charge of routinely 
collecting data regarding onboarding times and have access to the electronic medical 
records.  The investigators only retrieved data essential for project. The excel spreadsheet 
was saved in the primary investigator’s access limited S-drive folder, with a password 
protected spreadsheet. All computers were password protected and all data on the 
healthcare system’s computers are encrypted. The health reasons for any required fit for 
duties or pre-work screens, as well as substance found in the results of drug screens was 
not noted on the spreadsheet. Notations were made regarding any positive TST or QFT®-
GIT results, required chest x-ray dates and results, symptom review dates, and DHEC 
referrals. However, there was no record included on the spreadsheet to identify subjects.  
 
Summary 
The Iowa Model was utilized as a framework to evaluate the effectiveness of the 
quality project implementation and comparison of new hire tuberculosis screening with 
TST and QFT®-GIT (Melnyk & Fineout-Overholt, 2015). The quality improvement 
project arose out of a need to improve efficiency within the Employee Health department. 
Senior level management supported the decision to implement QFT®-GIT for new hires. 
IRB and the Healthcare System approved this study to assess differences in TST and 
QFT®-GIT methods for tuberculosis screening for new employees in regards to 
tuberculosis screening clearance time, overall onboarding time, compliance with 
screening within 10 days of hire date, and, costs. Data was collected without identifiers to 
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protect the health information of the subjects.




FINDINGS AND CONCLUSIONS 
Introduction 
The purpose of this chapter is to present the findings and conclusions, 
implications for nursing practice and future evidence-based projects and dissemination 
activities for this quality improvement project. The purpose of this DNP project was to 
compare baseline testing for new healthcare employees with QuantiFERON®-TB Gold 
In-Tube Test (QFT®-GIT) to the two step PPD TB skin test in regards to tuberculosis 
screening time, overall onboarding time, compliance with tuberculosis screening within 
10 days of orientation, and costs. This quality improvement project assessed whether 
implementation of the QFT®-GIT in lieu of the two step TST, met the organizational 
goal to reduce the number of days to complete tuberculosis screening, reduce overall 
Employee Health onboarding clearance time, and improve compliance with completion 
of tuberculosis screening within 10 days of hire date, while maintaining cost-
effectiveness. The findings will be presented in relation to the primary questions 
discussed in chapter three.  
The data was collected by Agility medical record chart review and from new hire 
spreadsheets in Employee Health. When hire data or job title was not available in agility, 
data was obtained from the Human Resources Capital Management system. For statistical 
analyses, race was identified as white, black or other. For comparison purposes, data was 
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divided into two groups including the “TST group” and the “QFT group”. The 2015 
sample included subjects who had tuberculosis screening with the two step tuberculin 
skin test as a standard of care was identified as the TST group. The 2016 sample was 
screening with the QFT®-GIT as the standard and was identified as the QFT group. The 
data was analyzed by descriptive and inferential statistics utilizing SAS 9.4. Descriptive 
statistical analysis included frequency procedures, measures of central tendency and 
spread. Inferential statistics included T-test, Pearson correlation, fisher exact test, general 
linear model (GLM) and chi-square. P-values of less than or equal to .05 were considered 




The initial sample included 537 subjects who had pre-placement assessments at 
the healthcare system’s Employee Health department in April and May of 2015 and 2016. 
Subjects were excluded from the study if they were volunteers (n=40), new hire subjects 
with positive drug screens (n=6), subjects who failed to report for employment (n=4) or 
failed fit for duty examination (n=1), and subjects who failed pre-work screen (n=1) or 
did not show for pre-work screen (n=1). The final sample included 484 new hire 
employees comprising 81.4% female subjects (see Table 1). The three most frequently 
hired age groups included ages 21, 25, and 27 years. The mean age for the sample was 
35.08 (n=484) (see Table 1). There were 323 Caucasian subjects (66.73%), 112 African 
American (Black) (23.14%), 13 Hispanic (2.69%), 12 Asian (2.48%), and 24 other 
(4.96%). The most frequent job title for the sample was registered nurses (n=111), 
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followed by nursing support (n =62). Of the sample, 227 had TST testing and 257 had 




Frequency distribution for demographic variables  
 


























90                 18.60 
394               81.40 
 
 
24                 4.96 
24                 4.96                 
23                 4.75 
413              85.33 
 
 
323               66.73 
112               23.14 
13                   2.69 
12                   2.48 
24                   4.96 
 
 
          111                23.03 
62                12.86 
32                  6.4 
15                  3.11 
14                  6.64 
          245                47.96  
 
 
 The mean number of days for completing all onboarding requirements to begin 
orientation was 6.40 days. The mean number of days to complete tuberculosis screening 
by TST was 8.06, ranging from 0-36 days.  One hundred twenty-four subjects supplied 
documentation of at least one previous TST, thereby reducing the number of days 
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required for subsequent testing. Seven subjects required repeated TST’s due to failure to 
follow up for TST reading. TB clear days included the amount of time required for 
tuberculosis screening and was 5.92 mean days for the TST and the QFT groups.  
However, Quantiferon® testing yielded an average 4.11 days to complete testing with a 
range of 1 to 10 days. There were four positive QFT® results with 3 of those being 
borderline less than 1.0. The mean number of days for drug screen results was 2.71 days 
with a maximum of 19 days resulting from subjects who had 2 dilute drug screens, 
necessitating a hair drug screen. Thirty-six employees were required to have pre-work 
screen tests, averaging 5.68 days to complete. Six subjects were required to bring 
documentation from their personal health care provider regarding work status. 
Nonparametric testing did not demonstrate was a statistically significant relationship 
between race and number of clear days (p=0.0942), fit for duty days (p=0.1823), drug 
screen days (p=0.0712), QuantiFERON® result days (p=0.9555), TB clear days 
(p=0.0718), TST clear days (p=0.0879), and pre-work screen days (p=0.9920) (Table 
4.2). 
 Table 4.2 
N, means, standard deviation, minimum, maximum for select variables  
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TB clear days 
























































Question 1. Did implementation of QFT®-GIT reduce the number of days to 
complete tuberculosis screening for new hires? 
There was a statistically significant difference in number of days to complete 
tuberculosis screening for the QFT® group in comparison to the TST group (p<.0001) 
(see Table 3). The average mean number of days to clear tuberculosis screening was 8.03 
for TST and 4.11 for the QFT®.  When comparing age between the two groups for 




N, mean, standard deviation for select variables by group 
 
a. t-test p=0.0849 
b. t-test p<.0001 
 
Question 2. Did implementation of QFT®-GIT for new hires reduce the 
overall number of days to complete onboarding? 
Findings indicated a statistically significant difference in the overall number of 
days to complete Employee Health screening for the QFT®-GIT in comparison to the 
Variable TST group 
 
N     Mean     Std. 
QFT group 
 
N     Mean     Std. 
Agea 
 
TB screen clear days b 
 
QFT complete days 
 
TST complete days 
227     34.11   11.78 
 
224      8.03      7.16 
 
0             .           . 
 
223      8.06      7.16 
 
257     35.93   11.27 
 
257     4.08     1.29 
 
255      4.11     1.26 
 
0 
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TST group (p<.0001), even when factoring in other new hire screening requirements. A 
reduction in number of onboarding days was demonstrated when using the QFT method 
as compared to the TST group (7.92 TST group; QFT® group 5.07, p<.0001). There was 
no statistically significant difference between the TST and the QFT® groups in the 
number of days to complete drug screens (p=0.8009), fit for duties (p=0.8009), or pre-
work screens (p=0.1265) (see Table 4.4).  
 
Table 4.4 
N, mean, standard deviation for select onboarding variables by group 
 
Variable TST group 
 
N     Mean     Std.  
QFT group 
 
N     Mean     Std. 
Clear daysa 
 
Drug screen daysb 
 
Fit for duty daysc 
 
Pre-work screen daysd 
 
PCP note days 
223    7.92      6.54 
 
225      2.74       2.84 
 
11        10.18     5.10 
 
20           6.6       5.0 
 
  6           7.17      8.57 
256     5.07       2.68 
 
256     2.68       1.61 
 
25       6.96       3.52 
 
11       4.00       4.00 
 
0             .          . 
a. t-test p<.0001 
b. t-test p=0.8009 
c. t-test p=0.0768 
d. t-test p=0.1265 
 
Data was further analyzed to determine if there was a correlation between 
onboarding clearance time and age, TST clear days, QFT®-GIT clear days, drug screen 
days, fit for duty days, pre-work screen days, or PCP note days. A weak but positive 
correlation was demonstrated between overall onboarding time and age (r=0.10094, 
p=0.0268) (see Table 14). However, findings showed a statistically significant stronger 
positive relationship between overall onboarding time and number of days to complete 
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TST screening (r=0.71838, p<.0001) and number of days for clearance by QFT® 
(r=0.62275, p<.0001).  A positive relationship was also found between onboarding 
clearance time with number of days to complete drug screens (r=0.30298, p<.0001). 
There was also a positive relationship between the number of days and fit for duties 
(r=0.76433, p<.0001), however, only 36 subjects were required to complete the 
examination. For onboarding time with the number of days to complete pre-work screens, 
a positive correlation was found among six subjects (r=0.68600, p<.0001) but none was 
found between onboarding clearance time and the number of days to supply 
documentation clearance from the PCP (r=0.40584, p=0.4247) (see Table 4.5). 
 
Table 4.5 
Spearman Correlation of selected variables for onboarding clearance days 
 
Variable Onboarding Clear Days 
N                                      Correlation 
Agea 
TST clear daysb 
QFT days b 
Drug screen days b 
Fit for duty days b 
Pre-work screen days b 
PCP note days c 
481                                    0.10094 
223                                    0.71838     
255                                    0.62275        
479                                    0.30298          
36                                      0.76433 
31                                      0.68600 





Question 3. Did implementation of QFT®-GIT for new employees improve 
compliance with completion of tuberculosis screening within 10 days of 




Analyses showed a statistically significant improvement in compliance with the 
QFT® group in comparison to the TST group (p<.0001). Overall, the compliance rate for 
completing the tuberculosis screening was 99.29% in the TST group and 100% the QFT 
group. There was no statistical difference for tuberculosis screening compliance between 
races. However, there was a statistically significant difference in compliance between 
genders with an increase in compliance among female employees (97.96%; p=.0010) (see 
Table 6). Three employees failed to complete two step TSTs. Ten employees failed to 
have at least one TST read prior to orientation. Sixteen employees in the TST group 
failed to complete tuberculosis screening within 10 days of orientation.  No QFT group 
subjects failed to complete screening within 10 days of hire date Table 4.6).  
 
Table 4.6 
Frequency distribution for clear within 10 days 
 
Variables Yes 
N                   % 
No 














            385               97.96 
  82               91.11 
 
 
309               95.96 
109               97.32 
  49               100 
 
 
210               92.92 
257               100 
 
8                  2.04 
8                  8.89 
 
 
13               4.04 
3                2.68 
0                0 
 
 
16               7.08 
0                 0 
a. Fisher exact test p value= .0010 
b. Fisher exact test p value= .3092 
c. Fisher exact test p value<.0001  
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Q4. Was implementation of QFT®-GIT cost-effective? 
The average cost for a two-step TST in Employee Health was estimated at $87.87 
per person and for QFT® $101.66 (cost of lab test, supplies, staff time for review of 
results). At initial glance, the QFT®-GITs appears to cost more per person ($13.79).  
However, further consideration is warranted when factoring other variables. Ten subjects 
failed to have at least one TST read and had to be replaced which required a second TST 
at an additional cost of $30.01- $37.76 per person (total costs of $377.60).  Sixteen 
subjects failed to complete screening within 10 days of orientation which resulted in an 
increase in Corporate cost to allocate Employee Health staff time recalling these new 
hired employees ($25 per hour x 8 hours per week used for recalls = $200.00 per week).   
If the 16 noncompliant new hire employees were RNs and were delayed start dates, 
Corporate would have had to contract with a staffing agency for 16 locum tenens nurses 
while waiting for the new hire employees to begin work.  This locum tenens contract 
would have resulted in an additional potential cost of $76,800 per month ($30/hr. for each 
locum tenens for full time x 160 hours in month = $4,800 x 16 employees = $76,800).  
Four subjects in the TST group did not complete both steps of the two-step tuberculin 
skin test within the specified time frame, which potentially placed the system at risk for 
DHEC penalties ranging from $100 for the first violation and up to $5,000 for a third 
violation (S.C. Department of Health and Environmental Control, 2015). Occupational 
Health Safety Administration penalties could be 12,675 to 126,749 each (OSHA, 2017).  
Fortunately, Employee Health staff were vigilant in their efforts to have new hires 
complete the testing but again allocating staff time was costly to Corporate.   
Accounting for the QFT® cost is easily done as a single test in comparison to 
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TST testing which includes other cost variables such as staff time incurred for 
noncompliant new hires in regards to follow up and TST re-testing and overall costs for 
locum tenens use to fill temporary vacancies. Overall, the costs are for utilizing the 
QFT® for new hire screenings demonstrated a cost savings to the healthcare system (see 
Table 4.7).  
 
Table 4.7 
Average estimated costs based on data collection 
 
Estimated Annual TST screening cost Estimated Annual QFT®-GIT cost 
For 2,000 compliant                   $175,740 
  + cost of noncompliant replace       8,823 
Total                                           $184,563      
 Minus brought  hx step 1      18,347 
   Minus hx +PPD                      1,479 
Total                                           $164,737 
 
Plus locum tenens cost               $576,000 
Plus DHEC fines x 20= $2,000 - 
$100,000 
Plus OSHA fines 20 x $12,675= $253,500 
                  
For 2,000 compliant           $203,320 
+ Repeat QFT®-GIT 1 monthly                    
656 
Minus hx +PPD $53x 60/yr.=           
3,180 
Total                                         $200,796 





Data analyses revealed that utilization of the QFT®-GIT for tuberculosis 
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screening of new hire healthcare employees in place of the TST significantly reduced 
tuberculosis screening and onboarding time while improving compliance with 
tuberculosis screening within 10 days of hire date (p<.0001). The mean tuberculosis 
screening time for both screening methods combined was 5.92, while TST screening time 
was 8.03 days and 4.11 days for the QFT® group. TST screening can be completed 
within 2 days for those that bring in documentation of previous TST, however the range 
in TST screening time was from 0 to 36 days. In contrast, screening time with the QFT®-
GIT was 1-10 days with the average of 3-4 days. The only QFT® group subjects that 
required 10 days or more for repeat testing were due to borderline positive test results. 
Overall, the healthcare system was able to increase the number of pre-placement visits in 
Employee Health from 104 pre-placement visits in September of 2015 to 187 in July of 
2016. This 56% increase in volume contributed to improved satisfaction for the senior 
management and hiring managers by increasing the volume and decreasing delays in 
orientation. 
More efficient onboarding time has been shown to improve employee satisfaction 
and retention, although not measured in this DNP project.  Anecdotal feedback back from 
hiring managers and senior management indicated an improvement in satisfaction with 
the Employee Health new hire process.  They fully appreciated the decrease in 
onboarding time, quicker start dates for new hires, less delays in orientation, and an 
increase in volume of new hire visits. Employee Health manager admits to receiving less 
complaints regarding appointment availability for screening processes and orientation 
start dates for new hires.  Streamlining processes also facilitated regulatory site visits 
with DHEC because the QFT®-GIT data is more easily retrievable and accurate.  Clearly, 
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the cost of QFT®-GIT is more than a TST, but as a single test but agencies should 
account for other variables in the cost analyses including staffing costs, lab testing, and 
locum tenens use.  Streamlining processes and improved efficiency are critical to 
Corporate overhead costs and compliance.  
 
Implications for Practice 
 Employee and Occupational health staff confront barriers with processes and 
compliance with tuberculosis testing with TSTs for new hire employees. The QFT®-GIT 
significantly reduced screening time and onboarding time and improve compliance. 
Organizations should consider implementation of an IGRA in order to streamline 
processes for onboarding new hires. Of course, new processes require negotiations 
between hospital departments and lab vendors, changes in policy and procedures, and 
Employee Health staff development for IGRA testing procedures in order to facilitate 
new hires and onboarding. 
 
Future Research 
Future research should include detailed cost analyses comparing screening with 
TST versus QFT®-GITs for both new hires and annual testing. A pilot study could 
provide foundation for future research to compare annual screening with QFT®-GIT and 
TST. Analyses could include measurements of process improvement, screening time, and 
employee satisfaction surveys for onboarding. Another area of future study would be 
implementation of an IGRA for patients being transferred to nursing homes or other long 
term care facilities to determine costs associated with extended hospital stays.  Similarly, 
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IGRA’s might prove useful in reducing hospitalization days for other patients awaiting 
transfer to other facilities.  Additionally, more studies are needed to analyze whether 
IGRAs predict active tuberculosis. Further study should be conducted to determine the 
predictive serum levels for borderline GRA and factors yielding false-positive or false-




 The review of the literature for this study was presented at the Fourteenth Annual 
Research Symposium: Research Impacting Clinical Practice sponsored by Upstate AHEC 
on September 30, 2016. Introduction to the problem, purpose of the review and methods 
for literature search were presented. Results of the literature review included process 
improvement, cost effectiveness, accuracy and conversions/reversions was shared. 
Discussions involved comparison of the TST and QFT® were reviewed (see Appendix 
D). A manuscript for the for Association of Occupational Health Professionals Journal 
(AOHP Journal) will be submitted for publication. An abstract of this quality 
improvement project has also been submitted for presentation at the AOHP conference in 
Denver, Colorado in September of 2017 (see Appendix E). Results will be shared with 
the new hire committee, the Vice-President of Human Resources, Employee Health, and 
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Evidence Table Abbreviation Guide 
_________________________________________________________________ 
 
IGRA     Interferon Gamma Release Assay 
 
TST     Tuberculosis Skin Test 
 
QFT®-GIT    QuantiFERON®-TB   Gold In-Tube Test 
 
LTBI     Latent Tuberculosis Infection 
 
BAMT     Blood Assay for Mycobacterium Tuberculosis 
 
CDC     Centers for Disease Control 
 
BCG     Bacillus Calmette-Guerin vaccine 
 
HCW     Healthcare Worker 
 















    




Foster-Chang, S. A., 
Manning, M. L., & 
Chandler, L. (2014). 
Tuberculosis screening of 
new  hospital 
employees: Compliance, 
clearance to work Time, 
and cost using tuberculin 
skin test and Interferon-
Gamma Release 
Assays. Workplace Health 




(Foster-Chang et al., 2014) 
 
Level V- Organization 
Experience/Quality 
Improvement 
 Quality B Good- purpose is 
clearly stated, findings are 
relevant, recommendations 
clear, consistent results in a 
single setting, good 
literature review 








IGRA sample size =100 
Sample size using 
retrospective chart 
review using TST in 
2011=100 
 




A) New employees 
offered IGRA or TST 
for screening: all chose 
IGRA between March 
19 and May 30,2013 
 
B) Retrospective chart 
review of new 
employees using TST 












lists limitations. Sample size is good 
-100 with IGRA compared with 100 
sample in 2012 and 100 in 2011= 
300 sample size 
 
Internal Validity- Not a controlled 
study so there are other variables 
that could be the cause of the result. 
Some investigator bias- expected 
the decrease in clearance and 
increase in compliance. No attrition 
 
External Validity- The conclusion 
can apply to similar sized healthcare 
settings with similar age group of 
employees but perhaps not to other 
employers or healthcare settings in 
other countries. The author did not 
overly generalize.  
Construct validity- Good. Measured 
clearance time as stated. 
 
Reliability- It was admitted that 
clearance time was affected by 
vacation of the provider that signs 
off on clearance, and a chart was 
misplaced. Failure to return rate was 
estimated and could be higher or 





There was a reduction in time to 
clearance with average reduction from 
13.18 days 2011 w TST to 5.91 days. 
Time to clearance based on screening 
method with and without prior TB 
screen significant p <.0001. 
 
Statistically significant compliance 
rates – 77% to 97% -2011/2013 p 
<.0001 and 2012/2013 p <.001. 
Meaning statistically increased 
compliance rate with IGRA vs TST. 
Compliance= completions of pre-
placement process within 14 days or 
less.  
 
Cost savings found 78.53 vs 47.02 per 
person. No statistical analysis with 
several assumptions regarding failure 
to return rate, staffing costs.  
 
















Lack of “true 
gold standard for 

















- T-SPOT®.TB used for 
IGRA 
Precision- statistically significant 
result p<.0001 for clearance time. 
95% confidence interval 





Mazurek, G.H., Jereb, J., 
Vernon, A., LoBue, 
P. Goldberg, S., & Castro, 
K. (2010). Updated 
guidelines for using 
interferon gamma release 
assays to detect 
mycobacterium tuberculosi









(Mazurek et al., 2010) 
Evidence Level IV Clinical 
Practice 
Quality A High 




Group of experts 
reviewed 96 out of 152 






, agreement of tests 
with each other or with 
TST, association with 
risk for TB. Meeting 




commentaries from test 
manufacturers. Multiple 
appropriate experts 
used- AAP, Am 
Thoracic Society, 
Advisory Council 
elimination of TB, 
Assoc Public Health 
lab, CDC, FDA, 
Infectious Disease 
Society, Army, Air 
Force, VA, clinicians, 




Internal Validity- Threat 
includes the use of package 
inserts and test company 
information that is subject to 
bias. There is some discussion 
about confounds in some of the 
examined studies in some of 
the discussion. This Article 
size would be too large to 
discuss all of them. Study 
included some non-
experimental studies/articles 
which limits the validity. 
 
External Validity- the volume 
of studies reviewed and 
number of experts reviewing 
should limit threats to external 
validity.  
Reliability- Reviews large 
number of articles and 
compares results in multiple 




Recommendations given for General use of 
IGRAs- may be used for surveillance, 
qualitative & quantitative interpretation 
should be used, evaluate feasibility, do not 
use low risk in general;  
 
Test Selection, Situations which IGRA 
preferred- groups w low return rates, BCG 
vaccine; TST preferred- children <5;  
 
Either TST or IGRA may be used without 
preference- recent contacts with TB, 
periodic occupational exposure to TB;   
 
Testing with IGRA & TST may be 
considered- when risk or progression 
increased, when initial test positive and 
second test encourages compliance, low 
risk for infection and progression, repeat 
when result indeterminate, borderline or 
invalid;  
 
Medical Management after testing- 
Diagnosis of TB should not be based on 
IGRA or TST alone, +TST or IGRA should 
be evaluated for likelihood TB infection, 
LTBI- exclude active dx with symptoms 
exam & Chest x-ray, discordant test results- 
individualized judgement 
 
Specificity QFT®-GIT- 99% 
Conclusions 
 





Further study to 
focus on value and 
limits of IGRA 









described.   
Sensitivity QFT®-GIT-81% 
 
Recent exposure strongly associated with 
positive IGRA 




Wrighton-Smith, P., Sneed, L., 
Humphrey, F., Tao, X., & 
Bernacki, E. (2012, July). 
Screening health care workers 
with interferon-y release assay 
versus tuberculin skin test: 
impact on costs and adherence to 
testing (the Switch study). 
Journal of Occupational and 
Environmental Medicine, 54(7). 
doi: 
10.1097/JOM.0b013e318254620f 
(Wrighton-Smith et al., 2012) 
 
John Hopkins Dearholt & Dang 
(2012) evidence level II: Quasi-
Experimental-includes 
intervention, standard of care as a 
control, and some randomization. 
Quality: B- Good, sufficient 
sample size, some control, 
reasonable recommendation, 
some references to scientific 
evidence 
 
Dearholt, S. L., & Dang, 





employees of John 
Hopkins. 
Purpose- measure 
cost & adherence 
annual and new hire 
screening.  
-Measured material 
& labor costs- 
average labor cost. 
-2nd- time motion to 
measure time with 




-3rd- 743 cohort 
new hire and annual 




TST and IGRA to 
gather data on 
positivity rates. 
Also questionnaire 






Potential Bias- Oxford Immune provided 
tests free of charge and education grant to 
John Hopkins of $49,300- manufacturer of T-
SPOT®.TB 
 
Internal validity- Participation voluntary.  
 
Possible validity threat- Employee Labor 
costs estimated 
 
External Validity- salary had to be estimated 
which could slightly skew results. I’m not 
sure I would include employee time away 
from work in measurement of the cost but it 
is an interesting approach to consider.  
 
Precision -Multiple hypothesis measured 
could account for significant p value by 
chance 
 
Precision-This study did an excellent job 
testing 38 other variables to see if they 
impacted test cost and they did not! 
 
I did not see statistical analysis of 
significance 
 
Reliability- there will be different salary 




Cost of TST $54.09 per 
annual and $81.38 two 
step new hire- most due to 
staff time, and patient 
time off work. Adding in 
follow up of positives and 
symptom screens= $73.20 
per person and new hire 
90.80pp – nonreturn rate 
considered.  
 
TST overall cost per 
person $73.20 
 
TST Adherence 99.1%, 
97.53%-total 98.54% 
 
IGRA Annual $78.05, 
new hire- $64.47 (did not 
add in cost of missing 
work) 
 
IGRA overall cost 
$73.20 
 
IGRA Adherence 99.98 
(annual) and 100% (new) 
 
Overall costs of screening 
with IGRA is the same as 
Conclusions 
 
 TST program costs 
are high due to staff 
burden- $73.20 per 
person 
IGRA results in 
better adherence and 
saves if the test is 
$54.83 or less per test 
 
Positivity tests 
showed high rate of 
those with prior 
known TST positives 
are false-positives- 




preference of IGRA 
vs TST 
 
Costly- those who do 
not follow up for 
reading- adherence 
70.8- 98.5% would 
save $366,793 per 
year  
-IGRA positive rate 
lower than TST 
-parallel- 62.5% 







Practice: Models and guidelines 
(2nd Edition). Indianapolis, IN, 
USA: Sigma Theta Tau 
International.  Retrieved 
from http://www.ebrary.com  
epidemiological 
statists of TB 
screens over 1 year 
to estimate cost and 
adherence rates 
Limitations Mentioned by author- did not 
consider accuracy of TST vs IGRA. IGRA 
conversion rate assumed equal to TST 
because serial testing not conducted. 
Enrollment bias in positivity portion- 
impractical to test all employees with both 
TST and IGRA 
 





IGRA- test cost at which 




-18.5% blood draw 
undesirable 







Reference, Type, Quality 
Article 4 
Swindells, J. E., Aliyu, S. H., 
Enoch, D. A., & Abubakar, I. 
(2009). Role of interferon-
gamma release assays in 
healthcare workers. J Hosp 
Infect, 73(2), 101-108. 
doi:10.1016/j.jhin.2009.05.005 
(Swindells et al., 2009) 
Level III –Systematic review 
of mixed types of 
articles  
Quality B Good- results 
reasonably 
consistent, references 
to scientific literature. 
Conclusions were a 
little confusing 




Systematic review- of 82 
studies, 29 suitable, 7 
excluded non-English. 2 re 




between IGRA & TST; 
Agreement IGRA & TST in 
BCG naïve; IGRA on long 
term exposure; IGRA in 
contact investigation; IGRA 
& sequential testing; 
correlation between IGRA & 
C-X-ray 
They do not specify 
difference in articles that 




Used a valid search strategy-
pub med and listed search 
terms. However, searched 
studies from 1990-2008- 
older studies may not be as 
reliable since IGRA’s only 
began use in 2001 with the 
most recent in 2008. Authors 
do separate T-SPOT®.TB 
articles from QFT® but I 
cannot tell that they 
separated the older QFT®, 
QFT® gold vs QFT®-GIT. 
This can affect validity and 
reliability. 
Also, included studies from 
different countries which can 
affect generalizability. 
 
Only 2 reviewers- there 
could be some bias. 
 
The authors do not discuss 





Poor agreement between 
IGRA and TST in low 
incidence countries-but 
related to BCG vaccination. 
Higher correlation in 2 
higher TB incidence 
countries.  
 
IGRA’s did show better 
correlation with markers of 
TB exposure during contact 
investigation than TST.  
 
States T-SPOT®.TB has not 
been adequately assessed. 
This is probably due to date 
of this study of 2009 and the 
development of T-
SPOT®.TB was 2008. The 
few studies did show 




Role of IGRA for 
chemoprophylaxis unclear 
but may be alternative to 
TST for detecting 
conversions.  
T-SPOT®.TB not 
adequately studied at the 
time of this article. 
 
Positive QFT® associated 
greater exposure to TB.  
 
Discordance between TST 
and QFT® probably related 
to false positive TST due to 
BCG- only cites 2 studies to 
back up this conclusion. 
 
Studies on boosting of TST 
show conflicting results. 
 
States role of IGRA in 
healthcare workers appears 
favorable but more studies 
are needed. Predictive values 
are conflicting. But then 
states specificity for IGRA is 
improved compared to TST 
and will help prevent 
inappropriate prophylaxis. 
















Weddle, G., Hamilton, M., 
Potthoff, D., Rivera, D., & 
Jackson, M. (2014). 
QuantiFERON-TB gold in-
tube testing for tuberculosis 
in healthcare professionals. 





(Weddle et al., 2014) 
 
This study combined to 
areas of assessment with one 
part being non-experimental 
cohort and the second part 
quasi-experimental- mixed 
method. I will use the non-
research appraisal tool.  
Level per John Hopkins 
appraisal tool:  
Level V Quality 
Improvement 
Quality B Good- purpose is 
clear, findings clear and 
relevant, recommendations 
clear and linked to findings. 
Description of methods a 
little unclear. 








children’s hospital w 
low incidence of TB 
and to determine 
need for repeat 
testing for employees 




approved by IRB. 
Reviewed 
occupational health 
records for TB risk 
factors.  
Collected repeat 
QFT®-GIT in 34 




Conclusions regarding repeat testing of + QFT® is 
related to the results of the study leading to good 
conclusion validity. The results were statistically 
significant P= .01 
 
However, no recommendation was really given as to 
what to do with the result of no association with risk 
factors and QFT® result.  
 
Internal Validity- It is unclear as to whether the repeat 
QFT®-GIT was looked at retrospectively or done at 
the time of this study. 34 of the 47 positive testers 
followed up. There is no discussion as to why the 
other 13 did not follow up- some attrition bias.  
 
External Validity-good conclusion, however would 
only generalize to low incidence areas which is not 
clearly spelled out in abstract findings. 
 
Construct validity- It is clear that the researchers are 
measuring what they intend to measure. 
 
Reliability- For the repeat QFT® the sample is 
relatively small- 34- reliability would be enhanced 
with larger sample and improve statistical significance  
 
Precision- appropriate application of p values however 
which statistical test was used is not listed. Confidence 
interval not discussed. 
 
There is a larger sample size for the retrospective 
portion which examines risk factors- 707 employee 
records assessed which improves reliability and 




IFNy mean lower 
for those with 
repeat negative 
results compared 




difference for risk 
factors between + 





occur for healthcare 
providers with QFT®-
GIT borderline 1 
IU/ml or less. Repeat 
testing recommended. 
However, there was 
overlap and cutoff for 




conditions or minor 
infections could have 
activated T-cells. Did 
cite studies that 
supported this finding.  
 
Risk factors for TB 
such as birth country, 
contact with high-risk 
persons and hx of 1 + 




GIT test results. The 
study did not mention 
association or 
assessment of those 
with BCG vaccination 
which would have 
been important to look 
at in this study. 










Article 6  
 
Cummings, K., Smith, 
T., Shogren, E., 
Khakoo, R., 
Sharmilarani, N., 
Bunner, L., … 
Weissman, D. (2009, 
November). 
Prospective comparison 
of tuberculin skin test 
and QuantiFERON-TB 
gold in-tube assay for 
detection of latent 
tuberculosis infection 
among healthcare 
workers in a low-
incidence setting 
 
(Cummings et al., 
2009) 
 
Evidence level II 
Quasi- Experimental 
B Good Quality- 
consistent results, 
reasonable sample size 
for this study, 
reasonable conclusions. 
 





Convenience sample: June 
2007 to Feb 2008, WVU new 
hire health care workers 
 
182 sample size which was 
68% of 266 invited.   
Procedure: 
1. Informed Consent written.  
2. Blood draw first QFT®-
GIT.  
3. Up to 3 weeks later step 1 
TST. 4. Second QFT®-GIT 1 




-IRB approval obtained 
-National Institute 




-Any ELISA QFT®-GIT that 
was positive or indeterminate 
was repeated. If tests agreed, 
results were confirmed. If tests 
disagreed, 3rd test was 
completed and confirmed result 
from mean of all values. 
 
Analyses: 
-Calculated % agreement TST 
and first QFT®-GIT. 
-specificity determined by no 
reported risk factors. 
Threats 
 
Threat to external validity- 
Lacks randomization.  
Selection bias- convenience 
sample 
 
Threat to precision & 
Validity 
Used Tubersol & Aplisol 
brands for TST which can 
have variation. Aplisol has 
shown higher rates of false-
positives.  
 
Internal validity threat 
 Did the reader interpret the 
TST result accurately? 
4 reports as positive. 
3 QFT®-GIT positives- 
study calculated % 
agreement as low but there 
were not many positives to 
measure 
-only 85 (47%) showed for 
second QFT®-GIT- attrition 
bias 
Precision threat 
It is unclear if the TST is 
what caused the result of 2 
2nd QFT®-GIT to be positive  
 
- Enhances reliability- 96% 
born in US, 93% did not 
have BCG vaccine, 62% no 




-agreement between TST and 
QFT®-GIT for those without 
risk factors on negative results= 
99% 
 
-Agreement of positive results = 
0% 
 
-2 with negative 1st QFT®-GIT 
had positive QFT®-GIT 
 
-4 had positive QFT®-GIT but 
negative TST 
 
-3 +TST but – QFT®-GIt 
 
-1 +TST and +QFT®-GIT 
 
-69% of indeterminate QFT®-
GIT were confirmed by second 
ELISA (11 0f 16, the other 5 
negative) 
 
-HCW w DM or Immuno 
therapy had greater odds of 
confirmed indeterminate (6.8 
odds ratio, CI 95%) 
 
-Days between TST and 2nd 
QFT®-GIT- no statistical 
significant difference.  
 
-there was higher IFN-y 
concentration on second QFT®-






-Tests did not agree on + 
results 
 
-most disagreement was 
+TST with negative QFT®-
GIT 
 
-reanalysis of 5 QFT®-GIT 
that had + results, only 
confirmed 2- conclusion that 
reanalysis may identify initial 
+ test results as negative.  
 
-immunosuppression 
consistent with low response 
to mitogen 
 
-effect of difference in 




-Fewer visits for QFT®-GIT 
valuable 
 
Author listed limitations: 
-short follow up time 
-limited sample size 
-variation in timing of tests 
and brands of PPD 
-Some HCW agreed to test 
but did not follow up 







Likelihood ratio X2 
-compared results 1st and 2nd 
QFT®-GIT by mixed-model 
repeated measures of analysis 
of Variance (ANOVA) 
- covariate-duration of time 
between 1st TST and second 
QFT®-GIT 
-compared effect of 1 
intervening TST with 2 
intervening TST 
Reliability Threats: 
- large age range 28-62 years 
-8 had diabetes or recent 
immunosuppressive therapy 
which can affect results of 
















Perio, M. A., Tsevat, J., Roselle, 
G., Kralovic, S., Eckman, M. 
(2009, January 26). Cost-
effectiveness of interferon 
gamma release assays vs 
tuberculin skin tests in health 
care workers. Journal of 
American Medical Association: 




(dePerio et al., 2009) 
 
 
Level V Financial Evaluation 
(cohort) 
A High Quality- clear objective, 
consistent results, good lit 
review, thorough methods 
(Dearholt & Dang,2012) 
Methods 
 
Estimates based on RN salaries at VHA 
in 2007 
 
Markov state-transition model w 
societal perspective & lifetime horizon 
1yr 
- No LTBI, no INH, 
-No LTBI, INH partial, 
-No LTBI, INH complete, 
-LTBI, no INH, 
-LTBI, INH partial, 
-LTBI, INH complete 
 
-effectiveness measured in quality-
adjusted life years (QALYs) 
 
-hypothetical 35 yr old HCW, pay 
based on RN 
 
-compared TST, QFT®-G, QFT®-GIT 
 
-analysis vaccinated BCG vs not 
 
-accounted for indeterminate QFT® or 
failure to return for TST reading 
 
-used statistics from VHA for 
probabilities of return for TST 
read/placements 
 
-direct & indirect costs considered 
including missed work 
 




- Used hypothetical 
scenario 
-age 35 but did run 
analysis for ages 25-55 
with same results 
Construct validity-
attempted to 
generalize to entire 
HCW population 
based on hypothetical 
results 
-study is in 2009 so 
figures for salary and 
cost of IGRA are not 
equivalent to today  
-good-performed 
probalistic sensitivity 
analysis by Monte 
Carlo simulation 
-used only RN pay for 
calculations- does not 




-did not assess 
transmission of TB & 
costs/benefits 
-did not examine 
subsequent annual 
TST or QFT® 
Findings 
 
-TST costlier & less 




sensitivity is better 
than QFT®-G then 
QFT®-GIT becomes 
more cost effective 
 
-less cost if QFT®-G 
kit is $32, QFT®-GIT 
$36 or less 
 
-QFT®-G & QFT®-
GIT cost savings 
compared to TST in 












-QFT®-G & QFT®-GIT are 
more effective & less costly 
compared to TST for 
detecting LTBI in HCW 
 
-time costs saved with less 
missed work time and 
QALYs.  
 
-IGRAs less costly if run in 
batches of 12 for non bCG 
and 4 for BCG-vax 
 
-QFT®-GIT least costly and 
most effective 











Lamberti, M., Uccello, R., 
Monaco, M. G. L., Muoio, 
M., Feola, D., Sannolo, N., 
Nienhaus, A., & Chiodini, P. 
(2015). Tuberculin skin test 
and QuantiFERON® test 
agreement and influencing 
factors in tuberculosis 
screening of healthcare 
workers: a systematic review 
and meta-analysis. Journal of 
Occupational Medicine and 
Toxicology, 10(2),1-13. doi: 
10.1186/s12995-015-0044-y 
 
(Lamberti et al., 2015) 
 
Level III Systematic review 




Quality- A High- used 
statistics to generate a new 
effect size, listed inclusion 
and exclusion criteria, 
complete flow diagram of 
studies, large sample size, 
comprehensive review 
(Dearholt & Dang, 2012) 
Methods 
 
-Preferred Reporting Items 
for Systematic Reviews and 
Meta-Analysis. 
-PubMed 
Search terms-workers and 
tuberculosis or TB infection 
or TB disease or TB and 
tuberculin skin test or 
tuberculin skin testing and 
Quantiferon®- 2004-2013 
 
-inclusion-screening LTBI in 
HCW w TST & QFT®, 
comparison between TST & 
QFT®, sample vaccine rates, 
English 
 
-Excluded- duplicates, case 
reports, editorials, close 
contacts, immunologic or 
lab, NTM, HIB, chronic 
rheumatologic, infl bowel. 
 
-29 included out of 1,430 
 
-10 mm cutoff +PPD only  
 





QFT®-G with QFT®-GIT 
-study assumed that TST is 
an accurate test for LTBI.  
-review went back a little far 
2004 
 
Author- should include 




-One third of TST & QFT® 
results discordant. K value 
random effect 0.28 (CI 95%) 
 
-K 0.25 (95% CI)TST & 
QFT® agreement in low 
incidence group, 0.19 
intermediate, 0.38 in high 
group 
 
-best agreement in high 
incidence group 
-worst agreement 











-lower rate of QFT® positive 
attribute to higher specificity 
than TST- higher specificity 
to mycobacterium tb 
 
-BCG vaccination reduced 
agreement- TST + increasing 
risk of false positives 
 
-discordant QFT® + vs TST 
negative increased with age 
over 40 and 50 
 
-increasing working year and 
positivity of both tests 
 
-TST should continue for 
low prevalence of 
vaccination or high incidence 
of TB infection 
 
-QFT® is helpful for areas w 
higher BCG vaccination 
 
-physicians should consider 
TB incidence, vaccination 
status, age and working 
seniority when choosing 
tests.  












Jensen, P. A., Lambert, L. A., 
Iademarco, M. F., Ridzon, 
R., & Cdc. (2005). 
Guidelines for preventing the 
transmission of 
Mycobacterium tuberculosis 
in health-care settings, 2005. 
MMWR Recomm Rep, 





(Jensen et al., 2006) 
 
 
Evidence Level IV Clinical 
Practice Guidelines 
Quality: A High even though 
not developed in the past 5 
years. There is an addendum 
that is 2010. Sponsored by 
CDC this is nationally 
recognized guidelines based 
on scientific evidence 




-update of 1994 
guidelines 
-based on epidemiology 
reports, evidence-based 
science and content 
experts- experts in TB, 
infection control, 
environmental control, 





Very lengthy document 
and lengthy list of 
references that would be 
difficult for one person 
to review. 
 
-not updated in the past 5 
years except for an 
addendum 
 
-did not list search 
strategy 
 
-expertise is evident 
Findings 
 
-lengthy document listing practice guidelines 
for preventing Tb including screening of 
healthcare workers and infection control for 
patients. I will focus on applicable sections 
for screening in my setting due to length of 
this article. 
 
-Low risk facilities-  
New hires- 2 step PPD or 1 BAMT 
If hx positive- symptom review 
No annual screening required 
 
-outlines how to complete 2 step and when to 
read 
 
-2 step minimizes boosting leading to 
unwarranted suspicion of TB with 
subsequent testing 
 
-baseline tests should be within 10 days of 
HCW starting employment 
 
-medium risk- 
Same for new hires 
Annual PPD or BAMT for all HCW 
 
-states BAMT is more specific than skin 
testing 
 
-BAMT recommended for BCG vaccinated 
 
-Outlines follow up for exposures 
 
-HCW with + should have Chest X-ray and 
be assessed for LTBI treatment 
Conclusions 
 
Guidelines require 2 
step PPD or 1 
BAMT for new 
hires regardless of 
risk.  
IGRA’s- QFT® or 
T-SPOT®.TB are 
acceptable per 2010 
addendum 











Gonzalez, M., & Conlon, H. 
A. (2013). Updating a 
tuberculosis surveillance 
program: considering all of 
the variables. Workplace 
Health & Safety, 61(6), 271-




(Gonzalez & Conlon, 2013) 
 
Level V Quality 
Improvement. Quality- B 
Good- clearly stated aims, 
single setting only, good 
references 
(Dearholt & Dang, 2012) 
Methods 
 
-organizational needs assessment 
based on: CDC requirement, 




1. Identify specific 
organization elements 
and processes 
2. Match organizational 
elements to testing 
methods 
3. 13 item chart was 
created to compare each 
methods attributes 
Evaluate employee population 
and decide which test meets 
surveillance needs considering 
resources of organization 
Threats 
 
-reliability threat- results 
can really only be 
generalized to this 
practice setting but 
method of determining 
which method TST or 
QFT® to use can be 
applied.  
 
-Validity threat- some 
author bias- attempts to 




This organization chose: 
-TST for annual testing of all 
without BCG vaccine.  
-annual for those with BCG-







-employee exposure to TB- 
QFT® 






-I don’t know that I agree 
with this organizations 
choices. The evidence does 
not point to doing QFT®’s 
just because someone is 
pregnant. CDC 
recommendations are not to 
just do a symptom 
assessment on BCG 
vaccinated. The article did 
not say it was for BCG 
vaccinated with +TST. I do 
realize this organization has 
lab limitations that our 
organization does not have.  
 
-my take away for this article 
is the process to assess the 
organization specific needs. 












Diel, R., Loddenkemper, 
R., Meywald-Walter, 
Gottschalk, R., & 
Nienhaus, A. (2009). 
Comparative performance 
of tuberculin skin test, 
QuantiFERON®-TB-gold 
in tube assay, and  T-
SPOT®.TB . TB test in 
contact investigations for 
tuberculosis. Chest, 
135(4), 1011-1018.  doi: 
10.1378/chest.08-2048 
 
(Diel et al., 2009) 
 
Evidence level II Quasi-
experimental 
Quality B good- 
reasonable conclusions, 
large sample size, 
reproducible 
(Dearholt & Dang, 2012) 
Methods 
 
-started with 2004 close 
contacts of culture confirmed 
TB. 
-eliminated 6 w hx prior +TST 
and 2 with prior tx for active 
tb.  
-842+ TST > 5mm had blood 
drawn for QFT® and T-
SPOT®.TB 
-22 of those T-SPOT®.TB 
result could not be determine- 
not enough lymphocytes, 7 
indeterminate T-SPOT®.TB 








-215 recalled case coughing 






-51 healthcare workers 
-44 nonintimate friends 
-11 copatients 
-5 sports club members 
 
-multiple regression analysis 
Threats 
 
Reliability- may not be 
able to reproduce due to 
high rate of BCG 
vaccination in this 
group 
-increased age and 
foreign born was 
associated with higher 
rate IGRA positive 
despite trying to exclude 
those with prior TB 
exposure- could be 
confounding variable 
 
-this study was focused 
on community more 
than HCW so less 




-not a random sample 
-small attrition bias-  
-attempted to control 
confound variable of 
being household or 
intimate contact but was 




-Agreement between QFT® and T-
SPOT®.TB high 93.9% k value 0.852 
w CI 0.78 to 0.92 
 
-BCG vaccination was associated with 
negative IGRA p<0.0001 
 
-contacts who report coughing of 
source more likely + IGRA- QFT® 
49.8%, T-SPOT®.TB  23.1%p, 0.0001 
 
-no significant + IGRA and cumulative 
exposure time of contacts p < 0.0001 
 
-contacts of AFB-positive more likely 
IGRA + than AFB negative p < 0.0001 
 
-contact with AFB-positive >40 hrs 
were 6x higher rate of +IGRA 
 
- Higher cutoff of TST >15 mm was 
more likely associated for IGRA 
positive suggesting high specificity.  
 
- Significant association between + 
IGRA and increase age, foreign origin, 
AFB positive source, source case cough 
and exposure time 
 
-Discordant results between QFT® and 
T-SPOT®.TB improved with 
increasing cutoffs to 9 spots for   T-
SPOT®.TB , QFT® IU/mL 0.6 but 
only slight gain of 4.8% 
Conclusions 
 
-IGRA reduce LTBI 
screening to those truly 
infected and is better for 
contact investigation 
 
-Using QFT® or T-
SPOT®.TB would reduce 
LTBI suspects to be 
investigated by 70% 
 
-IGRA more accurate 


















Veeser, P. I., Smith, P. K., 
Handy, B., & Martin, S. 
R. (2007). Tuberculosis 
screening on a health 
science campus: use of 
QuantiFERON®-TB gold 
test for students and 
employees. Journal of 
American College Health, 










(Veeser et al., 2007) 
 
Evidence Level 5 
Program Evaluations 
Quality- B Good 
Clear objectives, some 
scientific evidence 
(Dearholt & Dang, 2012) 
Methods 
 
-Retrospective Chart Review 
June 2005 to Aug 2006 
-QFT® use for- past positive 
but not documented by health 
dept, questionable report past 
+, hx BCG, UHS TST + 
-Setting University of 
Tennessee Health Science 
Center- 2,200students, 6,000 
employees 
 









threat- small sample size 
-lacks randomization 
-Did not run any 




-94 nonreactive, 10 reactive (8 students 
& 2 employees), 5 indeterminate  
-7 reactive students had BCG, 1 
undocumented past + TST 
-1 employee reactive with documented 
+TST and 1 employee undocumented 
past + TST 
 
-85% of tested nonreactive, 






TB gold for students and 
employees for listed 
situations.  
 
-3 with past +TST but 
nonreactive QFT®-G may 
have had improper 
readings or reaction to 
thimerosal. 
 
-benefits in completion 
rates of TB screening, 
result reporting and 
surveillance capacity 












Zwerling, A., van den 
Hof, S., Scholten, J., 
Cobelens, F., Menzies, 
D., & Pai, M. (2012). 
Interferon-gamma 
release assays for 
tuberculosis screening 
of healthcare workers: 
a systematic review. 




(Zwerling et al., 2012) 
 





Quality- A High 
Clear objectives, 
multiple databases 
used, details of studies 
presented, conclusions 
logical 




-Systematic Review of studies: 
1-compare IGRA performance in HCW 
2- IGRA correlation to occupational exposure to 
TB compared to TST 
3- Rate of IGRA conversions & Reversions in 
relation to IGRA and occupational exposure 
compared to TST 
4- summarize cost-effectiveness studies 
 
-Databases-PubMed, Embase, Biosis, Web of 
Science up to Oct 2010. 




-detailed search string 
 
-Created hierarchy of reference standards- no 
studies found at 2 highest. From low to high: 
Concordance with TST, Sensitivity & Specificity 
in active TB, Correlation w exposure, Predictive 
value of IGRA for active TB, Efficacy of 
preventive therapy based on IGRA results figure 
1. 
 
-calculated Fishers exact 95% CI or prevalence 
estimates 
 
-separated studies by high, intermediate, low 
incidence settings 
 
-50 total studies: 





Authors note publication 
bias is always a concern. 




QFT®’s together when 





citations- bias threat 
 
-included different 




-high incidence- TST 
and IGRA positivity 
rates high, IGRA 
slightly lower 
Low & Moderate- 25 
studies- lower 
prevalence of + QFT® 
or  T-SPOT®.TB than 





between TST & 
IGRA. Agreement is 
improved with higher 







studies show positive 
association between 
IGRA + and risk 
factors- high risk ward 
work, Work in TB 
clinic or geriatric care, 




-conversion rates vary 
Conclusions 
 
-IGRAs well correlated 
with TB infection risk 
factors in low & 
intermediate incidence 
 
-One-time screening may 
result in lower prevalence 
of + tests and less LTBI 
tx.  
 
-prevalence of +IGRA 
lower than TST 
 
-IGRA higher rate 
reversions and 
conversions if using 




increase over baseline. 
Few studies examine this 







3 feasibility & test implementation 
2 new studies after 10/2010 
 
-further details online supplement 
 
-79% of studies QFT® only (35), 7% (3)  T-
SPOT®.TB  only, 14% both IGRAs 
-14% only IGRA testing 
11% (5) high incidence 
-study size 12 to 1313 HCW for total 11,963 
 











Nienhaus, A., Schablon, A., 
Costa, J.T., & Diel, R. 
(2011). Systematic review of 
cost and cost-effectiveness of 
different TB-screening 
strategies. BMC Health 




(Nienhaus et al., 2011) 
 
Evidence level III 
Systematic review 
 
Quality- B Good- used 
comprehensive database and 
search strategy, inclusions 
criteria listed, articles up to 
10 years old 
(Dearholt & Dang, 2012) 
Methods 
 




German & English 
Identified 76 references, 
narrowed to 13 
Inclusion: study design cost 
analysis or cost-
effectiveness. Population- 
high risk groups- HCW, 
immigrants, close contacts 
Outcome-cost, ratios 






other groups besides HCW 
which can be a threat to 
generalizability for purposes 
of my study.  
 
-precision-had to calculate 
cost ratios for different 




-assumptions regarding TST 
specificity varied widely 
between the studies making 
comparison difficult 
-different cost ratio 
assumptions and test 
parameters between TST and 
IGRA varied and therefore 




-in all studies the TST only 
strategy was most expensive’ 
-all 13 studies showed 
decrease in costs with use of 
IGRAs 
-in 4 out of 7 dual step 
studies- IGRA after +TST- 
was least expensive and in 2 





-Studies show strong 
evidence in support of cost-
effectiveness of using IGRA 
for screening high risk 
groups- HCW, immigrants 
from high-incidence 
countries, close contacts 











Pai, M., Zwerling, A., & 
Menzies, D. (2008, August 
5). Systematic review: T-
cell-based assays for the 
diagnosis of latent 
tuberculosis infection: an 
update. Annals of Internal 




(Pai et al., 2008) 
 
Evidence level III 
Systematic review mixed 
with meta analysis  
 
Quality- B Good- 
Thorough literature searches 
of reputable databases, used 
statistics 
(Dearholt & Dang, 2012) 
Methods 
 
-Search PubMed thru 2008 
-added 20 new studies to a 
previous analysis and 
eliminated those with less than 
10 participants and those with 
known immunocompromised 
 
-Fixed effects meta-analysis 
with correction for over 
dispersion 
-Sensitivity- microbiologically 
confirmed active TB, not 
including immunocompromised 
-specificity- healthy low-risk 
participants without known 
exposure to tb 
 
-2 independent reviewers 




-summarized results in forest 
plots 
-to pool estimated- fixed effects 
meta-analysis with correction of 
variability using MetaDiSc 
 
-evaluated heterogeneity with 
chi-square andI2 tests 
 
Used 38 articles 





-most studies small 
-no gold standard for dx of 
TB 
-variable TST methods 
and cutoff 





78% QFT®-TB G (95%CI) 
 
70% QFT®-GIT (CI 63-
78%) 
 




99% for non-BCG for both 
QFT®s (CI 98-100%) 
 
96% BCG vaccinated (CI 94-
98%) 
 
T-SPOT®.TB 93% (CI 86-
100%) 
TST97% (CI 95-99%) 
Conclusions 
-IGRAs have excellent 
specificity unaffected by 
BCG 
 
TST specificity high in non-
BCG vax but low in BCG-
Vax 
 
Sensitivity of IGRA & TST 
not consistent but T-
SPOT®.TB is more sensitive  
T-SPOT®.TB than QFT® 
and TST 











Slater, M., Welland, G., Pai, 
M., Parsonnet, J., & Banaei, 
N. (2013, October 15). 
Challenges with quantiferon-
TB gold assay for large-
scale, routine screening of 
U.S. healthcare workers. 
American Journal of 






(Slater et al., 2013) 
 
Evidence level V 
Organizational Experience- 
Program evaluation 
Quality level B Good- 
project aim clearly stated, 
methods and results 
adequately described, clear 
interpretation. 
 
(Dearholt & Dang, 2012) 
Methods 
 
-Retrospective review of 
QFT® results of HCW with 
2 or more QFT® tests June 
2008-July 2010 at SUMC.  
-SUMC-611 bed hospital, 14 
cases TB per year 
-9,153 HCW annual QFT® 
results 
-new positives had repeated 
QFT® in within 6 weeks 
-2008 QFT®-GIT upgrade 
 
-independent group t tests to 
compare variables 
-z statistic for proportions 
-linear regression compare 
independent variables 
-kappa to assess agreement 
between QFT® assays 
Threats 
 
-attrition bias-11.1% n=40 
did not follow up for repeat 
testing- staff turnover, 
refusal or preference 
-there is no clear standard for 
when to repeat QFT®s 
-construct-generalizability 
threat- lack of gold standard 
to dx LTBI 
-Lack of risk factor data in 
cohort- other variables could 
contribute such as exposures 
during the year. 
-precision- intervals between 
tests non-standardized 
-no randomization 
-changing lab practices over 




-repeat QFT® conversion 
rate was 4.4% and short term 
reversion rate 64.8% (short 
term is testing < 60 days 
between tests) 
 
-of 1,223 (13.4%) initially 
+QFT®, 67.5% stayed 
positive (828) 
 
-of 8,227 – QFT®, 4.4% 
(361) converted. High 
proportion fell between 0.35 
to 1.0 IU/ml cutoff 
 
-positives were retested and 
64% reverted short term. 
Long term tested 63% 
reverted 
 
-11.1% did not return for 
repeat testing 
 
-changing QFT® cutoff 
would help conversion rates 
Conclusions 
 
-short term retesting new 
QFT® conversions is 
feasible to reduce false-
positives  
-Short term retesting of 
+conversions revealed 67% 
reversion to negative.  
 
-QFT® standardization is 
needed 
-cutoff variability needs 
examined. 
-Variability sources may 
include incubation time, 
ELISA between run, 
Manufacture related, 
immunologic factors 
-manufacturer definition of 
QFT® conversion is inflated 
and incompatible with low 
risk setting. 
-higher QFT® cutoff is 
needed 
-cutoff of 5.3 yields similar 
cutoff of institutions 
historical TST 












Dorman, S. E., Belknap, 
R., Graviss, E. A., Reves, 
R., Schluger, N., 
Weinfurter, P., . . . Daley, 
C. (2014, January 1). 
Interferon-y release 
assays and tuberculin skin 
testing for diagnosis of 
latent tuberculosis 
infection in healthcare 
workers in the United 
States. American Journal 
of Respiratory Critical 









Quality A high- 
generalizable, consistent 
results, large sample size, 
conclusions derived from 




- Longitudinal, cross- sectional 
- 2,563 HCW 
- 4 healthcare systems in US- 
Denver, Houston, Baltimore, New 
York City 
- Case rate low- 4-9 per 100,000 
- QFT®-GIT, T-SPOT®.TB, and 
TST (tubersol) baseline, 6 
months, 18 months 2/2008 to 
3/2011 
- QFT®-GIT, T-SPOT®.TB  
collected  and TST immediately 
after phlebotomy (2 step if 
needed) 
- Interviewed at each visit 
- +TST were asked to repeat TST 
but counseled of risks 
 
Exclusion- 
- Current or prior TB 
- Prior anaphylaxis to TST 
- TST past 6 months 
 
Substudies- 
- 2 sets of IGRA 2 weeks apart 
without TST in between 
- Concordant negative or 
concordant positive baseline 
included 
- Repeat ELISA testing for all 
positives started midway through 
the study 
 
Boosting Sub study- 
- Repeat IGRA in 7-21 days after 
Threats 
 
-To prevent bias and 
improve reliability-the lab 
staff did not access 
clinical information or 
prior IGRA results and 
staff performing one type 
IGRA did not access 
result of other IGRA 
 
-Author did an excellent 
job of listing 
limitations/threats- 
-Absence of gold-standard 
-attrition- good-low rate 
of loss to follow up 
-reliability threat- cannot 
generalize study to 
immunosuppressed or 
areas with higher rates of 
TB 
-cannot generalize to 
Europe or areas with 
lower rate of + IGRA 
compared to TST- these 
areas may use different 
tuberculin and higher 
rates of BCG 
-not all +TST patients 
accepted repeat TST 
-Results could vary with 
different kinds of PPD 






with – IGRA 
associated with 






SPOT®.TB , 0.9% 
TST 




to negative at 6 
months 
 
-sub study if IGRA 
retesting without 
TST 




T-SPOT®.TB at 2 








-majority of new positive TST 
and IGRAs were false-positive 
-reversions for all 3 tests were 
observed in 50% participants 
-none had conversions to all 3 
tests at once 
-conversions were not 
associated with TB exposure 
risk 
-Sub study- half of new 
conversions by QFT®-GIT 
were not confirmed by ELISA 
-IGRA specificity in US HCW 
at low risk is less than 
previously reported by prior 
studies 
-borderline cutoff would not 
help clinically because only a 
small proportion 15-18% of 
converters were close to cut 
points 
-IGRAs play a role for HCW 
with BC vaccine as positive 
TST but negative IGRA was 
strongly associated. 
-false-positive conversions 
occur 6-9 times more w IGRA 
than TST – balance use with 
logistical advantages 
-repeat testing of new 
converters should be 
considered 
-repeat ELISA from stimulated 
plasma for QFT®-GIT + may 
be useful 







baseline IGRA and TST 
 
Statistics- 
- K coefficient- agreement 
measures 
- Two-proportions z test 
- McNemar’s test- dependent 
proportions 
- Holm-Bonferroni- multiple 
comparisons 
- T test-compare mean changes 
IGRA 
- Reproducibility & repeatability 
sub studies used assess variability 
- Linear mixed-effects models 
- Within subject standard deviation 
and intraclass correlation 
coefficient 
 







Reference, Type, Quality 
 
Article- 18- 
 Loddenkember, R., Diel, R., 
& Nienhaus, A. (2012, July). 
To repeat or not to repeat- 
that is the question! Chest, 
142(1), 11. doi: 
10.1378/chest.12-0045 
 
(Loddenkemper et al., 2012) 
 
Level- V- Literature 
Review/Expert opinion- 
editorial 
Quality B- fairly definitive 
conclusions. Short article 
with only one true article 
review 
 
Article recommended by 




Methods not discussed in this 
short article. Good research 
is referenced however. 
Discussed research that is in 




-small number of articles 
reviewed 
-no discussion of limitations 




-High income, low TB 
incidence countries- 
evidence points toward 
positive predictive values for 
IGRAs higher than TST. 
 
-gray zone 0.35 to 1.0 would 
reduce conversion to <1%  
-using gray zone 
approximately every second 
HCW will revert to negative 
Conclusions 
 
-simple positive- negative 
interpretation of IGRA serial 
testing of HCW 




chemotherapy only for IGRA 
> 1.0 
 
-IGRAs should be repeated 
in routine TB screening in + 
testers 
 
-Chest X-rays not needed in 
asymptomatic HCW with 
reversion in IGRA regardless 
of first positive IGRA 
concentration 







Reference, Type, Quality 
 
Article 19 
Schablon, A., Nienhaus, A., 
Ringshausen, F. C., Preisser, 
A. M., & Peters, C. (2014, 
December). Occupational 
screening for tuberculosis and 
the use of a borderline zone 
for interpretation of the IGRA 
in German healthcare 




(Schablon et al., 2014) 
 
Evidence level II Quasi-
experimental 
Quality B Good 
(Dearholt & Dang, 2012) 
 
Article recommended by 




Convenience sample, cohort 
of screenings in HCW-
hospital, nursing home, and 
outpatient- conducted in 
occupational health clinic 
3,823 had one QFT® 
817 had second QFT®- 
whether patients had second 
QFT® was not standardized- 
occupational health 
physician determined need 
based on exposure or 
working on high risk ward 
-questionnaire to assess risk 
-low incidence country 
 








- second QFT® not 
standardized 
- German study- could be 
higher risk than is US but it 
is listed as low incidence. 
-This included serial testing, 
not just baseline.  
-Some author bias is 
apparent as they specifically 
examined articles regarding 
variability in results and 
cutoffs. I think there was an 
expectation of the cutoff 
being too high.  




-Positive QFT® risk factors= 
age >55, foreign birth, hx 
TB, internal medicine work, 
infection ward work, 
geriatric care work. 
 
-Conversion rate 2.8% 
-Reversion 37.3% 
-changing conversion 
definition to <0.2 to >0.7 





Borderline zone 0.2 to < 0.7 
may avoid X-rays and meds 
that are not needed. 
 
No case of active Tb found- 
screening should be 
restricted to HCW w 
unprotected contact 











Rangaka, M. X., Wilkinson, 
K. A., Glynn, J. R., Ling, D., 
Menzies, D., Mwansa-
Kambafwile, J., . . . & Pai, 
M. (2012, January). 
Predictive value of 
interferon-y release assays 
for incident active 
tuberculosis: a systematic 
review and meta-analysis. 
Lancet Infectious Disease, 




(Rangaka et al., 2012) 
 
Evidence level III –
systematic review with meta 
analysis, combo type of 
studies 
 
Quality- A High- thorough 
literature search, conducted 
quality assessment, new 
statistics, definitive 
conclusions 
(Dearholt & Dang, 2012) 
 
Article recommended by 
region 4 DHEC MD 
Methods 
 
-PubMed, EMbase, Biosis, 
Web of Science 
-studies up to 6/30/11 IGRA 
predictive value 




study group selection, 
comparability of groups, 







Main interest- person-years 
incidence rates of disease 
-calculated incidence rate 
rations for disease 
progression in IGRA + vs – 
and also for TST 
-DerSimonian & Laired 
random effects relative risk 
w 95% CI 
-heterogeneity-I2 statistic 
-country level stratification-
high income, low, middle 
Threats 
 
-did not limit articles to 5 
years 
-most studies did not “fully 
answer” whether IGRA 
could predict active tb 
-Authors note- most studies 
have bias because they do 
not assess other risk factors 
for tb 
-could not do formal 
assessment of publication 
bias- assumed some bias 
-most IGRA studies have 
some “industry involvement” 
which may lead to bias 
-most studies did not 
examine high income 
settings 
 
This article made efforts to 
improve validity through 
quality assessment of articles 
and statistics applied, 
discussed limitations and 




between + result and TB 
-IGRA + and TST + were 
about the same for risk of tb 
-proportion of IGRA + was 
lower than for TST 
Conclusions 
 
-neither IGRA or TST have 
high accuracy prediction 
active TB 
 
-use of IGRA might reduce 
number of people who take 
preventive meds 
 
-Which test you use should 
be based on population, 
logistics, cost, patient 
preference rather than just 
predictive ability 












Banaei, N.,Gaur, R. L., & 
Pai, M. (2016). 
Interferon-y release 
assays for latent 
tuberculosis: what are the 
sources of variability? 





(Banaei et al., 2016) 




Quality A High- clear 
expertise, definitive 
conclusions 
(Dearholt & Dang, 2012) 
 
Article recommended by 

















-did not discuss 
methods for 
conclusions but 
appears to be 
updating a previous 
review.  
-did not list method 
for search of 
articles 





Higher rate of false- positives with IGRA 
 
Sources of Variability- 
-Preanalytical 
  - evening blood draw related to higher response value with 
QFT®-GIT 
   -Inadequate disinfection- can contaminate tubes 
    -correct order of tubes may matter- nil, antigen, mitogen- 
tube contamination- antigen contaminated with mitogen = 
false +, contamination of nil tube with mitogen = false 
negative 
   -volume of blood can alter result- inverse TB response 
    - vigorous shaking may increase IFN-y response- false + or 
false – 
   - processing day 1-4 hr. before antigen stimulation can 
lower t cells 
   -incubation delay- declines TB response 
    -indeterminate results increase in autumn and winter- 
transport in lower temp may affect result-particularly with T-
SPOT®.TB 
    - longer incubation = does not increase TB response 
 
Analytical 
-biologic fluid uncontrolled factors 
-pipetting imprecision 
-centrifugation error 
-error in washing steps 
-operator error in measurement of signal 
-between run variability=+ 0.6 for all, + .24 for those with 
initial borderline response 
-conversion 9%, reversion 7% 
 
Post-analytical 




-neither IGRA or TST 
have high accuracy 
prediction active TB 
 
-use of IGRA might 
reduce number of 
people who take 
preventive meds 
 
-Which test you use 
should be based on 
population, logistics, 
cost, patient 
preference rather than 
just predictive ability 








- Some reports of false + in faulty antigen tubes 
- Potential bacterial contamination 
 
Immunologic 
- Boosting by TST= increase 
Immunomodulation microbes- skin microorganisms such as 
staff 











Nienhaus, A. (2013). Clinical 
review of literature 
pertaining to the use of 
interferon gamma release 
assays for tuberculosis 
screening in healthcare 
workers: Evidence base and 
clinical experience with 
Quantiferon-TB Gold 
(QFT®). HCW Clinical 









Level V Literature 
Review/Expert Opinion 
Quality Good B 
 
Expertise credible, logical 
opinions for conclusions 





-Discussion of TB, TST, 
IGRA pros and cons with 
literature review following 
-11 studies reviewed with 











-HCW 2-5x increase risk if 
TB 
- study supports use of 
QFT® vs TST in neonates 
exposed to HCW w TB 
-greater specific of QFT® 
over TST 
-a single positive IGRA, may 
not be infection 
-QFT®-G and QFT®-GIT, 
more effective & less costly 
than TST whether vaccinated 
with BCG or not 
-IGRA appropriate for serial 
screening HCW in low 
incidence country w high 
vaccination rates 
-IGRAs cost effective for 
screening high risk 
individuals in low incidence 
setting 
- specificity IGRA higher 
than TST, correlated w 
exposure better 
-IGRA reduces false-
positives from BCG 
-good correlation betw 





 -IGRA is appropriate for 
HCW tuberculosis screening 
 
-Advantages of IGRA: 
-single visit 
-use of positive & -controls 
-unaffected by BCG vaccine  
-objective interpretation 
 
-Superior specificity over 
TST in countries with low 
TB burden 
-Saves 25-85% of chest x-
rays 















Graban, M., & Filby, D. 
(2015). “Lean” the new hire 
onboarding process for 
healthcare workers: 
evaluating the Quantiferon 








Level V Case Report 
Quality B Good 
Clear objectives for the 
article, consistent 
recommendations (Dearholt 
& Dang, 2014) 
Methods 
 
Case study on how lean 
principles can improve new 
hire onboarding and TB 
screening process. 
 
-compares process to Toyota 







-published by Qiagen 
 
-did not directly report 




-Use of QFT® can result in 
7-9 days sooner clearance to 
work for new hires 
 
-Cost of unfilled positions, 
staff overtime can be 
significant in comparison to 
QFT® 
-labor costs savings for test 
administration 




-QFT® less expensive, 
faster, less false positives, 
reduces waste, reduces hiring 
delays and potentially lost 
candidates.  
-QFT® is in line with lean 
principles and is more 
efficient and less expensive 
 








EVIDENCE LEVEL AND QUALITY GUIDE 
Table B.1 Evidence and quality guide 
Level I      Experimental study, randomized 
controlled trial (RCT). Systematic review of RCTs, 
with or without meta-analysis 
A High Quality: consistent, generalizable results; sufficient 
sample size for the study design; adequate control; definitive 
conclusions; consistent recommendations based on comprehensive 
literature review that includes thorough references to scientific evidence 
 
B Good quality: Reasonably consistent results, sufficient 
sample size for the study design, some control, fairly definitive 
conclusions, reasonably consistent recommendations based on fairly 
comprehensive literature reviews that includes some reference to 
scientific evidence 
 
C Low quality or major flaws:  Little evidence with 
inconsistent results: insufficient sample size for the study design; 
conclusions cannot be drawn 
Level II     Quasi-experimental study. 
Systematic review of combination of RCTs and 
quasi-experimental, or quasi-experimental studies 
only, with or without meta-analysis    
Level III     Non-experimental study. 
Systematic review of a combination of RCTs, 
quasi-experimental and non-experimental studies, 
or non-experimental studies only, with or without 
meta-analysis. Qualitative study or systematic 
review with or without a meta-synthesis 







Level IV     Opinion of respected authorities 
and/or nationally recognized expert 
committees/consensus panels based on scientific 
evidence. Includes: clinical practice guidelines, 
consensus panels 
A High quality: Material officially sponsored by a professional, 
public, private organization, or government agency; documentation of a 
systematic literature search strategy; consistent results with sufficient 
numbers of well-designed studies; criteria based evaluation of overall 
scientific strength and quality of included studies and definitive conclusions; 
national expertise is clearly evident; developed or revised within the last 5 
years. 
 
B Good quality: Material officially sponsored by a professional, 
public private organization, or government agency: reasonably thorough and 
appropriate systematic literature search strategic; reasonably consistent 
results, sufficient numbers of well-designed studies; evaluation of strengths 
and limitations of included studies with fairly definitive conclusions; national 
expertise is clearly evident; developed or revised within the last 5 years 
 
C Low quality or major flaws:  Material not sponsored by and 
official organization or agency; undefined, poorly defined, or limited 
literature search strategy; no evaluation of strengths and limitations of 
included studies, insufficient evidence with inconsistent results, conclusions 
cannot be drawn; not revised within the last 5 years 
Level V     Based on experiential and non-
research evidence. Includes: Literature reviews; quality 
improvement, program or financial evaluation; Case 
reports; Opinion of nationally recognized experts based 











A High Quality:  Clear aims and objectives, consistent results across 
multiple settings; formal quality improvement, financial or program 
evaluation methods used; definitive conclusions, consistent recommendations 
with thorough reference to scientific evidence. 
 
B Good quality: Clear aims and objectives; consistent results in a 
single setting; formal quality improvement of financial or program evaluation 
methods used; reasonably consistent recommendations with some reference to 
scientific evidence 
 
C Low quality or major flaws: Unclear or missing aims and 
objectives; inconsistent results; poorly defined quality improvement, financial 
or program evaluation methods; recommendations cannot be made. 
















©The John Hopkins Hospital/The Johns Hopkins 
University 
(Dearholt & Dang, 2014) 
Literature Review, Expert Opinion, Case Report, Community 
Standard, Clinician Experience, Consumer Preference: 
A High Quality: Expertise is clearly evident: draws definitive 
conclusions; provides scientific rationale: thought leader in the field 
 
B Good quality: Expertise appears to be credible; draws fairly 
definitive conclusions: provides logical argument for opinions 
 
C Low quality or major flaws: Expertise is not discernable or is 
dubious: conclusions cannot be drawn 





 Used/Reprinted with permission from the University of Iowa Hospitals and 
Clinics. Copyright 1998. For permission to use or reproduce the model, please 
contact the University of Iowa Hospitals and Clinics at (319)384-90 
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NURSING RESEARCH COUNCIL PROPOSAL AND APPROVALS 
Evidence-Based Quality Improvement DNP Clinical Dissertation Project 
Tuberculosis Screening in New Healthcare Employees: A Comparison of 
QuantiFERON®-TB Gold In-Tube Test and Tuberculin Skin Test 
Principle Investigator: Mary Giovannetti, NP 
Co-Investigator: Stephanie Barnhill, NP 
Faculty/Committee: Dr. Stephanie Burgess, Dr. Karen McDonnell, Dr. Abbas Tavakoli 
To be conducted at: Spartanburg Regional Healthcare System 
PICOT: As a foreground question, among all adult newly hired healthcare employees at 
a healthcare system, how does baseline testing with QuantiFERON®-TB Gold In-Tube 
test (QFT®-GIT) compare with two step PPD TB skin test in regards to time for 
completion of tuberculosis screening and compliance with screening within 10 days of 
orientation over a 2-month time frame? 
Purpose 
The purpose of this quality improvement DNP project is to compare baseline 
testing with QuantiFERON®-TB Gold In-Tube test (QFT®-GIT) to the two step PPD TB 
skin test in regards to tuberculosis screening time, costs, overall onboarding clearance 
time, and compliance for new employees.   
Spartanburg Regional Healthcare System (SRHS) currently employees 
approximately 6,800 employees and experienced a 15% employee turnover rate in 2015 
and 2016 which led to staffing issues and utilization of expensive locum tenems 
temporary contract employees. There was an increase in hiring due to this turnover and 
an increased demand for Employee Health to expedite new hire clearance. Employee 
Health was asked to onboard new hires quicker and increase appointment availability. 
After careful review, it was found that the long process of tuberculosis screening 
contributed to the longer onboarding time for new hire employees.  
The Department of Health and Human Services Centers for Disease Control and 
Prevention (CDC) recommends that all healthcare workers receive initial screening for 
TB upon hire by a 2-step tuberculin skin test (TST) (Jensen et al., 2006). There are three 
main categories of problems with utilization of the two step tuberculin skin test: extended 
screening time, noncompliance, and potential inaccuracy in placement and results. 
Employee Health completes tuberculosis screening with the two step PPD skin test. This
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process takes 2-4 visits and can take 10 days to 3 weeks or more to complete. If the new 
employee fails to return for a placement or reading, orientation may be delayed.   
Tuberculin skin test was the only available test for TB screening until 2001 when 
Interferon gamma release assays (IGRA) were developed. IGRA’s can potentially 
overcome issues with TST tuberculosis clearance screening time and compliance, as well 
as problems with inaccurate results. In contrast to TST, IGRA’s do not react to 
nontuberculous mycobacteria or BCG vaccination. IGRA’s can also be completed in one 
visit and eliminate the need for multiple visits. Furthermore, IGRAs have been found to 
have a higher correlation to TB exposure than TSTs improving accuracy. IGRA’s are 
more expensive than TST’s, but utilization is expect to reduce costs associated with 
staffing requirements, inadequate testing results, poor employee compliance follow up, 
and potential DHEC citations for organization noncompliance (Mazurek et al., 2010).  In 
February of 2016, Employee Health implemented QFT®-TB Gold In-Tube Test for all 
new hires in place of the 2 step PPD. Preliminary assessment revealed that 
implementation of QFT® for new hires along with other factors has led to increase in 
available appointments, decrease in screening and onboarding time. This project will 
further analyze the data for publication in dissertation and in journal publication.  
Literature Review and Synthesis 
Twenty-three studies were included in the review of the literature. The articles 
were classified into levels I through IV according to John Hopkins Research and Non-
Research evidence appraisal tools (Dearholt & Dang, 2012). Level I includes 
experimental studies, II quasi-experimental, III Non-experimental, IV clinical practice 
guidelines, consensus or position statements, and level V literature review, expert 
opinion, community standard, clinician experience, and consumer preference (see 
Appendices B for level and quality guide). Of the 23 articles analyzed there were four 
level II articles, seven level III, two level IV, and 10 level V. Quality of the articles were 
also analyzed as shown in table 5 according to John Hopkins appraisal tools with ratings 
of A- high quality, B- Good quality, and C- Low Quality (Dearholt & Dang, 2014). 
Analysis of the literature revealed pros and cons to choosing the QFT®-GIT for 
TB skin testing for new healthcare workers. There are a number of positive logistical 
factors that would provide value for employee health offices while improving cost- 
effectiveness. Since QFT®-GITs are completed in one test, new hire onboarding and 
tuberculosis clearance time should be reduced. This will also reduce the burden on 
employee health staff time spent on tuberculosis clearance activities, and enhance 
convenience to the new hire (Foster-Chang et al., 2014; Graban & Filby, 2015; Veeser et 
al., 2007). Cost analysis revealed that IGRAs are cost effective (dePerio et al., 2009; 
Foster-Chang et al., 2014; Graban & Filby, 2015; Nienhaus, 2013; Nienhaus et al., 2011). 
The QFT®-GIT has high specificity but there are some concerns about sensitivity 
(Banaei et al., 2016; Cummings et al., 2009; Dorman et al., 2014; Loddenkemper et al., 
2012; Schablon et al., 2014; Slater et al., 2013; Weddle et al., 2014; Zwerling et al., 
2012). However, sensitivity of the QFT®-GIT improves with consideration of patients 
with active tuberculosis (Mazurek et al., 2010). Some studies have shown that there can 
be issues with conversions and reversion and a borderline cutoff with retesting may be 
appropriate (Dorman et al., 2014; Loddenkemper et al., 2012; Mazurek et al., 2010; 
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Schablon et al., 2014; Slater et al., 2013; Weddle et al., 2014; Zwerling et al., 2012). 
When interpreting results, the immunologic status of the patient should also be 
considered with indeterminate results (Cummings et al., 2009). Standardization of lab 
procedures can help overcome some of the variability in results (Banaei et al., 2016). 
Overall, there is good evidence to implement QFT®-GITs in new hire healthcare workers 
while considering all the interpretation factors. 
Study Design 
Employee Health was faced with a dilemma of increasing volume of new hires 
coming for appointments and increasing frustrations by management regarding delays in 
orientation. Employee Health management formed a new hire committee in Fall of 2015 
to investigate the factors involved with delays in orientation. One factor identified in 
orientation delays was the amount of time it takes for new employees to complete the 
two-step TST. The literature was reviewed and multiple steps were taken to investigate 
the ability for Employee Health to offer an IGRA for all new hires in order to reduce the 
amount of time it takes to be cleared for orientation. In February of 2016, Employee 
Health implemented a quality improvement project to reduce onboarding time for new 
hires by implementing the QFT®-GIT in place of the two-step TST.  
This quality improvement evidence-based project will be utilized to satisfy 
requirements for DNP clinical dissertation. The design will be descriptive comparative 
non-experimental which will compare the two methods of tuberculosis screening in 
regards to tuberculosis clearance time, compliance, costs, and overall onboarding time. 
 
Conceptual Framework and Feasibility 
The Iowa Model of Evidence-Based Practice to Promote Quality Care (Iowa 
Model) will be utilized to guide implementation of the project. Stakeholder support, 
sample access and size, financial, legal and ethical resources are substantial. An adequate 
sample size should be easily obtained through the retrospective chart review. This project 
should not incur any costs other than time for the investigator.  
Procedure and Data Collection 
The sample will include a convenience sample of all new hire potential employees 
that are scheduled for pre-placement assessment at the healthcare system Employee 
Health beginning March, April, and May 2016 utilizing the QFT®-GIT, and all new hires 
from March, April and May 2015 through November 2015 utilizing the two-step PPD 
screening.  
Data will be collected retrospectively by electronic medical record chart review 
by the primary investigator employed by the Employee Health Department. Data will be 
compiled in a password protected excel spreadsheet with all identifiers removed. Data 
collected on each subject will include: dates for each pre-placement visit and pre-
placement follow up visits, dates for TST placement and readings, dates for QFT®-GIT 
collection and dates results were received, dates for orientation, and dates for final 
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orientation clearance. Data regarding dates for completion of requirements that could 
delay orientation will also be collected including dates fit for duties, dates documentation 
was received for provider work notes, pre-work screen dates, and drug screen collection 
result dates. Notations will be made regarding any positive TST or QFT®-GIT results, 
required chest x-ray dates and results, symptom review dates, and DHEC referrals.  
 
Data Analysis 
 Once the survey data is entered into the encrypted file, the investigator in 
collaboration with a statistician will review the data and, create data in the form that 
would be useable in SAS for analyses. Data analysis will include both descriptive and 
inferential statistics using SAS 9.4. Frequency distribution will be included for 
categorical variables. The continuous variable statistics will include measures of central 
tendency (mean and median) and measures of spread (standard deviation and range). 
Inferential statistics will include T-test, Pearson correlation, and simple linear model. 
Findings with p-values less than or equal to .05 will be considered significant. 
Evaluation Plan 
Questions/Outcomes/Evidence-based measures 
Q1. Will implementation of QFT reduce the number of days to complete 
tuberculosis screening for new hires? 
 Retrospective data will be collected from electronic and paper Employee 
Health records. This data will be stored on a password protected 
spreadsheet without patient identifiers.  
 The number of days it takes to complete TST screening will include the 
time from placement of step 1 to reading of the 2nd step. If the new hire 
brought documentation of step 1, then only completion of step 2 will be 
recorded. If the new hire fails to complete a step and has to be replaced, 
then that time will also be included in the number of days for clearance.  
 Total tuberculosis screening clearance time for those completing the 
QFT®-GIT will include date of blood draw to date the result was 
reviewed. If the QFT®-GIT needs to be repeated for borderline positive 
result, this time will be included in overall screening time.  
 Those with a previous positive TST will be included with days to 
clearance being 1 day.  
 Data will be analyzed by simple t test. Regression model will be 
completed to control for demographic variables.  
Q2. Will implementation of QFT for new hires reduce the overall number of days 
to complete onboarding?  
 Time for onboarding will include days from first appointment to 
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completion of all requirements including tuberculosis screening, 
assessments, fit for duties, lab results, and review of any requested 
records. Completion of immunizations and Hepatitis B waivers will not be 
included because those are not completed until after orientation.  
 Data will be analyzed by t test 
Q3. Will implementation improve compliance with completion of tuberculosis 
screening within 10 days of orientation? 
 Compliance will be defined as completing both steps of the 2 step skin test 
within 10 days of orientation or completion of any required repeat QFT®-
GITs, symptom reviews, or chest x-rays. 
 The proportion test will be used to compare two proportions. 
Q4. Will implementation of QFT be cost-effective? 
 A simple review of associated costs with QFT versus PPD including staff time 
will be reviewed. Actual average salary of Employees in Employee Health in 
relation to time it takes to completion of testing and assessment requirements, 
phone calls to contact non-compliant employees, and call employees with results 
of lab testing will be considered. Cost of supplies will include the cost for the 
PPD derivative, the syringe/needle, and cost of lab charges for QFT®-GIT. Labor 
costs from missed work for the new hire will not be considered since the new hire 




 Upon approval of the Nursing Research Council, SRHS IRB, and USC IRB, data 
collection will begin. Data collection and analysis will be completed by the end of March 
2017 with DNP defense March 31, 2017. Manuscript with summary of findings will be 




An application for exempt status will be submitted to two IRBs: the healthcare 
system and University of South Carolina. The University of South Carolina typically 
grants exempt status for quality improvement projects which are focused on improving 
outcomes/processes in the setting and are not research to generate new knowledge. After 
approval, the investigator will begin to collect data. The primary investigator is in charge 
of routinely collecting data regarding onboarding times and has access to the electronic 
medical records.  The investigator will only retrieve data essential for project. The excel 
spreadsheet will be saved in the investigator’s access limited S-drive folder, with a 
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password protected spreadsheet. All computers are password protected and all data on the 
healthcare system’s computers are encrypted. All identifiers will be removed from the 
spreadsheets. The investigator has completed Collaborative IRB Training Initiative 
(CITI) courses. Data will be disseminated in the aggregate.  
 
Nursing Research Council 
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Study Name: Tuberculosis Screening in New Healthcare Employees: A Comparison of 
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Upstate School of Nursing 
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QuantiFERON®-TB Gold In-Tube Test for Baseline Tuberculosis Screening 
in New Healthcare Employees: A Review of the Literature 
 
Author:  Mary Giovannetti, MSN, APRN, BC-FNP,  
  Manager, Spartanburg Regional Healthcare System Employee Health    
  Nurse Practitioner, Medical Group of the Carolinas Occupational Health 
  DNP Student, College of Nursing, University of South Carolina 
Contact: mgiovannetti@srhs.com, 864-497-4087 (cell phone) 
 
Additional Authors:  Stephanie Burgess, PhD, APRN, BC, FAANP,  
   Clinical Professor, Associate Dean for Practice, Director 
DNP/MSN,     College of Nursing, University of South Carolina 
 
              Karen McDonnell, PhD, RN, OCN 
   Assistant Professor 
   College of Nursing, University of South Carolina 
 
Abstract 
Introduction: The two step tuberculin skin test is recommended by Centers for Disease 
Control and Prevention for all new healthcare workers. The two step TST has limitations 
including compliance with both steps, subjective reader interpretation, and false-positive 
results. This can be problematic for Employee Health departments and cause delays in 
orientation. A systematic review of the literature was conducted to determine the 
evidence regarding implementation of Interferon Gamma Release Assays (IGRA) in 
Employee Health for new hire employees. This literature review is preliminary work for 
an evidence-based project to determine if baseline testing with QuantiFERON®-TB Gold 
In-Tube test (QFT®-GIT) will reduce tuberculosis screening time and improve 
compliance in new employees at Spartanburg Regional Healthcare System.  
 
Methods: CINAHL, PubMed, and Science Direct were searched with keywords IGRA, 
Interferon Gamma, tuberculosis screening, quantiferon, employee, healthcare worker, and 
tuberculosis. Studies published in English, conducted in low or medium TB incidence 
settings which included information regarding IGRA testing in healthcare workers 
including QFT®, QFT®-TB Gold, QFT®-GIT, or T-spot from 2005 to present met the 
inclusion criteria. 
   
159 
 
Results/Limitations/Conclusions: Twenty-three studies were included in the literature 
review.  The John Hopkins nursing evidence-based practice model and guidelines was 
utilized to rate the evidence and quality of the studies. There were five level II studies, six 
level III, two level IV and ten level V. Eight studies were high quality, and fifteen studies 
were rated good. Low quality studies were excluded. The analysis of the literature was 
grouped into topics of the tuberculosis screening process, cost, accuracy, and 
conversions/reversions. Synthesis of the literature revealed a number of positive logistical 
factors that would provide value for employee health offices including reduced number of 
visits for the new hire and reduced burden on employee health office staff time spent on 
tuberculosis clearance. The cost analysis revealed that utilization of IGRAs has been 
found to be cost effective and in some cases saves money. The literature showed that the 
QFT®-GIT has high specificity but there are conflicting reports on sensitivity.  There 
may be reductions in false-positives due to elimination of subjective reader interpretation 
and IGRAs do not react to other non-mycobacterium tuberculosis. The review also 
showed that positive results in a borderline interpretation zone can have conversions and 
reversions with some studies recommending retesting. One limitation of this review is 
that there was no level I study found. In conclusion, the literature review showed that 
utilization of the QFT®-GIT has potential to improve tuberculosis screening processes, 
reduce costs, reduce false-positive results with improved specificity, and has the potential 
to contribute to reduced tuberculosis screening time and improve compliance. 
 
Implications for practice: Employee Health and occupational health departments that 
are required to conduct tuberculosis screening for new hire employees should conduct a 
needs assessment in their organization and review the evidence to determine if IGRAs 
would improve processes, be cost effective, and align with organization priorities. 
Organizations implementing IGRAs for new hires should develop policies and 
procedures with consideration of the evidence with regards to sensitivity, specificity, 
conversions, and reversions with consideration for retesting guidelines.  
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according to the following evaluation criteria. Preference will be given to abstracts that include 
appropriate detail.   
 
 Originality of presentation 
 Overall quality of content  
 Relevance/timeliness to current issues 
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Abstract/Presentation Overview - Describe the basic content of the proposed presentation – a 
minimum of 50 words and maximum of 300 words is needed. 
Authors: Mary Giovannetti, DNP, APRN, BC-FNP; Stephanie Burgess, PhD, APRN, BC, 
FAANP; Karen McDonnell, PhD, RN, OCN; Abbas Tavakoli, DrPH, MPH, ME; Stephanie Barnhill, 
MSN, APRN, BC-FNP 
Background: Streamlining onboarding processes for new hires to maximize efficiency 
and reduce costs while meeting regulatory requirements is a constant challenge for 
healthcare systems’ Employee Health staff.  Health screening is a required step and includes 
obtaining a detailed health history, tuberculosis screening, drug screens, immunizations, fit 
for duty examinations, obtaining medical records, clarification of disability accommodations, 
pre-work screens, and other tests which are time consuming and result in delays in hire dates. 
Faced with a high volume of potential new employee hires a major southeast healthcare 
system was concerned about delays in new hire start dates.  The two-step tuberculin skin test 
administration and follow-up process was identified as a potential area for improved 
onboarding efficiency. 
Method: A quality improvement study was designed and implemented to compare 
baseline testing for new employees with an Interferon-Gamma Release Assay (IGRA) known 
as QuantiFERON®-TB Gold In-Tube Test (QFT®-GIT) to the two step PPD Tuberculin Skin Test 
(TST) for tuberculosis screening time, overall onboarding time, compliance with screening 
within 10 days of hire date, and associated costs. A retrospective electronic record review 
included a sample of 484 new hire employees.  
Results: Results showed that the QFT®-GIT for tuberculosis screening in comparison 
to the TST testing significantly reduced tuberculosis screening time for new hire employees 
(TST = 8.03 days, QFT®-GIT = 4.11 days; p<.0001) and overall onboarding time (TST = 7.92 
days, QFT®-GIT = 5.07 days; p<.0001) while improving compliance with tuberculosis screening 
within 10 days of hire date (TST = 92.92%, QFT®-GIT =100%; p<.0001).  
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Conclusions: The utilization of QFT®-GIT for tuberculosis screening of new employees 
significantly reduced screening and onboarding time while improving compliance with 
screening within 10 days of the hire date.  
Implications:   Healthcare systems should consider implementation of an IGRA in 
order to streamline processes for onboarding new employees. New processes require 
negotiations between healthcare systems and lab vendors, changes in policies and 




Learning Outcome:  
Learners will be able to describe how implementation of an Interferon Gamma Release Assay 
(IGRA) can be utilized for tuberculosis screening of new healthcare workers.  
 
Description of current state: Delays in orientation and health clearance due to 
long process of tuberculosis screening 
 
Description of desired 
achievable state: 




Identify at least three 
objectives for the proposed 
presentation.  
 
Provide an outline of the content for each objective. It 
must be more than a restatement of the objective. 
 
1. Discuss problems with 
tuberculosis screening 
for healthcare workers 
Review author’s department experience with TST’s and 
onboarding and have learners interactively discuss their 
experience with TST’s or IGRA’s for tuberculosis 
screening.  
2. Describe pros and cons 
of Interferon Gamma 
Release Assays 
Summarize the Review literature results of 23 articles 
including: TB screening process, cost, accuracy, 
conversions/reversions 
3. Identify steps for 
implementation of 
IGRAs for new 
healthcare employees 
Discuss how the healthcare system implemented the 
IGRA including successes and problem resolution. 




Review results of data analysis for sample of 485 subjects. 
5.   
 
What level do you consider your presentation?  
 Basic    Intermediate   Advanced 
 
What time frame is needed?  Check all that apply.  
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Background: Streamlining onboarding processes for new hires to maximize 
efficiency and reduce costs while meeting regulatory requirements is a constant challenge 
for healthcare systems’ Employee Health staff.  Health screening is a required step and 
includes obtaining a detailed health history, tuberculosis screening, drug screens, 
immunizations, fit for duty examinations, obtaining medical records, clarification of 
disability accommodations, pre-work screens, and other tests which are time consuming 
and result in delays in hire dates. Faced with a high volume of potential new employee 
hires a major southeast healthcare system was concerned about delays in new hire start 
dates.  The two-step tuberculin skin test administration and follow-up process was 
identified as a potential area for improved onboarding efficiency. 
Method: A quality improvement study was designed and implemented to 
compare baseline testing for new employees with an Interferon-Gamma Release Assay 
(IGRA) known as QuantiFERON®-TB Gold In-Tube Test (QFT®-GIT) to the two step 
PPD Tuberculin Skin Test (TST) for tuberculosis screening time, overall onboarding 
time, compliance with screening within 10 days of hire date, and associated costs. A 
retrospective electronic record review included a sample of 484 new hire employees.  
Results: Results showed that the QFT®-GIT for tuberculosis screening in 
comparison to the TST testing significantly reduced tuberculosis screening time for new 
hire employees (TST = 8.03 days, QFT®-GIT = 4.11 days; p<.0001) and overall 
onboarding time (TST = 7.92 days, QFT®-GIT = 5.07 days; p<.0001) while improving 
compliance with tuberculosis screening within 10 days of hire date (TST = 92.92%, 
QFT®-GIT =100%; p<.0001).  
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Conclusions: The utilization of QFT®-GIT for tuberculosis screening of new 
employees significantly reduced screening and onboarding time while improving 
compliance with screening within 10 days of the hire date. Anecdotal feedback from 
hiring managers and senior management indicated improved satisfaction with the 
Employee Health hiring process.  
Implications:   Healthcare systems should consider implementation of an IGRA 
to streamline processes for onboarding new employees. New processes require 
negotiations between healthcare systems and lab vendors, changes in policies and 
procedures, and employee health and laboratory staff development. Future research 




Employee health offices are challenged with streamlining onboarding processes 
for new hires to maximize corporate efficiency and reduce costs meeting regulatory 
requirements.  Health screening is a key step and includes multifaceted components such 
as obtaining a detailed health history, tuberculosis screening, drug screens, 
immunizations, fit for duty examinations, obtaining medical records, clarification of 
disability accommodations, and other pre-work screens which are often time consuming 
resulting in delays in hire dates. A large healthcare system experienced a high volume 
new hires and concern regarding delays in new hire start dates. The Healthcare System 
Corporate Administration engaged the Employee Health Manager to assess and develop 
solutions for increased onboarding efficiency.  A potential area identified as a concern 
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was the two-step tuberculin skin test administration and follow-up process.  The purpose 
of this quality improvement study was to compare baseline testing for new healthcare 
employees with QuantiFERON®-TB Gold In-Tube Test (QFT®-GIT) to the two step 
PPD Tuberculin skin test (TST) for tuberculosis screening time, overall onboarding time, 
compliance with screening within 10 days of hire date, and associated costs. 
 
Tuberculosis Screening 
Historically, the tuberculin skin test was the only available test for TB screening 
until 2001, when Interferon gamma release assays (IGRA) were developed. Interferon 
gamma release assays are blood tests which specifically measure the interferon-gamma 
released by T cells in response to white blood cells exposed to TB, thus releasing  
interferon-gamma (TFN-ƴ )(Swindells, Aliyu, Enoch, & Abubakar, 2009) Two currently 
available IGRAs include the QuantiFERON®-Gold In-Tube Test (QFT®-GIT) and the 
T-SPOT®.TB. The T-SPOT®.TB measures the number of interferon gamma producing 
cells by counting spots and is collected in one blood tube (Foster-Chang, Manning, & 
Chandler, 2014). In contrast, the QFT®-GIT measures the TFN-ƴ protein response 
quantitatively utilizing whole blood enzyme linked immunosorbent assay (ELISA). The 
procedure for testing includes drawing one milliliter of blood collected in 3 tubes 
including the nil (negative control), TB antigen (ESAT-6, CFP-10, and TB7.7), and 
mitogen (positive control). All tubes are gently shaken 10 times and must be transferred 
to a 37ºC+ 1 incubator within 16 hours. Results are measured by TB antigen minus nil 
and positive is > 0.35 IU/ml. Results are measured by TB antigen minus nil and positive 
is > 0.35 IU/ml (Nienhaus, 2013). 
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IGRA’s can potentially overcome barriers with TST extended tuberculosis 
clearance screening time, noncompliance, and inaccuracies in results. In contrast to TST, 
IGRA’s do not react to nontuberculous mycobacteria or BCG vaccination. IGRA’s can 
also be completed in one visit and eliminate the need for multiple visits. Furthermore, 
IGRAs were found to have a higher correlation to TB exposure than TSTs, thus, 
improving accuracy. IGRA’s are more expensive than TST’s, but utilization can reduce 
costs associated with onboarding, staff time for TST implementation and follow-up 
processes, and reducing potential regulatory citations for organizational noncompliance 
(Mazurek et al., 2010).   
 
Literature Review 
A review of literature was conducted for levels of evidence, quality, and summary 
to compare TST testing and a blood assay for mycobacterium tuberculosis screening of 
new hires for a healthcare system. Database searches included CINAHL, PubMed and 
Science Direct.  Search terms included a combination of IGRA, Interferon gamma, 
tuberculosis screening, quantiferon, employee, healthcare worker, and tuberculosis.  
Search inclusion criteria included studies published in English conducted in low or 
medium TB incidence settings from 2005 to present with relevant information to IGRA 
testing in healthcare workers including QFT®, QFT®-TB Gold, QFT®-GIT, or T-
SPOT®.TB. Studies were excluded that were conducted primarily in high TB incidence 
settings, did not include healthcare workers, were published in other languages, and those 
that involved only children or immune compromised patients. Articles were limited to the 
past 10 years.  However, the Centers for Disease Control (CDC) study published in 2005 
   
171 
 
was included since it provides the guidance for landmark regulatory compliance for 
occupational health onboarding. Twenty-three studies were included in the final literature 
review.  The John Hopkins nursing evidence-based practice model and guidelines were 
utilized to appraise the evidence.  The search yielded There five level II studies, six level 
III, two level IV and ten level V. Eight studies were high quality, and fifteen studies were 
rated good.  Low quality studies were excluded.  
 
The literature analysis was organized into topics of the tuberculosis screening 
process, cost, accuracy, and conversions/reversions. Synthesis of the literature revealed a 
number of positive logistical factors that provided value for employee health offices 
including reduced number of visits for the new hire and reduced burden on employee 
health office staff time spent on tuberculosis clearance and follow-up while improving 
compliance (Cummings et al., 2009; Foster-Chang et al., 2014; Gonzalez & Conlon, 
2013; Graban & Filby, 2015; Mazurek et al., 2010; Rangaka et al., 2012; Veeser, Smith, 
Handy, & Martin, 2007; Wrighton-Smith, Sneed, Humphreys, Tao, & Bernacki, 2012). 
Since QFT®-GITs are completed at  one visit , new hire onboarding and tuberculosis 
clearance time was reduced (Cummings et al., 2009; Foster-Chang et al., 2014; Graban & 
Filby, 2015; Mazurek et al., 2010). Studies also found an enhanced convenience to the 
new hire using QFT®-GITs testing (Foster-Chang et al., 2014; Graban & Filby, 2015; Veeser 
et al., 2007). Cost analysis revealed that IGRAs are cost effective by reducing staff testing 
and follow-up time,  reducing missed work time, and reducing treatment for false-
positive results  (dePerio, Tsevat, Roselle, Kralovic, & Eckman, 2009; Foster-Chang et 
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al., 2014; Graban & Filby, 2015; Nienhaus, 2013; Nienhaus, Schablon, Costa, & Diel, 
2011).  
 
The literature also demonstrated that the QFT®-GIT has high specificity but there 
are conflicting reports on sensitivity (Banaei, Gaur, & Pai, 2016; Cummings et al., 2009; 
Dorman et al., 2014; Loddenkemper, Diel, & Nienhaus, 2012; Schablon, Nienhaus, 
Ringshausen, Preisser, & Peters, 2014; Slater, Welland, Pai, Parsonnet, & Banaei, 2013; 
Weddle, Hamilton, Potthoff, Rivera, & Jackson, 2014; Zwerling et al., 2012).). 
Explanations offered were reductions in false-positives due to elimination of subjective 
reader interpretation and the lack of reaction of IGRAs to other non-mycobacterium 
tuberculosis (Dorman et al., 2014; Lamberti et al., 2015; Rangaka et al., 2012; Swindells 
et al., 2009) . However, sensitivity of the QFT®-GIT improves with consideration of 
patients with active tuberculosis (Mazurek et al., 2010). Some studies have shown that 
there can be issues with conversions and reversion and a borderline cutoff with retesting 
may be appropriate (Dorman et al., 2014; Loddenkemper et al., 2012; Mazurek et al., 
2010; Schablon et al., 2014; Slater et al., 2013; Weddle et al., 2014; Zwerling et al., 
2012). When interpreting results, the immunologic status of the patient should also be 
considered with indeterminate results (Cummings et al., 2009). Standardization of lab 
procedures can help overcome some of the variability in results (Banaei et al., 2016).  
 
One limitation of the review was the lack of Level I studies. In conclusion, the 
literature review showed that utilization of the QFT®-GIT has potential to improve 
tuberculosis screening processes, reduce costs, reduce false-positive results with 
   
173 
 
improved specificity, and has the potential to contribute to reduced tuberculosis screening 
time and improve compliance (Banaei et al., 2016; Cummings et al., 2009; Dorman et al., 
2014; Foster-Chang et al., 2014; Graban & Filby, 2015; Loddenkemper et al., 2012; 
Nienhaus, 2013; Nienhaus et al., 2011; Schablon et al., 2014; Slater et al., 2013; Veeser 




Historically, the healthcare system completed two-step tuberculosis skin testing 
for new hire employees. With the increase volume of new hires, hiring managers and 
Corporate Administration requested that Employee Health expedite onboarding time for 
new hires.  Hiring managers expressed frustration with delays in onboarding times for 
new hires, especially for TST screening processes. Thus, Corporate Administration 
directed Employee Health to investigate new processes for onboarding new hires and 
develop recommendations.  In the Fall of 2015, the Employee Health Manager convened 
a new hire committee to review all onboarding processes and to recommend changes to 
streamline processes. Information regarding the benefits of implementation of QFT®-
GITs for new hire tuberculosis screening was presented to the new hire committee, the 
Vice-President of Human Resources, and Employee Health staff.  Support was obtained, 
and Employee Health staff initiated a new procedure, specifically QFT®-GIT testing for 
new hires. Employee Health staff received training for policies and procedures for 
implementing the QFT®-GIT. The internal lab and an outside vendor lab was advised of 
the changes and capacity for incubation was determined. The state regulatory agency was 
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contacted to ensure that the blood test would be accepted and further guidance was 
sought for retesting borderline positive results of less than 1 was obtained. In February of 
2016, the healthcare system began QFT®-GITs for tuberculosis screening of all new hire 
employees.  At the time of formation of the new hire committee, the Employee Health 
office completed 100-125 pre-placement visits per month. By July of 2016, the Employee 




The setting for the quality improvement project was a major southeast healthcare 
system comprising of 6,800 employees and consisting of 2 acute care hospitals, a post-
acute facility, hospice facility, home health agency, multiple outpatient offices, and other 
specialty healthcare services. The healthcare system is identified as a TB low risk facility 
per CDC guidelines.  The healthcare system contracts with a local lab vendor to complete 
QFT®-GIT at a negotiated price of $53 per QFT®-GIT.  Since CDC recommendations 
do not have a preference of QFT versus T-spot®, the QFT®-GIT was selected for the 
project (Mazureck et al., 2010).   
 
Data Collection 
Data was collected by the primary author retrospectively through electronic 
medical record review, new hire spreadsheets, and the human resources database. All 
data was stored in a password protected excel spreadsheet with all personal identifiers 
removed that could be traced back to the new hire.  Data points collected included 
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tuberculosis screening time (TB clear days), either total number of days to complete two 
step TST placement and readings or number of days for results of the QFT®-GIT. If any 
testing by TST or QFT®-GIT was positive, then time for completion of symptom review 
and chest x-ray was included in tuberculosis screening time. Overall onboarding time 
(clear days) included placement and reading of at least one TST, QFT®-GIT result and/or 
symptom assessment, drug screen results, lab results, and if required chest x-ray, fit for 
duty examination, pre-work screens, or personal provider work notes. 
 
Sample 
The initial sample included 537 subjects who had pre-placement assessments at 
the healthcare system’s Employee Health department in April and May of 2015 and 2016. 
Subjects were excluded from the study included volunteers (n=40), new hire subjects 
with positive drug screens (n=6), subjects who failed to report for employment (n=4) or 
failed fit for duty examination (n=1), subjects who failed pre-work screen (n=1) or did 
not show for pre-work screen (n=1). The final sample size included 484 new hire 
employees comprising 81.4% female subjects (see Table 1). The three most frequently 
hired age groups included ages 21, 25, and 27 years. The mean age for the sample was 
35.08 (n=484) (see Table 1). There were 323 Caucasian subjects (66.73), 112 African 
American (Black) (23.14), 13 Hispanic (2.69), 12 Asian (2.48), and 24 other (4.96). The 
most frequent job title for the sample was registered nurses (n=111), followed by nursing 
support (n =62). Of the sample, 227 had TST testing and 257 had QFT Testing.  
 
 




The mean number of days for completing all onboarding requirements to begin 
orientation was 6.40 days. The mean number of days to complete tuberculosis screening 
by TST was 8.06, ranging from 0-36 days.  One hundred twenty-four subjects supplied 
documentation of at least one previous TST, thereby reducing the number of days 
required for subsequent testing. Seven subjects required repeated TST’s due to failure to 
follow up for TST reading. TB clear days included the amount of time required for 
tuberculosis screening and was 5.92 mean days for the TST and the QFT groups.  
However, Quantiferon® testing yielded an average 4.11 days to complete testing with a 
range of 1 to 10 days. There were four positive QFT® results with 3 of those being 
borderline less than 1.0. The mean number of days for drug screen results was 2.71 days 
with a maximum of 19 days resulting from subjects who had 2 dilute drug screens, 
necessitating a hair drug screen. Thirty-six employees were required to have pre-work 
screen tests, averaging 5.68 days to complete. Six subjects were required to bring 
documentation from their personal health care provider regarding work status (see Table 
2). 
 
Question 1. Will implementation of QFT®-GIT reduce the number of days to 
complete tuberculosis screening for new hires? 
There was a statistically significant difference in number of mean days to 
complete tuberculosis screening for the QFT® group in comparison to the TST group 
(p<.0001) (see Table 3). The average mean number of days to clear tuberculosis 
screening was 8.03 for TST and 4.11 for the QFT®.  When comparing mean age between 
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the two groups for testing completion days, there was no statistically significant 
difference (p=0.0849) (see Table 3). 
 
Question 2. Will implementation of QFT®-GIT for new hires reduce the 
overall number of days to complete onboarding? 
Findings indicated a statistically significant difference in the overall number of 
mean days to complete Employee Health screening for the QFT®-GIT in comparison to 
the TST group (p<.0001) even when adding in other new hire screening requirements. A 
reduction in number of days was demonstrated for onboarding days when using the QFT 
method from 7.92 (TST group) to 5.07 (QFT® group) (p<.0001). There was no 
statistically significant difference between the TST and the QFT® groups in the number 
of mean days to complete drug screens (p=0.8009), fit for duties (p=0.8009), or pre-work 
screens (p=0.1265) (see Table 4).  
Data was further analyzed to determine if there was a correlation between 
onboarding clearance time and age, TST clear days, QFT®-GIT clear days, drug screen 
days, fit for duty days, pre-work screen days, or PCP note days. A weak but positive 
correlation was demonstrated between overall onboarding time and age (r=0.10094, 
p=0.0268) (see Table 5). However, findings showed a statistically significant stronger 
positive relationship between overall onboarding time and number of days to complete 
TST screening (r=0.71838, p<.0001) and number of days for clearance by QFT® 
(r=0.62275, p<.0001).  A positive relationship was also found between onboarding 
clearance time with number of days to complete drug screens (r=0.30298, p<.0001). 
There was also a positive relationship between the number of days and fit for duties 
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(r=0.76433, p<.0001), however, only 36 subjects were required to complete the 
examination. For onboarding time with the number of days to complete pre-work screens, 
a positive correlation was found among six subjects (r=0.68600, p<.0001) but none was 
found between onboarding clearance time and the number of days to bring documentation 
clearance from the PCP (r=0.40584, p=0.4247) (see Table 5). 
 
Question 3. Will implementation of QFT®-GIT for new employees improve 
compliance with completion of tuberculosis screening within 10 days of 
orientation? 
Analyses showed a statistically significant improvement in compliance with the 
QFT® group in comparison to the TST group (p<.0001) (see Table 6). Overall, the 
compliance rate for completing the tuberculosis screening was 99.29% in the TST group 
and 100% the QFT group. There was no statistical difference for tuberculosis screening 
compliance between races. However, there was a statistically significant difference in 
compliance between genders with an increase in compliance among female employees 
(97.96%; p=.0010) (see Table 6). Three employees failed to complete two step TSTs. Ten 
employees failed to have at least one TST with a final reading prior to orientation. 
Sixteen employees in the TST group failed to complete tuberculosis screening within 10 
days of orientation.  No QFT group subjects failed to complete screening within 10 days 
of hire date.  
 
Q4. Will implementation of QFT®-GIT be cost-effective? 
The average cost for a two-step TST in Employee Health was estimated at $87.87 
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per person and for QFT® $101.66 (cost of lab test, supplies, staff time for review of 
results). At initial glance, the QFT®-GITs appears to cost more per person ($13.79).  
However, further consideration is warranted when factoring other variables. Seven 
subjects failed to have at least one TST read and had to be replaced which required a 
second TST at an additional cost of $30.01- $37.76 per person (total costs of $210.07).  
Sixteen subjects failed to complete screening within 10 days of orientation which resulted 
in an increase in Corporate cost to allocate Employee Health staff time recalling these 
new hired employees ($25 per hour x 8 hours per week used for recalls = $200.00 per 
week).  Corporate could have been forced to contract with a staffing agency for 16 locum 
tenens nurses while onboarding new hire employees to replace those who failed to 
comply with initial testing resulting in an additional cost of $76,800 per month ($30/hr 
for each locum tenens for full time x 160 hours in month = $4,800 x 16 employees = 
$76,800).  Four subjects in the TST group did not complete both steps of the two-step 
tuberculin skin test within the specified time frame, which potentially placed the system 
at risk for DHEC penalties ranging from $12,675 to $126,749 each for violations 
(S.C.Department of Health and Environmental Control, 2015). Occupational Health 
Safety Administration (OSHA, 2017).  Fortunately, Employee Health staff were vigilant 
in their efforts to complete the testing later but again allocating staff time was costly to 
Corporate.   
Conclusions 
The utilization of the QFT®-GIT for tuberculosis screening of new hire 
healthcare employees in comparison to the TST testing significantly reduced tuberculosis 
screening and onboarding time while improving compliance with tuberculosis screening 
   
180 
 
within 10 days of hire date (p<.0001; TST = 8.03 days, 4.11 days = QFT group). 
Anecdotal feedback back from hiring managers and senior management indicated an 
improvement in satisfaction with the Employee Health new hire process.  They fully 
appreciated the decrease in onboarding time, quicker start dates for new hires, less delays 
in orientation, and an increase in volume of new hire visits. Employee Health manager 
admits to receiving less complaints regarding appointment availability for screening 
processes and orientation start dates for new hires.  Streamlining processes has also 
facilitated regulatory site visits with the QFT®-GIT because data is more easily 
retrievable and accurate.  Clearly, the cost of QFT®-GIT can be more as a single test but 
agencies should account for other variables in the cost analyses including, staffing costs, 
lab testing, and locum tenens use.  Streamlining processes and improved efficiency are 
critical to Corporate overhead costs and compliance.  
 
Implications for Practice and Future Research 
Organizations should consider implementation of an IGRA to streamline 
processes for onboarding new hires. Of course, new processes require negotiations 
between hospital departments and lab vendors, changes in policy and procedures, and 
Employee Health staff development for IGRA testing procedures to facilitate new hires 
onboarding.   
Future research should include discrete cost analyses comparing screening with 
TST versus QFT®-GITs for both new hires and annual testing. A pilot study could 
provide foundation for future research to compare annual screening with QFT®-GIT and 
TST. Analyses could include measurements of process improvement, screening time, and 
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Frequency distribution for demographic variables  
 


























90                 18.60 
394               81.40 
 
 
24                 4.96 
24                 4.96                 
23                 4.75 
413              85.33 
 
 
323               66.73 
112               23.14 
13                   2.69 
12                   2.48 
24                   4.96 
 
 
          111                23.03 
62                12.86 
32                  6.4 
15                  3.11 
14                  6.64 





















N, means, standard deviation, minimum, maximum for select variables 
 
 
Table H.3  
N, mean, standard deviation for select variables by group 
 
a. t-test p=0.0849 














Variable Label N Mean 
Std 












TST clear days 
TB clear days 


















































Variable TST group 
 
N     Mean     Std. 
QFT group 
 
N     Mean     Std. 
Agea 
 
TB screen clear days b 
 
QFT complete days 
 
TST complete days 
227     34.11   11.78 
 
224      8.03      7.16 
 
0             .           . 
 
223      8.06      7.16 
 
257     35.93   11.27 
 
257     4.08     1.29 
 
255      4.11     1.26 
 
0 




N, mean, standard deviation for select onboarding variables by group 
 
Variable TST group 
 
N     Mean     Std.  
QFT group 
 
N     Mean     Std. 
Clear daysa 
 
Drug screen daysb 
 
Fit for duty daysc 
 
Pre-work screen daysd 
 
PCP note days 
223    7.92      6.54 
 
225      2.74       2.84 
 
11        10.18     5.10 
 
20           6.6       5.0 
 
  6           7.17      8.57 
256     5.07       2.68 
 
256     2.68       1.61 
 
25       6.96       3.52 
 
11       4.00       4.00 
 
0             .          . 
 
a. t-test p<.0001 
b. t-test p=0.8009 
c. t-test p=0.0768 




Spearman Correlation of selected variables for onboarding clearance days 
 
Variable Onboarding Clear Days 
N                                      Correlation 
Agea 
TST clear daysb 
QFT days b 
Drug screen days b 
Fit for duty days b 
Pre-work screen days b 
PCP note days c 
481                                    0.10094 
223                                    0.71838     
255                                    0.62275        
479                                    0.30298          
36                                      0.76433 
31                                      0.68600 













N                   % 
No 














            385               97.96 
  82               91.11 
 
 
309               95.96 
109               97.32 
  49              100 
 
 
210               92.92 
257               100 
 
8                  2.04 
8                8.89 
 
 
13              4.04 
3                2.68 
0                0 
 
 
16               7.08 
0                 0 
d. Fisher exact test p value = .0010 
e. Fisher exact test p value = .3092 
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